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The cell wall of Mycobacterium tuberculosis has a very complex ultrastructure, consisting of 
mycolic acids, an array of polysaccharides and surface exposed antigenic glycolipids. These 
cell wall components play a vital role in pathogenicity and virulence and hence, are attractive 
drug targets. Recent advances in TB drug discovery have produced a plethora of candidate 
drug molecules, Many of them target mycolic acid biosynthesis and transport.  
 A major part of the thesis work consists of biochemical and structural characterisation 
of proteins involved in mycolic acids biosynthesis and transport using a combination of 
genetic and biophysical tools. Through deletion of fabH, its non-essentiality for growth and 
survival of mycobacteria was demonstrated, and suggested the possibility of a functional 
substitute.  
 Using an array of biophysical tools, MmpL3, the protein involved in the transport of 
mycolic acids, was characterised and preliminary structural studies revealed that MmpL3 
exists as a dimer. The possibility of the formation of protein complex with MmpL3 at the 
core, to achieve the transport of mycolic acids was also investigated. Although no facilitator 
protein was identified, our studies characterised the genes co-localised in mmpL3 cluster. 
 The latter part of the thesis deals with the identification and characterisation of 
glycosyltransferases involved in the biosynthesis of lipooligosaccharides (LOS) in M. 
kansasii. LOS’s are surface exposed, highly polar antigenic glycolipids, present in several 
mycobacterial species. Using targeted gene deletion, a mutant strain defective in LOS 
production was obtained that has provided the first insights into LOS biosynthesis in M. 
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Phylogenetically, mycobacteria belong to the eubacteria or actinomycete group. These are a 
large group of Gram positive bacteria and are characterised by their high GC content.Within 
this group, mycobacteria belong to one branch, termed the CMN, which stands for  
Mycobacterium, Corynebacterium and Nocordia, owing to their close similarity in cell wall 
ultra structure (Brennan & Nikaido 1995). The cell wall of this group of bacteria is 
characterised by the presence of meso-diaminopimellic acid and N-glycolylated muramic acid 
in peptidoglycan. In addition, the presence of the cell wall polysaccharide arabinogalactan 
(AG) and mycolic acids distinguishes this group of bacteria from others (Lederer et al. 1975; 
Brennan & Nikaido 1995). To put into perspective the complexity of the mycobacterial cell 
wall, the aforementioned unique components make up majority of the cell wall. 
Mycobacteria are typically unicellular, aerobic, rod shaped to curved rods or cocco-
bacilli. They vary between 1 to 4 µm in length and 0.2 to 0.6 µm in width (Wayne and 
Kubica, 1986). The cells take up Carbol fuchsin when stained by the Ziehl-Neelsen method 
due to the presence of high amounts of mycolic acids in their cell wall and are hence grouped 
under acid-fast bacteria (Goren et al. 1978). Mycolic acids along with other unique complex 
lipids constitute 60% of the cell wall, rendering it highly hydrophobic, endowing the 
organism with a permeability barrier and innate resistance to therapeutic agents and host 
defences (Acharya & Goldman 1970; Minnikin et al. 2002; Karakousis et al. 2004).
The mycobacterial cell wall core is composed of peptidoglycan which is covalently 
linked to the mycolyl arabinogalactan to form the mycolyl-arabinogalactan- peptidoglycan
(mAGP complex) (McNeil et al. 1990; Kremer et al. 2003; Dover et al. 2004; Brennan 2003; 
Besra et al. 1995) and the outer region consists of glycolipids, polysaccharides, lipoglycans,
which intercalate within the mycolic acid layer (Brennan &Nikaido 1995; Brennan &  Crick 
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2007). Thus, this unique cell wall is also an attractive drug target for antimycobacterials
(Banerjee et al. 1994; Forbes et al. 1962). 
The unique cell wall of the mycobacteria renders pathogenicity to the genera; 
however, not all the species are pathogenic. Well known human pathogens of the genera 
include M. tuberculosis that causes TB and M. leprae that causes Leprosy. The genera also 
include opportunistic human pathogens that cause TB like disease in humans. These include 
M. avium, M. canetti and M. kansasii. Further, mycobacterial species are divided into fast and 
slow growers depending on their generation time. Table 1-1 lists fast growing and slow 
growing mycobacterial species.
Table 1-1 List of fast and slow growing Mycobacteria
Fast growing mycobacteria Slow growing mycobacteria
Mycobacterium smegmatis Mycobacterium tuberculosis
Mycobacterium aurum Mycobacterium bovis BCG
Mycobacterium chelonae Mycobacterium canetti
Mycobacterium duvalii Mycobacterium kansasii
Mycobacterium flavescens Mycobacterium avium
Mycobacterium fortuitum Mycobacterium malmoense
Mycobacterium gadium Mycobacterium ulcerans
Mycobacterium komossense Mycobacterium gastri
Mycobacterium phlei Mycobacterium genavense
Mycobacterium porcinum Mycobacterium haemophilum
Mycobacterium rhodesiae Mycobacterium intercellulare
Mycobacterium shinshuense Mycobacterium leprae












Tuberculosis (TB) is the oldest known infectious disease and is the second leading cause of 
death from an infectious disease worldwide, after the human immune deficiency virus (HIV). 
TB is caused by the bacillus M. tuberculosis. It typically affects the lungs (pulmonary 
tuberculosis), but can also affect other sites as well (extra pulmonary tuberculosis) (WHO, 
2013). Pathogenesis of TB will be discussed in detail in section 1.4.
Molecular and biochemical tools have helped to identify TB infection from various 
archaeological samples. Early studies were carried out using isolation and identification of M. 
tuberculosis specific DNA from the Egyptian and Peruvian mummies (Salo et al. 1994; 
Crubézy et al. 1998). Later, use of cell wall lipids as biomarkers has helped identify TB 
infection from 9000 year old mummy and a 17,000 year old bison skeleton (Donoghue 2009; 
Hershkovitz et al. 2008; Rothschild et al. 2001; Lee et al. 2012). 
Although molecular studies points at existence of TB from 17,000 years ago, it was 
only in 1882 that the etiological agent of TB was first identified. German physician Robert 
Koch discovered the etiological agent of TB and also introduced ‘sanitoria’ as a preventive 
measure (Koch 1882; Cox 1923). 
1.3 Epidemiology
Although effective chemotherapy has helped control TB over the years, TB stills remains a 
global burden due to high mortality rates. 9.3 million new TB cases were reported in 2012 
with 1.3 million deaths due to TB with lowest rates of incidence (0-4%) reported from 
developed countries including North America, Western Europe and Asia pacific countries. 
The highest rates of incidence were reported from sub-saharan Africa (>50%), India and 
China (20-49%). Intermediate rates of incidence (5-19%) were reported from Central and 
South America and Eastern Europe (WHO 2013). 
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TB co-infection with HIV remains a underlying threat in African countries, which 
account for nearly 75% of the estimated TB-HIV co-infection incidence globally (WHO 
2013). HIV has raised the risk of developing latent infections into active infection by 10-fold 
which has a direct impact on mortality due to both the diseases (Cole et al. 1998; Corbett et 
al. 2003)
1.4 Pathogenesis of tuberculosis
Pathogenic bacteria adopt different ways to stably infect their host and one of the effective 
ways is to reside intracellularly, which protects the pathogen from a variety of humoral 
defense mechanisms (Kaufmann, 1993). Our early understanding of M. tuberculosis 
pathogenicity comes from work conducted on rabbit models (Lurie, 1964). M. tuberculosis 
primarily infects the lungs and resides in alveolar macrophages (Ernst, 1998). The infection is 
transmitted through aerosols and post inhalation, the bacilli could face a number of fates; a 
strong host immune system may clear the bacilli resulting in no infection or in 
immunocompromised individuals, the pathogen could establish disease or could evade the 




Figure 1-1Pathogenesis of Tuberculosis in the infected host
In the early stages of infection, the pathogen multiplies within an infected 
macrophage until the macrophage bursts and releases the bacilli (Long & Schwartzman 2014; 
Russell, 2007). The released bacilli attract more macrophages causing a localised pro-
inflammatory response recruiting mononuclear cells and blood vessels to form a granuloma, a 
characteristic of M. tuberculosis infection (Russell, 2007; Podinovskaia et al. 2013; Long & 
Schwartzman 2014).  The granuloma consists of three layers with a core consisting of 
infected macrophages, surrounded by foamy macrophages and an outer layer composed of 
lymphocytes and extracellular components (Russell, 2007). The bacilli can remain in this 
condition to cause latent infection or within a weakened host, could result in rupture of the 
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granuloma and establish an infection. The eventual spread of the bacilli to the rest of the 
lungs or other parts of the body is the final stages of the disease (Dannenberg & Rook 1994).
Phagosome maturation and subsequent fusion with lysozome has been shown to be 
modulated by several factors. These include some cell wall components, such as lipo-
arabinomannan (LAM) (Sweet et al. 2010), phenolic glycolipid (PGL-1) (Robinson et al. 
2007) and trehalose dimycolate (TDM) (Indrigo et al. 2003) and secreted proteins, such as
the serine/threonine kinase PknG (Walburger et al. 2004). This process of arresting 
phagosome maturation is vital for the pathogen to evade the natural immunological response
and establish a stable infection. 
1.5 Anti TB drugs
1.5.1 History of TB drug discovery
In the early 1940’s streptomycin was first identified to have a bacteriostatic effecton bacilliby 
Feldman and Hinshaw (Anon 1946; Jones et al. 1944) and was used for treating TB. Later, p-
aminosalicylic acid (PAS) was used as a drug in isolation and in combination with 
streptomycin to treat TB (Graessle & Pietrowski 1949; Bernheim 1940; Yegian & 
Vanderlinde 1948; Anon 1950). The major breakthrough in TB treatment came with the 
discovery of isoniazid (INH) in the early 1950’s (Steenken & Wolinsky 1952). The next 
decade saw the development of several TB drugs including pyrazinamide (Muschenheim et 
al. 1954; McDermott et al. 1954; Tompsett et al. 1954; Yeager et al. 1952), cycloserine
(Albouy et al. 1955), ethambutol (Thomas et al. 1961; Forbes et al. 1962) and rifampin
(Sensi 1983). The current treatment involves administration of INH in combination with 




Over the years the mechanisms of action of these drugs have been elucidated and also 
the resistance have been mapped, which is discussed briefly below. INH and ethionamide 
target the biosynthesis of mycolic acids by inhibiting the enoyl-ACP reductase (InhA) which 
is part of fatty acid synthase-II (FAS-II) (Winder & Collins 1970; Banerjee et al. 1998; 
Kremer et al. 2003; Quémard et al. 1995). However, both are pro-drugs and need to be acted 
up on by catalase-peroxidase (katG) and a monooxygenase (ethA), respectively for 
conversion into an active metabolite (Zhang et al. 1992; Baulard et al. 2000; Khasnobis et al. 
2002). INH is converted to an isonicotinic acyl radical by KatG, which then reacts with 
nicotinamide dinucleotide (NAD) to form an INH-NAD adduct (Broussy et al. 2003; 
Rozwarski et al. 1998). Similarly, prothionamide (pro-drug of ehionamide) is converted to its 
active form 2-ethyl-4-aminopyridine by EthA, which abolishes mycolic acid biosynthesis 
through inhibiting InhA (Banerjee et al. 1994). The resistance to these compounds have been 
mapped using clinical isolates to mutations in inhA, katG and ndhII in case of INH and ethA 
and ethR in case of ETH (transcriptional regulator of ethA) (Zhang et al. 1992; Banerjee et al. 
1994; Morlock et al. 2003; Dover et al. 2004). Although INH and ETH are structural 
analogues and target the same enzyme, cross-resistance is relatively low which is explained 
by divergent activation mechanisms (Fattorini et al. 1999; Banerjee et al. 1998; Baulard et al. 
2000). The low cross-resistance observed was initially thought due to altered NADH/NAD 
ratios but was later surprisingly mapped to the mycothiol biosynthesis pathway (Vilchèze et 
al. 2005; Vilchèze et al. 2008; Vilchèze et al. 2011). 
Rifampin is a semi-synthetic derivative of rifamycin B and inhibits the β-subunit of 
RNA polymerase (RpoB), and is bactericidal against both active and slow-growing bacilli.
Rifamycin was shown to sterically inhibit translocation step in the synthesis of nascent 
mRNA by binding to RpoB subunit, bringning an abrupt end after transcribing two 
nucleotides (Kohanski et al., 2010; McClure et al., 1978). Resistance to RIF has been 
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mapped to rpoB (Taniguchi et al. 1996).  Ethambutol is a synthetic drug that was initially 
shown to inhibit the transfer of mycolic acids to the cell wall with a concomitant increase of 
secreted trehalose monomycolate (TMM) and trehalose dimycolate (TDM) (Kilburn & 
Takayama 1981). Later it was shown that ethambutol primarily affects arabinogalactan 
biosynthsis by blocking the enzymatic activity of EmbB, which is involved in the formation 
of the terminal hexaarabinofuranoside motif of arabinogalactan, thus affecting mycolylation 
(Escuyer et al. 2001; Belanger et al. 1996). Resistance to ethambutol was mapped to 
mutations in embB (M306V/L) using drug resistant M. tuberculosis isolates (Ramaswamy et 
al. 2004).  
Another first line drug pyrazinamide (PZA),which is also a pro-drug is converted into 
pyrazinoic acid (POA) by pyrazinamidase (Pzase) (Frothingham et al. 1996). PZA is most 
active against older cultures at an acidic pH and is believed to bring about cell death through 
affecting membrane potential by destructing the proton motive force (Zhang et al. 2003). 
Recent studies have shown that pyrazinamide brings about cell death by inhibiting trans-
translation process by blocking the action of ribosomal protein S1(RpsA) and pyrazinamide 
but not pyrazanoic acid, is shown to competitively bind FAS-I and inhibiting mycolic acid 
biosynthesis (Shi et al., 2011; Sayani et al., 2011). However, the resistance to pyrazinamide 
is mapped to pncA geneTable 1-22 details the anti-mycobacterial drugs and their target genes, 
and genes involved in resistance. 
As described above these drugs are used in combination to treat modern day TB. The 
standard regimen involves a two phase therapy designed to combat actively growing and 
dormant bacilli. The first phase employs treatment with first line anti-TB drugs for two 
months followed by four months of a continuous phase. The first line anti-tubercular drugs 
are INH, EMB, PZA and RIF (Table 1-2). The second line drugs include aminoglycosides 
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(e.g.kanamycin), polypeptides (e.g. capreomycin), fluoroquinolones (e.g. ciprofloxacin), 
thioamides (e.g. ethionamide), cycloserines and p-aminosalicylic acid. Rifabutin and 
marcolides constitutes third line drugs which are sparsely used and are less effective (Janin 
2007).
Table 1-2Anti-TB drugs and their target pathway.






Isoniazid (INH) ≤0.25 Bactericidal Mycolic acid 
biosynthesis
katG/inhA/ndh
Ehionamide 0.6-2.5 Bacteriostatic Mycolic acid 
biosynthesis
inhA/ethA
Rifampin (RIF) ≤0.125 Bactericidal RNA synthesis rpoB
Ethambutol
(EMB)














In 1991, World Health Organization (WHO) introduced “Directly Observed Therapy, Short-
course” (DOTS) to combat TB in an efficient way (Obermeyer et al. 2008). DOTS focus on 
the logistics of TB treatment along with actual chemotherapy. The logistics involve 
commitment from Government policy towards controlling TB, the supply of drugs and 
standardised reporting and recording of cases and outcome of treatment. Chemotherapy 
involves diagnosis based on sputum smear microscopy and DOTs administration. In 2006, 
the “Stop TB” campaign was initiated to focus on aneffective implementation of DOTS and 
to increase awareness of drug resistance. DOTS chemotherapy involves administration of a
cocktail of drugs for a minimum of 6 months for drug susceptible TB cases and up to 2 years 
for drug resistant TB cases. The current DOTS treatment consists of administration of INH, 
Chapter 1 Introduction
11
EMB, RIF and PZA daily for two months followed by INH and RIF thrice weekly for another 
4 months (Cox et al. 2006).
1.5.3 Drug resistance
Multi drug resistant (MDR) TB exhibits drug resistance towards at least two of the first line 
drugs INH and RIF. MDR-TB could result from either through primary infection with 
resistant bacteria or developed during the treatment phase. Non-compliance with the 
treatment regime and/or short drug supply, are the two important reasons for developing 
MDR-TB. Recent studies have shown that the pathogen could develop antibiotic resistance 
through mutations in the chromosomal targets rendering anti-TB agents ineffective (Cole 
1994). Globally, 3.7% of new cases and 20% of previously treated cases are estimated to be 
MDR-TB, of which 60% coming from India, China and the Russian Federation. These 
countries have reported a worrying 9-32% of new cases and nearly 50% of the previously 
treated cases to be MDR-TB. Treatment of MDR-TB is both expensive and for prolonged




duration, and requires more toxic second line anti-TB drugs. The treatment regimen (DOTS-
Plus-an alternative to DOTS strategy) lasts close to 18 months post smear negative using 4-6 
second line drugs selected on their efficacy and susceptibility testing (WHO 2013; Shin et al. 
2006).
Extensively drug resistant TB (XDR-TB) is an additionally challenging and a more 
dangerous variant. XDR-TB strains are resistant to INH, RIF and any of the fluoroquinolones 
along with resistance to at least one of amikamycin, kanamycin and capreomcyin, which are 
the injectable second line anti-TB drugs (Raviglione 2006). XDR-TB has been reported from 
92 countries globally and an estimated 9.6% of MDR-TB cases have XDR-TB, with a 
mortality rate of nearly 50% (WHO 2013). In December 2011, a new strain was reported 
from India which exhibited resistance to all of the first-line and the second-line drugs and is 
termed Totally Drug Resistance TB (TDR-TB), which poses further challenges to TB 
treatment.




1.5.4 New drugs and combination therapies in the pipeline
Research over the years has shown that the unique mycobacterial cell wall is one of the most 
attractive drug targets and several candidate drugs have now been identified. Apart from the 
development of new drugs, a new combination regimen NC-001 involving PA-824, 
moxifloxacin and pyrazinamide is in phase-II and has showed encouraging results (WHO 
2012). Currently there are 4 drugs in phase-III and 11 in phase-II clinical trials.  
Fluoroquinalones, gatifloxacin and moxifloxacin are all in phase-III and are shown to inhibit
DNA supercoiling in mycobacteria by inhibiting DNA gyrase (Tomioka et al. 1993; Sriram et 
al. 2006; Burman 2010). OPC-67683 is a pro-drug and is acted up on by Rv3547 to form an
active compound that inhibits mycolic acid biosynthesis and thereby bringing about cell 
death.  OPC-67683 has a MIC of 0.006-0.024 µM against drug susceptible and MDR-TB
strain (Matsumoto et al. 2006). This compound is currently in phase-III clinical trials (WHO 
2012). The diarylquinoline drug TMC-207 is currently being used in monotherapy 
(provisional FDA licence), kills the bacteria by targeting proton pump of the adenosine 
triphosphate (ATP) synthase (Andries et al. 2005; Sloan et al. 2013). Chemically SQ109 has 
the same core as that of ethambutol and targets mycolic acid transport by binding to MmpL3 
(Mycobacterial Membrane Protein Large 3) (Protopopova et al. 2005; Tahlan et al. 2012).
Recently, a sulfur containing compound has shown bactericidal activity against mycobacteria 
with a high specificity and potency. Benzothiozionone (BTZ) has a MIC value of 1-30 ng/ml 
and is currently in the pre-clinical phase.  BTZ binds to DprE1 and consequently blocks
arabinan biosynthesis and cell death is brought about by blocking the recycling of decaprenyl 
phosphate (Makarov et al. 2011; Batt et al. 2012; WHO 2012; Grover et al. 2014). Phase-III 
clinical trials testing gatifloxacin and moxifloxacin were expected to finish by the end of 
2013 and data will be made available shortly which should these new drugs available to treat 
TB (WHO 2013). Importantly all of the above discussed drugs have shown good potency 
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against even the drug resistant strains of TB (Makarov et al. 2011; Andries et al. 2005; 
Protopopova et al. 2005; Matsumoto et al. 2006; Sriram et al. 2006; WHO 2012; WHO 
2013). Apart from new drugs, there are number of vaccines have been proposed and are 
currently in different phases of vaccine development (WHO 2012; WHO 2013).
Figure 1-4 Development pipeline for new TB drugs.
1.6 The mycobacterial cell wall
The mycobacterial cell wall is composed of unique lipids and polysaccharides. Although 
mycobacteria are grouped under Gram positive bacteria the cell envelope differs from those 
of others in the group. The cell wall is unusually lipid rich, extremely hydrophobic and
contributes low permeability to hydrophilic drugs and rendering the organism resistant to 
therapeutic agents (Brennan & Nikaido 1995). The cell wall of mycobacteria is very complex 





 Cell wall matrix composed of a mycolyl-arabinogalactan-peptidoglycan (mAGP) 
complex
 Other non-covalently associated polysaccharides, phospholipids, glycolipids, waxes 
and proteins.
The cell wall skeleton is made up of peptidoglycan (PG) covalently linked to 
arabinogalactan (AG) which is esterified at the distal end to mycolic acids (Brennan 2003)
forming the mAGP complex mesh like structure. Solvent extractable lipids intercalate the 
mAGP core. In some cases the lipid rich cell wall is enveloped by a sugar rich capsule layer.
The composition of the capsule varies from species to species. For example, capsule found in 
M. tuberculosis, M. kansasii and M. gastri are polysaccharide rich whereas capsules of M.
smegmatis and M. phlei are mainly proteins. The capsule forms a interface between the 
bacteria and its environment (Daffé & Etienne 1999; Brennan & Nikaido 1995; Minnikin et 
al. 2002; Daffé & Lanée 2001).
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Figure 1-5 Arrangement of structural components of cell envelope of M. tuberculosis.PG-Peptidoglycan; 
AG-Arabinogalactan; LAM-Lipoarabinogalactan; PIM6-Phospho inositol hexa mannose; MA-Mycolic acids; 
TMM-Trehalose monomycolate; TDM-trehalose dimycolate; PDIM-Pthiocerol dimycocerosate; SL-Sulfolipid; 
DAT-Diacyl trehalose; FFA- Free fatty acid.
The Figure 1-5 presents the architecture of mycobacterial cell wall. This was first 
proposed by Minnikin D E (1982) and further modified by McNeil and Brennan in 1991 and 
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Minnikin D E et al. in 2002 (Davidson et al. 1982; McNeil & Brennan 1991; Minnikin et al. 
2002). According to the model proposed, the core cell wall contains covalently linked 
peptidoglycan, arabinogalactan and mycolic acid and other structural lipids forming the outer 
layer of the cell wall. Peptidoglycan associated with the plasma membrane on one side
provides a polysaccharide anchor on the outer surface to which mycolic acids are attached 
(McNeil & Brennan 1991; Chatterjee et al. 1991). A highly ordered galactan is covalently 
linked to peptidoglycan and attached to a branched arabinan, which is esterified to mycolic 
acids. The compact structure of the mAGP complex results in a highly hydrophobic layer of 
extremely low fluidity (Besra & Brennan 1997). Phenolic glycolipids (PGL), 
phthioceroldimycocerosates (PDIM), trehalose dimycolate also known as cord factor (TDM), 
sulfolipids (SL) and phosphotidyl-inositolmannosides (PIM) constitutes outer layer of the 
membrane. The cell wall also consists of lipoarabinomannan (LAM) and lipomannan (LM) 
originating from plasma membrane extending out into the outer membrane. In the following 
section these cell wall components will be discussed in detail.
1.6.1 Plasma membrane
The plasma membrane of mycobacteria is fairly less complex and is composed of a
phospholipid bilayer. The presence of unknown carbohydrates in the cell membrane has been 
reported, however these have not been characterised. This carbohydrates are believed to 
render the membrane uneven (Silva & Macedo 1983). One of the unique mycobacterial cell 
wall components phosphoinositol mannosides (PIMs) is found in the cell membrane. The 
inositol moiety is covalently linked to a glycerophospholipid in the cell membrane and is 
attached to mannose units through glycosidic linkages. The structures of higher homologues,
PIM3, PIM4, PIM5 and PIM6 have all been elucidated (Lee & Ballou 1964; Brennan & 
Ballou 1967; Brennan & Nikaido 1995). Further PIMs also form the lipid base for 
lipoarabinomannan (LAM) and lipomannan (LM) (Brennan & Nikaido 1995). These will be 
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discussed in detail below. Other components associated with the plasma membrane include 
polyterpene based ‘carotinoids’ (which give a characteristic yellow-orange colour for
photochromogenic mycobacteria, such as M. gordonae and M. kansasii) and menaquinones 
involved in electron transport, glycosylphosphopolyprenols, such as β-D-mannopyranosyl 
phosphodecaprenol and β-D-arabinofuranosyl phosphodecaprenol (Takayama & Goldman 
1970; Wolucka et al. 1994; Brennan & Nikaido 1995). 
1.6.2 Peptidoglycan
Mycobacterial peptidoglycan consists of a linear chain consisting of N-acetyl glucosamine 
(GlcNAc) and muramic acid (Mur) residues linked via β-(1→4) linkages (Schleifer & 
Kandler 1972). The muramic acid is branched with a pentapeptide side-chain consisting of L-
alanyl-D-isoglutaminyl-meso-diaminopimelyl-D-alanine and individual monomers cross-
linked through covalent linkage between meso-diaminepimelic acid (mDAP) and D-alanine 
residue. This type of cross-linking is observed in A1-type peptidoglycan and the presence of 
amidated muramic acid puts it into the A1γ class (Lederer et al. 1975; Schleifer & Kandler 
1972; Brennan & Nikaido 1995). 
Further studies have reported additional modifications in the peptidoglycan structure. 
Oxidation of N-acetyl to N-glycolyl forms of muramic acid is interesting, as it allows for 
extensive hydrogen bonding and helps in tightening the peptidoglycan structure (Brennan & 
Nikaido 1995; Azuma et al. 1970; Raymond et al. 2005). However, it is the mDAP that plays 
a key role in extensive cross-linking to form a mesh like structure. Apart from cross linking 
between mDAP and D-alanine, an additional cross-link is observed between two mDAP 
residues (Ghuysen et al. 1968; Wietzerbin et al. 1974). Further, these mDAP-mDAP linkages 
are extensive as the organism enters stationary phase (Wietzerbin et al. 1974). This results in
a very high percentage of cross-linking (70-80%) compared to E.coli (20-30%) (Usha et al. 
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2012). The extensively cross linked peptidoglycan forms the principal structural framework 
of the mycobacterial cell wall on which a complex lipophillic matrix is built (Alderwick et al. 
2007).
1.6.3 Arabinogalactan
Arabinogalactan (AG) is a complex heteropolysaccharide structure that covalently anchors 
the outer lipid layer to the inner peptidoglycan. Mass spectroscopic studies had helped early 
understanding of the sugar composition of arabinogalactan, however it was not until the late 
90’s that the complete structure of this polysaccharide was established (Figure 1-6) (Azuma 
et al. 1970; Kanetsuna et al. 1968; McNeil et al. 1987; Besra et al. 1995). Arabinogalactan is 
attached to peptidoglycan through a linker unit consisting of L-Rhap-(1→4)-α-D-GlcNAc
(McNeil et al. 1990; Besra et al. 1995). Arabinogalactan is synthesised on a decaprenyl 
phosphate (C50-P) lipid carrier prior to its transfer to the muramic acid residue of 
peptidoglycan. N-acetyl glucosamine and rhamnose residues are sequentially added on to 
decaprenyl phosphate (C50-P-P-GlcNAc-Rha) to provide a base for assembly of the linear 
galactan chain (Mikusová et al. 1996; Mills et al. 2004; Alderwick et al. 2006; Jankute et al. 
2012). The linear galactan chain is composed of β-D-galactofuranose residues linked through 
alternative β(1→5) and β(1→6) linkages (Belánová et al. 2008; Szczepina et al. 2010). The 
galactan chain is primed at position 8, 10 and 12 with a arabinofuronosyl residue, which is 
further elongated (α-1, 5) and branched (α-1, 3) (Besra et al. 1995; Birch et al. 2008). Chain
termination occurs with a unique hexaarabinofuranosyl (Ara6) motif with 2-β-D-
arabinofuranose and α-D-arabinofuranose residues providing the sites for mycolylation 
(Alderwick et al. 2006; Jankute et al. 2012; McNeil et al. 1994a).  
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Figure 1-6 Essential structural topography of M.tuberculosis arabinogalactan-peptidoglycan.
1.6.4 Mycolic acids
As defined by Asselineau and Lederer, mycolic acids are α-alkyl, β-hydroxy fatty acids (C70-
C90) and are essential components of the mycobacterium cell wall (Asselineau & Lederer 
1950; Takayama et al. 2005). The structure of mycolic acids and functional groups associated 
with it, were elucidated during the 1960’s by concerted efforts of several research groups 
(Lannelle 1963). Mycolic acids could be classified depending on the chemical modifications 
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observed in the meromycolate chain or the main chain of the mycolic acid. The non-
oxygenated mycolates are termed as α-mycolates. This is the abundant form (>70%) found in 
the cell wall of M. tuberculosis. The oxygenated mycolates sub-divided into methoxy and 
keto-mycolates, are less abundant form (10 to15%). Presence of a methyl branch adjacent to 
cyclopropane ring, cis or trans double bonds, provide additional modifications to the
oxygentated and non-oxygenated mycolic acids (Minnikin et al. 1982). The functional group 
forms the basis of classification of mycolic acids and is useful in taxonomic identification. 
For example, the M. tuberculosis cell wall has α, methoxy and ketomycolates while M.
smegmatis has α, α’ and epoxy mycolates (Davidson et al. 1982; Yuan & Barry 1996).
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Figure 1-7 Representative structures of different types and classes mycolic acids from mycobacterial
species. αsubtypes α, α1, α2 and α’ all lacking oxygen functions. M-methoxy, K-keto, W-wax ester, E-epoxy 
and ω-1M- ω-1 methoxy are all oxygenated.
The evidence for association of mycolic acids with arabinogalactan came from 
chemical isolation of D-arabinose-5-mycolate fragments (Azuma et al. 1968; Kanetsuna et al. 
1969). Later it was confirmed that mycolic acids are esterified to the non-reducing termini of 
arabinogalactan at all available O-5 positions of the Ara6 motif (as discussed in chapter 1.6.3) 
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(McNeil et al. 1991).Two thirds of this terminal Ara6 motifs are mycolylated and it is 
presumed that mycolic acids are arranged perpendicular to the cell membrane and parallel 
with respect to each other, forming a compact structure that serves as a permeability barrier 
while rendering structural rigidity to the cell wall (Minnikin et al. 2002). Protruding through 
regular gaps that exist in the mycolic acid layer are lipoglycans, e.g. LAM, that presents 
themselves to the cell surface (Chatterjee et al. 1991).
1.6.5 Lipomannan and Lipoarabinomannan
Interspersed within the mycobacterial cell wall, are found complex, structurally related 
glycolipids and lipoglycans. These are anchored to the cytoplasmic membrane through a
common phosphotidyl-myo-inositol (PI) anchor (Hunter & J.Brennan 1990). Chemically the
PI unit is based on an acylated sn-glycero-phosphate and is attached to myo-inositol (Lee & 
Ballou 1964; Ballou et al. 1963). Phosphotidyl-myo-inositol is mannosylated at 2-OH 
position to generate PIM1. Acylation of the mannose residue at 3-OH or 6-OH position yields 
AcPIM1. Acylation of mannose at both 3-OH and 6-OH position would yield Ac2PIM1.
Further mannosylation at 6-OH position of inositol produces AcPIM2/Ac2PIM2 (Korduláková 
et al. 2002; Korduláková et al. 2003; Jackson et al. 2000). Majority of PIMs exist as
dimannosides (PIM2) or hexamannosides (PIM6).
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Figure 1-8 Essential structural topography of M.tuberculosislipomannan (LM) and lipoarabinomannan (LAM). R1
and R2on MPI anchor indicate acylation at 1-OH and 2-OH position onthe glycerol of the MPI anchor, R3-
acylation at 3-OH of the inositol and R4- acylation at 6-OH position of Manp. Sites of species specific 
glycosylation of the LM and LAM are indicated with m, n, o, p and q.
A linear mannan backbone extends from the mannose linked to the O-6 position of 
inositol in PIM2 to produce lipomannan (LM). The extending Manp units are linked via α-
(1→6) linkages with intermittent α-(1→2) branches (Chatterjee & Khoo 1998; Besra & 
Brennan 1997). 
LAM is synthesised on a LM backbone with the addition of a branched arabinan 
motif. The point of arabinan attachment has not been identified to date (Jankute et al. 2012). 
The arabinan polymer consists of up to 60 α-(1→5)-Araf units composed of branched 
hexaarabinofurano-sides (Ara6) and linear tetraarabinofuranosides (Ara4) (Chatterjee et al. 
1991; Chatterjee et al. 1993; McNeil et al. 1994b). In M. tuberculosis, termini of the non-
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reducing arabinan are capped with mannose residues linked through α-(1→2) linkage 
forming mannose-capped LAM (ManLAM) (Khoo et al. 2001). In other species, the arabinan 
is either capped with inositol (PILAM) or not capped (AraLAM) (Khoo et al. 1995). 
1.6.6 Solvent extractable lipids in the mycobacterial cell wall
While the inner membrane cell wall components are essential for mycobacterial survival, 
components of the outer membrane have been demonstrated to play a critical role in 
pathogenicity. In a recent review, Minnikin et al. (2015) drew up a link between 
pathogenicity and components of the outer membrane components such as 
lipooligosaccharides (LOSs), sulfolipids (SL) and phenolic glycolipids (PGLs). The mycolic 
acids of the mAGP complex provide a hydrophobic environment for the non-covalent 
assembly of this vast variety of lipophillic, amphiphillic and polar lipids. The composition of 
the outer cell membrane components varies among species of mycobacteria. 
1.6.6.1 Trehalose monomycolate and dimycolate
While mycobacterial specific mycolic acids are found esterified to arabinogalactan, they are 
also found non-covalently assembled in the outer membrane bound to trehalose. Trehalose is 
a non-reducing disaccharide of glucose (α-D-glucopyranosyl-α-D-glucopyranoside), and is 
found in acylated forms with fatty acyl chains and mycolic acids. Mono-mycolylated 
trehalose was isolated and characterised and was postulated to be the form in which they are 
transported across the membrane (Takayama & Armstrong 1976; Takayama & Armstrong 
1977; Takayama et al. 2005). Later, this hypothesis was confirmed through genetic studies 
(Varela et al. 2012). Trehalose monomycolate (TMM) serves as substrate for mycolylation of 
arabinogalactan and also for the formation of ‘cord factor’ trehalose dimycolate (TDM)
(Belisle et al. 1997; Puech et al. 2002). Mycolic acids are also found in free form and bound 
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to other residues such as glucose (glucose monomycolate) and glycerol (glycerol
monomycolate). The role of these in pathogenicity is discussed following sections. 
Figure 1-9 Structures of trehalose bound mycolates, TMM and TDM.
1.6.7 Methyl branched acyl trehaloses
The mycobacterial cell wall is characterised by an array of complex glycolipids based on 
trehalose. However, methyl-branched acyltrehaloses are exclusively present in MTBC 
organisms suggesting their possible role in virulence. Diacyltrehaloses (DATs) were first 
isolated and characterised by Besra et al. (1992) and showed that these are based on 
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mycosanoic (DAT1) or mycolipanolic acids (DAT2). More structurally related and heavily
acylated lipids occur in M. tuberculosis, the pentaacyl trehaloses (PATs) and triacyl 
trehaloses (TATs) (Minnikin et al. 1985; Muñoz et al. 1997). These methyl-branched acyl 
trehaloses are amphillic in nature and suggest to act as a conduit between the hydrophobic 
mycolic acid layers and the polar capsule material (Minnikin et al. 2002), and has been
shown to be effective diagnostic molecules (Muñoz et al. 1997).
Figure 1-10 Structures of methyl branched acyl trehaloses, diacyl trehalose -1(DAT1), triacyl trehalose 




1.6.8 Phthiocerol dimycocerates (PDIMs) and phenolic glycolipids (PGLs)
PDIMs and PGLs are complex cell wall associated lipids that play a pivotal role in 
pathogenesis. These are very large (C>90) hydrophobic molecules and are constituents of the 
outer membrane of the mycobacterial cell wall (Minnikin et al. 2015, In press). Chemically 
these are long chain diols esterified by multi-methyl branched mycocerosic acids (Minnikin 
et al. 1985; Daffe & Laneelle 1988). PDIMs are based on three closely related long chain 
diols- phthiocerol A, phthiocerol B and phthiodiolones. Phthiocerols linked to phenol residue 
at the distal end forms the base for phenolphthiocerol dimycocerosates and characterised by 
the species-specific antigenic oligosaccharides attached to phenol and hence are commonly 
termed phenolic glycolipids (PGLs) (Daffe & Laneelle 1988; Minnikin et al. 2002). PDIMs 
and PGLs are shown to be modified in highly virulent Beijing strains of M. tuberuculosis, 
where phthiotriols and phenolphthiotriol replace phthiocerols and phenolphthiocerols (Huet 
et al. 2009). Further, the length of the oligosaccharide attached to phenol residue varies 
among PGLs found in different species of mycobacteria.
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Figure 1-11 Structures of phthiocerols dimycocerosates (PDIMs) and phenolic glycolipids (PGLs). 
Different ‘R’ groups found in PDIMs and PGLs are shown inside the box.
1.6.9 Sulfolipids
Sulfolipids belong to a group of lipids termed acyltrehaloses along with TMMs, TDMs, 
DATs and PATs, however, they are uniquely characterised by the presence of a sulfated 
trehalose. Chemically, sulfolipid is a 2,3,6,6-tetraacyl 2’ sulfotrehalose. Tetraacyl chains 
composed of one-short chain saturated fatty acid, usually palmitic or strearic acid, and a 
different long-chain multi-methyl branched fatty acids, termed as phthioceranic acid and 
hydroxyl phthioceranic acids are attached to the sulfated trehalose (Goren et al. 1976). The 




Figure 1-12 Structure of sulfated tetracyl trehalose (SL) from M.tuberculosis.
1.6.10 Lipooligosaccharides
Several mycobacterial species are characterised by the presence of highly polar 
oligosaccharide containing lipids in their outer membrane and these include phenolic 
glycolipids (PGLs), lipooligosaccharides (LOSs) and glycopeptidolipids (GPLs) (Asselineau 
& Laneelle 1998). A detailed account of PGLs was given in 1.6.8. This section gives a brief 
account of GPLs and LOSs. GPLs are composed of a fatty acyl chain and a peptide core, 
which is made up of D-phenylalanine, D-allo-threonine, D-alanine and L-alanine. 
Glycosylation varies across pathogenic and non-pathogenic bacteria. GPLs have been shown 
to play a role in sliding motility and pathogenesis (Recht & Kolter 2001; Villeneuve et al. 
2003).
Lipooligosaccharides (LOSs) are highly polar, trehalose associated surface 
glycolipids and are present in several species of mycobacteriaand restricted to opportunistic 
pathogens and non-pathogens. LOSs have been identified and characterised from various 
mycobacterial species, which include the opportunistic pathogen M. kansasii (Hunter et al. 
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1985), M. gastri (Gilleronl & Vercauterent 1993), M. szulgai (Hunter et al. 1988), M.
malmoense (M McNeil et al. 1987), M. gordonae (Besra et al. 1993), M. marinum (Minnikin 
et al. 1989) and the M. tuberculosis complex strain M. canetti (Daffe et al. 1991). Obligate 
human pathogens M. tuberculosis and M. leprae do not produce LOSs. 
Structures of LOSs have been elucidated from many of these species which revealed a 
common polyacylated trehalose core with further glycosylations. The nature of the acyl-chain 
and position of linkage varies from species to species. Similarly, the oligosaccharide is either 
linked to C3, C4 or C6 of trehalose and the length of the oligosaccharide could vary between 2 
to 13 sugar residues (Besra et al. 1993; Hunter et al. 1983).The nature of the sugar residues 
that make up oligosaccharide component varies largely among different species and species 
specific sugar residues have been identified to date (Minnikin et al. 1989; Hunter et al. 1984; 
Rombouts et al. 2009). Although, a definitive role of LOSs is not yet completely understood, 
they have been shown to play a role in virulence and sliding motility. A detailed account of 
LOS biosynthesis and its role in pathogenesis is discussed in Chapter 6.
Figure 1-13 Structure of lipooligosaccharides from different mycobacterial species. Oligosaccharide 
compositions from two representative species are shown in the figure. Classes of LOSs produced by different 
mycobacterial species is tabulated below.
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Table 1-3 Composition of LOSs from different mycobacterial species. Multiple numbers of identical 
residues are denoted by ‘n’. (Adopted from Table 1-3 in PhD thesis titled “Mycobacterial Glycolipids –












KanNacyl (1→3)-Fucp (1→4)-(β-D-Xylp)n (1→4)-






























































1.7 Role of cell wall components in Virulence
The mycobacterial cell wall is complex and composed of several unique components. While 
some of these components are essential for its survival, some play a vital role in 
pathogenesis. This section attempts to shed light on factors that play an important role 
establishing infection and the progression of disease. 
While mycolic acid biosynthesis is indispensable, alteration in its structure or 
modifications is tolerated, but shown to affect virulence. Strains lacking the distal 
cyclopropanation on α-mycolates were reported to have growth defects in mice lung and 
failed to persist during infection. Cycloproponation modifications have also been shown to 
affect macrophage activation (Glickman et al. 2000; Rao et al. 2006; Rao et al. 2005). Recent 
studies have shown that the distal oxygen containing modifications on the meromycolate 
chain are important in suppressing IL-12 production (Dao et al. 2008). Other mycolic acid 
containing cell wall components also play pivotal role in infection. TDM, also known as cord 
factor, plays an important role in the recruitment of cells in granuloma formation and also 
modulates expression and production of cytokines (Indrigo et al. 2003; Hunter et al. 2006; 
Lima et al. 2001). Although, no direct evidence shows that DATs and PATs play a role in 
virulence, these are exclusively present in virulent strains, which points at possible role in 
virulence (Minnikin et al. 2015 In press). 
Cox et al.(1999) reported that the loss of PDIMs leads to aattenuation of M. 
tuberculosis in lungs, but not in other organs viz liver and spleen, however the molecular 
mechanism was not determined. PDIM deficient cells have been shown to be hypersensitive 
to reactive nitrogen oxide released by activated macrophages with an associated elevation in 
TNF-α and IL-6 release (Rousseau et al. 2004; Reed et al. 2004). Other important classes of 
lipids found exclusively in virulent strains of mycobacteria are the sulfolipids (Middlebrook 
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et al. 1959). Domenech et al (2004) have shown that the transport of sulfolipids across the 
membrane is important for virulence and a reduced ability to survive intracellularly 
(Domenech et al. 2004; Domenech et al. 2005). This was supported by further studies with a 
∆phoP attenuated strain that also showed a role for sulfolipids along with DATs and PATs in 
virulence (Asensio et al. 2006). However, a recent study has contradicted the above 
observations, which claims PDIMs and not sulfolipids are crucial for attenuation (Chesne-
Seck et al. 2008).
The mycobacterial cell wall consists of several antigenic glycolipids of which LM and 
LAM are present universally across mycobacterial species. However, the LAM/LM ratio 
which varies from highly pathogenic to facultative pathogenic strains, may play a role in 
virulence (Briken et al. 2004). LM of mycobacteria are strongly proinflamatory and induce
the production of IL-8, IL12 and TNF-α (Vignal et al. 2003; Briken et al. 2004). Also, PI-
capped LAM has shown cytokine induction in human macrophages (Guerardel et al. 2002). 
However, LAM, Ara-LAM and Man-LAM do not show any pro-inflamatory activities 
(Guerardel et al. 2002; Dao et al. 2004; Vignal et al. 2003; Briken et al. 2004). Recently, 
LAM was shown to play important role in reducing/arresting phagosome maturation by 
incorporation into membrane rafts of macrophages through its phosphor-myo-inositol anchor 
(Welin et al. 2008).
Lipooligosaccharides are surface exposed highly polar antigenic glycolipids. 
Although, comprehensive information is not available for role of LOSs in pathogenicity, 
there have been attempts to study these using purified LOSs and LOS deficient mutants. LOS 
deficient mutants have been reported to exhibit increased virulence in Zebrafish embryos 
(van der Woude et al. 2012). Further, purified LOSs from M. marinum were shown to inhibit 
TNF-α secretion from LPS activated human macrophages (Rombouts et al. 2009). Recently, 
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a relationship between LOS production and uptake of cells by macrophages was established 
showing LOS deficient strains were efficiently phagocytosed (Alibaud et al. 2014). However, 
further studies are required to understand a clear role of LOSs in pathogenicity.
1.8 Aims and objectives
TB accounts for nearly 1.3 million deaths annually and is a massive burden both on 
humanitarian and on the economy. Treating TB is a big challenge and is complicated by the 
advent of drug resistance strains, including the recently isolated, what is termed as ‘totally 
drug resistance’ (TDR) strains (Udwadia et al. 2012; WHO 2013). Development of new anti-
TB drugs is of paramount importance to fight the deadly disease. 
Biochemical knowledge of mycobacterial cellular processes is a key aspect in drug 
development cascade. The unique cell wall is both a friend and a foe for mycobacteria, while 
it protects the cell by acting as a permeability barrier against therapeutic agents; it also 
provides high value drug targets. Three out of four front line drugs target the biosynthesis of 
cell wall components and in recent years several new drug targets have been identified, also 
are involved in the biosynthesis and transport of cell wall components (Banerjee et al. 1994; 
Telenti et al. 1997; Batt et al. 2012; Tahlan et al. 2012). One of the vital cell wall 
components is mycolic acids, which along with arabinogalactan forms the core of the cell 
wall. Biochemical knowledge of biosynthesis and transport of mycolic acids have provided 
useful insights on its essentiality for survival and pathogenesis apart from offering novel drug 
targets (Banerjee et al. 1994; Bhatt et al. 2005; Banerjee et al. 1998; Lai & Cronan 2003; 
Varela et al. 2012; A. Bhatt, Fujiwara, et al. 2007; Scarsdale et al. 2001; Sassetti et al. 2001). 
However, there are some unanswered questions with respect to our current understanding of 
mycolic acids biosynthesis, processing and transport.  One of the objectives of this thesis is to 
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test the essentiality of fabH which is thought to play a crucial role in initiating the FAS-II 
cycle of fatty acid/mycolic acid biosynthesis. fabH, is thus believed to be essential for the 
survival of the organisms although TraSH analysis suggest that it may be non-essential for 
the growth and survival of M. tuberculosis. We seek to answer this question regarding its 
essentiality unambiguously and further, we have also attempted to evaluate functional 
redundancies and/or possibility of alternative pathways that could shunt the substrates into 
FAS-II for synthesis of fatty acid/mycolic acids. 
Although mycolic acid biosynthesis has been studied for many years, research into its 
transport gained speed only recently. Several new class of antibiotics have been shown to 
target MmpL3 mediated transport of mycolic acids (Varela et al. 2012; Tahlan et al. 2012; La 
Rosa et al. 2012; Remuiñán et al. 2013; Brown et al. 2011). Although genetic evidence 
points at MmpL3 as the drug target, direct evidence in terms of protein-inhibitor interactions, 
binding studies or co-crystallisation are still elusive. To answer these questions, we sought to 
express, purify and characterise the MmpL3 protein and carry out biophysical and structural 
studies and explore possibilities of ligand binding and co-crystallisation studies.
Previous studies have shown that the transport of complex lipids requires the coupling 
of biosynthesis, processing and transport. Other MmpLs involved in transport of PDIMs and 
siderophores have shown to form protein scaffolds to couple both biosynthesis and transport
(Jain & Cox 2005; Zheng et al. 2011; Wells et al. 2013). To find out whether MmpL3 also 
adopts a similar strategy to achieve transport of mycolic acids, we sought to investigate the 
function of uncharacterised genes in the mmpL3 cluster and also use MmpL3 as a bait protein 
to identify interacting partners. 
Lastly, the outer membrane of mycobacteria consists of several antigenic lipids that 
play critical role in virulence and immunomodulation. Of these outer membrane lipids, role 
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of LOSs has not been studied in detail and reasons for its absence in M.tuberculosis are still 
unknown. As a first step towards this, we seek to study biosynthesis and transport of LOSs in 
M. kansasii and M.canetii, which are genetically close to LOS deficient M. tuberculosis. A 
brief summary of project objectives outlined below; 
o Deletion of fabH in M. bovis BCG to probe its essentiality and identify any functional 
redundancies or alternative pathways that may substitute FabH catalysed reaction.
o Biophysical and structural studies of MmpL3.
o Identification of proteins associated with MmpL3 in assisting the transport of mycolic 
acids.
o Deletion of glycosyl transferases, polyketide synthases and mmpL genes in M.
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Mycolic acids are a major component of the cell wall and associated free lipids found in 
mycobacteria (Brennan & Nikaido 1995). These long-chain unique lipids are an integral part 
of the mycobacterial cell wall. Mycolic acids are covalently linked to arabionogalactan to 
form the mycolyl-arabinogalctan-peptidoglycan (mAGP) complex, the integrity of which is 
vital for in vitro and in vivo survival. The biosynthesis of mycolic acids is well studied and 
several genes have been shown to be essential for the survival of the bacteria. These include 
inhA (Vilchèze et al. 2000), fabG (Parish et al. 2007), kasA (Bhatt et al. 2005), pks13 
(Portevin et al. 2004), mmpL3 (Varela et al. 2012), and are  targeted by several anti-TB drugs 
(Winder & Collins 1970; Banerjee et al. 1994; Quémard et al. 1995; Kremer et al. 2000; 
Tahlan et al. 2012). While the absence of mycolic acids is detrimental to cell viability, any 
alteration either in its length or its fine structure is tolerated but is shown to affect cell wall 
permeability, thereby making the cell susceptible to lipophillic antibiotics and host cell 
antimicrobial molecules, such as defensin and lysozyme (Gao et al. 2003; Corrales et al. 
2012). It is for both of the above reasons that the biosynthesis of mycolic acids is seen as a 
potential target for drug development.  
The biosynthesis of mycolic acids is accomplished by the concerted efforts of two 
fatty acyl synthase (FAS) systems (Figure 2-1). α-alkyl and β-hydroxy (meromycolate) 
chains are synthesised separately by FAS-I and FAS-II respectively. Further modifications on 
meromycolate chain followed by the condensation of α-alkyl and modified meromycolate 
chains results in  mature mycolic acids  (Brennan & Nikaido 1995). 
FAS-I plays a housekeeping role by synthesising fatty acids de-novo, which are either 
used to produce membrane lipids or for further elongation into mycolic acids by FAS-II. 
FAS-I is a multifunctional, multi-domain enzyme that synthesises C16-18 CoA primers for 




further elongation by FAS-II and C26 substrates for condensation with meromycolate chain to 
produce mycolic acids (Takayama et al. 2005; Bhatt et al. 2008). 
FAS-II consists of array of enzymes elongating the fatty acyl-CoA substrates into a 
C56 mero-mycolate. While FAS-II from other bacteria, chloroplasts and mitochondria can 
initiate fatty acid synthesis de novo; mycobacterial FAS-II cannot initiate de novo synthesis 
and can only extend the substrates generated by FAS-I (Takayama et al. 2005; Barry et al. 
1998) . The fatty acyl Co-A generated by FAS-I are sequentially processed by β-ketoacyl 
AcpM synthase (KasA/KasB), β-ketoacyl AcpM reductase (MabA), β-hydroxyacyl AcpM 
dehydratase and enoyl AcpM reductase (InhA) (Takayama et al. 2005). The mero-mycolate 
chain produced by FAS-II undergoes species specific modifications and is transferred to 
condensing enzyme PKS13(Portevin et al. 2004), which condenses it with α-alkyl chain to 
produce mature mycolic acids. The post FAS-II modifications include cyclopropanation, 
introduction of cis/trans double bonds, methoxy, keto and/or epoxy groups. These 
modifications are essential to produce mature and functional mycolates (Kolattukudy et al. 
1997; Zimhony et al. 2004; Takayama et al. 2005). 
 
Acyl CoA bound substrates generated by FAS-I are channelled to FAS-II.  The 
transitions through a set of enzymes AcpM, mtFabD and mtFabH  (Wong et al. 2002; Choi et 
al. 2000a; Brown et al. 2005; Ghadbane et al. 2007). Since mycolates are shown to be vital 
for the survival and the genes involved in the pathway are shown to be essential, fabH was 
also believed to be essential and play critical role (Choi et al. 2000b). Previously, fabH 
orthologues from other Gram positive (Lactococcus lactis) and Gram negative (E. coli) 
bacteria, where it plays a critical role in the synthesis of short-chain fatty acid primers for the 
initiation of FAS-II biosynthesis, were shown to be essential supporting this hypothesis (Lai 
& Cronan 2003). Transposon site hybridization (TraSH) is a genetic tool that allows rapid 
functional characterisation of genes required for grown under different conditions. TraSH 




analysis of mycobacterial genes lists fabH as a non-essential gene as opposed to earlier 
observations made in other bacteria (Sassetti et al. 2001; Sassetti et al. 2003) and additionally 
M. leprae which has minimum ‘essential’ genome and has a intact cell wall does not possess 
fabH (Cole et al. 2001; Kapopoulouet al. 2011). Also there have been no successful reports of 
a fabH deletion mutant. However, some of the genes listed as non-essential in the TraSH 
analysis have been later shown to be essential, for example mmpL3 (Varela et al. 2012).  
 
 
Figure 2-1 Schematic presentation of pathway for the biosynthesis of Mycolic acid biosynthesis in M. 
tuberculosis.The C16-26 CoA substrates produced by FAS-I are condensed with malonyl- AcpM by mtFabH and 
channelled into FAS-II for the generation of meromycolate chain. α-fatty acyl chain and the meromycolate 
chains are condensed by a polyketide synthase (Pks13) to produce nascent mycolic acids. Malonyl-AcpM also 
acts as a source of C2 donor for the β-ketoacyl-ACP synthases, KasA ad KasB. Several processing enzymes are 
involved in processing of mycolic acids to produce mature, trehalose bound form, which is transported across 
the membrane by MmpL3 for cell wall mycolylation and other functions. 




FabH is a type-III β-ketoacyl synthase, that catalyses the reaction that bridges FAS-I 
and FAS-II. The acyl CoA primers synthesised by FAS-I are condensed through a 
decarboxylative condensation with malonyl-AcpM and feed into FAS-II. Substrate specificity 
experiments have shown that mtFabH has a distinct preference for long-chain acyl Co-A 
primers over short-chain CoA primers, and over AcpM primers (Choi et al. 2000b; Laurent 
Kremer et al. 2002). The catalytic triad of Cys-His-Asn is conserved across β-ketoacyl 
synthases, however the key amino acid changes in the binding pocket allows binding of 
longer acyl CoA chains (Scarsdale et al. 2001).   
As discussed, the present understanding of the essentiality of fabH is ambiguous. 
Although, structural and enzymatic studies strongly suggest a key role in mycolic acid 
biosynthesis, there is no functional evidence to support the hypothesis. In this chapter, we 
have probed the essentiality of fabH. Further we also probed for functional redundancies in 
the β-ketoacyl synthase activity. Initial bioinformatics studies showed the presence of 
polyketide synthase (PKS) in the M. tuberculosis genome, the function of which is not yet 
known. PKS18 is a type-III polyketide synthase which is evolutionarily related to plant 
chalcone synthases (CHS), and contains an active site characteristic of mycobacterial β-
ketoacyl synthases. Although PKS18 shares very low sequence homology with FabH, they 
are structurally related. Further, in-vitro substrate specificity studies also indicate that Pks18 
could possibly replace the function of FabH.  Interestingly, M. leprae which also produces 
mycolic acids, lack both fabH and pks18 and it is likely that M. leprae KasA/KasB could 
perform FabH role. However, M. tuberculosis KasA/KasB have been characterised but are 
not shown to substitute FabH function in M. tuberculosis. In the light of this we decided to 
probe the function of FabH and Pks18 using genetic tools. 




Our data suggest that fabH is non-essential for the growth of M. bovis BCG in 
agreement with TraSH data. This prompted us to look at other alternative routes of initiation 
of FAS-II biosynthesis. We have probed the function of pks18 as a functional substitute for 
fabH.  
2.2 Materials and Methods 
2.2.1 In-silico analysis 
The gene sequences for fabH (Rv0533c) andpks18 (Rv1372) were obtained from TB genome 
database Tuberculist (http://genolist.pasteur.fr-/TubercuList/ ). Structural analysis of Pks18 
for β-ketoacyl synthase activity was cited from Saxena et al. (2003). 
2.2.2 Plasmids, strains and DNA manipulation 
Table 2-1lists the plasmids, bacterial strains and mycobacteriophages used in this study. E. 
coli strains were routinely cultured in LB broth at 37°C. M. smegmatis strain mc
2
155 was 
cultured at 37°C in tryptic soy broth (TSB) with 0.05% Tween 80. The generation and 
propagation of mycobacteriophages was done on a lawn of M. smegmatis at 30°C in 7H10 
basal plates overlaid with 7H9 soft agar as described in Chapter 7. High titres of 
mycobacteriophages were generated using protocols described in Chaper 7 (Larsen et al. 
2007).  M. bovis BCG and M. tuberculosis were grown in 7H9 broth supplemented with 10% 
OADC (oleic acid, albumin, dextrose and catalase) and 0.05% Tween 80, at 37°C. For plate 
growth, 7H10 media was supplemented with 10% OADC and incubated at 37°C. Antibiotics 
were routinely used for selection; hygromycin was used at 150µg/ml for E. coli, and at 
100µg/ml for M. smegmatis and 50µg/ml for M. bovis BCG; kanamycin was used at 50µg/ml 
for E. coli and at 25µg/ml for M. smegmatis and M. bovis BCG; apramycin was used at 
50µg/ml for E. coli and M. bovis BCG. 




Table 2-1 Bacterial strains, plasmids and mycobacteriophages used in this studies described in this 
chapter 
Plasmids, phages and strains Description Reference 
Plasmids   
p0004S Cosmid vector containing Hyg-
sacB cassette 
Larsen et al., 2007 
p∆fabH Derivative of p0004s cosmid 
obtained by cloning upstream and 
downstream flanks of mt.fabh 
(Rv0533c) 
Spivey V 
p∆pks18 Derivative of p0004s cosmid 
obtained by cloning upstream and 
downstream flanks of mt.pks18 
(Rv1372) 
Spivey V 
p∆fabH_Apra Derivative of p0004s_Apramycin 
cosmid obtained by cloning 
upstream and downstream flanks 
of mt.fabh (Rv0533c) 
Spivey V 
p∆pks18_Apra Derivative of p0004s_Apramycin 
cosmid obtained by cloning 
upstream and downstream flanks 




, E.coli-mycobacterial shuttle 
vector (ColE1-MPhsp60) 
Stover et al., 1991 
pMV261- fabH Functional copy of mt.fabH cloned 
into pMV261 shuttle vector 
Spivey V 
pMV261- pks18 Functional copy of mt.pks18 
cloned into pMV261 shuttle vector 
Spivey V 
Phages   
phAE159 Thermo sensitive, conditionally 
replicating shuttle phasmid derived 
fromlytic mycobactiophage TM4 
Larsen et al., 2007 
ph∆fabH Derivative of phAE159 obtained 
by cloning p∆fabHinto its PacI site 
This work 
ph∆pks18 Derivative of phAE159 obtained 
by cloning p∆pks18into its PacI 
site 
This work 
ph∆fabH_Apra Derivative of phAE159 obtained 
by cloning p∆fabH_Aprainto its 
PacI site 
This work 
ph∆pks18_Apra Derivative of phAE159 obtained 
by cloning p∆pks18_Aprainto its 
PacI site 
This work 
Bacterial strains   
E. coli Top 10 F– mcrA Δ(mrr-hsdRMS-mcrBC) 
Φ80lacZΔM15 
ΔlacX74 recA1 araD139 Δ(ara 
leu) 7697 galU galK rpsL 
(StrR) endA1 nupG 
Invitrogen 




E. coli HB101 E.coli K-12 _F- mcrB mrr 
hsdS20(rB- mB-) recA13 leuB6 
ara-14 proA2 lacY1 galK2 xyl-5 








Snapper et al., 1990 
M. bovis BCG Wild type strain of M. bovis BCG 
var Pasteur  
 
M. tuberculosis H37Rv Wild type strain of M. tuberculosis  
∆fabH M. bovis BCG strain with mt.fabH 
replaced with Hyg-sacB cassette 
This work 
∆pks18 M. bovis strain with mt.pks18 
replaced with Hyg-sacB cassette 
Bhatt A, University 
of Birmingham  
∆fabH_Apra M. bovis BCG strain with mt.fabH 
replaced with Apramycin cassette 
This work 
 
2.2.3 Construction of knockout phage for deletion of mt.fabH and mt.pks18 
The allelic exchange substrate plasmids listed in Table 2-1(gift from V. Spivey, University of 
Birmingham) were cloned into phAE159 at the PacI site and packaged into empty λ-phage 
heads. The packaged phasmids were transduced into E. coli HB101 cells. The positive 
phasmid for each gene was transformed by electroporation into M. smegmatis mc
2
155 and 
recovered at 30°C for one generation time (3-4 hrs) in 1 ml of TSB containing 0.05% Tween 
80. The recovered cells were split into 200 µl and 800 µl and mixed with 100 µl of log phase 
M. smegmatis and 5 ml of molten 7H9 soft agar. This mix was overlaid on 7H10 basal plates 
and incubated at 30°C for 2-3 days for plaques to be formed. The plates were soaked in 
mycobacteriophage (MP) buffer for 4-6 hrs and syringe filtered and either used straight away 
or stored at 4°C. 
2.2.4 Generation of null mutants 
Specialised transduction of M. bovis BCG to generate ∆fabH was performed as described for 
other mycobacterial species (Bardarov et al. 2002). M. bovis BCG was grown in 7H9 media 
containing 10% OADC and 0.05% Tween 80 to an OD600nm of 0.8 and harvested by 




centrifugation. The cell pellet was washed twice with an equal volume of MP buffer. Finally, 





lysate (1 ml) was mixed with 1 ml of cells for transduction and 1 ml of MP buffer mixed with 
1 ml of cells for control reaction and incubated at 37°C,  harvested and recovered in 7H9 
media containing 10% OADC and 0.05% Tween 80 for 24hrs at 37°C. The recovered cells 
were harvested and resuspended in 400-600 µl of 7H9 media and plated on 7H10 agar 
containing 10% OADC and 50 µg/ml hygromycin (or 50 µg/ml apramycin where applicable) 
as a selection marker. Upon 3-4 weeks of incubation, hygromycin (or apramycin) resistant 
colonies that appear on the plates were inoculated into 10 ml of 7H9 media containing 10% 
OADC, 0.05% Tween 80 and 50 µg/ml of hygromycin B (or 50 µg/ml apramycin where 
applicable) for genomic DNA extraction and further characterisation. Allelic exchange of 
each gene with the hyg cassette (or apramycin cassette) in transductants was confirmed by 
southern blot. 
2.2.5 Generation of double knock out of fabH andpks18 
Specialised transduction of ∆fabH and ∆pks18 were carried out in an attempt to generate 
∆fabH::pks18 double knock out. ∆fabH, ∆fabH_apra and ∆pks18 cultures were grown in 7H9 
media containing 10% OADC and 0.05% Tween 80 to an OD600nm of 0.8 and harvested by 
centrifugation. The cell pellet was washed twice with an equal volume of MP buffer. Finally, 





lysate (1 ml) was mixed with 1 ml of cells for transduction; the combination of double 
mutants attempted is listed in Table 2-2. Control reactions were set up by adding 1ml of MP 
buffer to 1ml of cells. Transduced cells were incubated at 37°C for 24 hrs, followed by 
harvesting and recovering in 7H9 media containing 10% OADC and 0.05% Tween 80 for 24 
hrs at 37°C. The recovered cells were harvested and resuspended 400-600 µl of 7H9 media 
and plated on 7H10 agar containing 10% OADC and 50 µg/ml hygromycin B (or 50 µg/ml 




apramycin where applicable) as selection marker. Upon 3-4 weeks of incubation, hygromycin 
(or apramycin) resistant colonies that appear on the plates were inoculated into 10 ml of 7H9 
media containing 10% OADC, 0.05% Tween 80 and 50 µg/ml of hygromycin B (or 50 µg/ml 
apramycin where applicable) for genomic DNA extraction and further characterisation. 
Allelic exchange of each gene with the hygcassette (or apra cassette) in transductants was 
confirmed by Southern blot. 
Table 2-2 Generation of ∆fabH::pks18 double knock out 
Single knock out Mycobacteriophage Double knockout 
∆fabH ph∆pks18_apra ∆fabH::pks18 
∆fabH_apra ph∆pks18 ∆fabH_apra::pks18 
∆pks18 ph∆fabH_apra ∆pks18::fabH_apra 
 
2.2.6 Generation of complemented strains of mt.fabH and mt.pks18 
pMV261_fabH and pMV261_pks18 were electroporated into ∆fabH, ∆pks18 and ∆fabH_apra 
strains and selected on 7H10 agar plates containing 50 µg/ml hygromycin (or 50 µg/ml 
apramycin where applicable) and 25 µg/ml kanamycin. Table 2-3 lists complemented strains 
used in this study. 
Table 2-3 Complemented strains used in this study 
Plasmids Description Reference 
∆fabH-C-fabH ∆fabH complemented 
withpMV261-fabH 
This work 
∆fabH-C-pks18 ∆fabH complemented 
withpMV261-pks18 
This work 
∆fabH_apra_C-fabH ∆fabH _Apra complemented 
withpMV261-fabH 
This work 
∆fabH_apra_C-pks18 ∆fabH _Apra complemented 
withpMV261-pks18 
This work 
∆pks18_C-fabH ∆pks18 complemented 
withpMV261-fabH 
This work 








2.2.7 Extraction and analysis of lipids from M. bovis BCG strains 
M. bovis BCG, ∆fabH and ∆pks18 cultures were grown at 37°C, to mid-log phase in 10 ml of 
7H9 medium supplemented with 10% OADC and 0.05% Tween 80. [
14
C]-acetate, (50 µCi, 
57 mCi/mmol, GE Healthcare, Amersham Biosciences) was added to a mid-log phase and 
grown for a further 24 hrs to label lipids. The labelled bacterial cultures were harvested and 
washed with PBS. The washed pellet was resuspended in 2 ml of methanolic saline 
(methanol: 0.3% NaCl, 10:1 v/v) and apolar lipids extracted using 2 ml of petroleum ether 
(60-80 bp). Apolar lipids was analysed by 2-D TLC (Dobson et al. 1985) and visualised by 
autoradiography by exposing a Kodak MR film to the TLC plates overnight. 
2.2.8 Fatty acid methyl esters (FAMEs) and mycolic acid methyl esters 
(MAMEs) extraction from defatted cells and whole cells 
Alkaline hydrolysis was performed on de-fatted cells after the extraction of polar lipids as 
described in Chapter 7. Briefly, 2 ml of 5% aqueous tetrabutylammonium hydroxide (TBAH) 
was added to defatted cells and incubated at 100°C, overnight. Base hydrolysed fatty acids 
and mycolic acids were extracted as methyl esters by mixing with 4 ml of dichloromethane 
(CH2Cl2), 300 µl of methyl iodide (CH3I), and 2 ml of water for 30 min. Lower layer organic 
phase containing FAMEs and MAMEs were washed three times with water and dried, and re-
dissolved in diethyl ether. The organic layer was taken into separate tube and dried under air. 
The samples were dissolved in CH2Cl2 (200 µl), analysed by single dimension TLC using 
petroleum ether: acetone (95:5) and visualised by autoradiograph. 





2.3.1 In silico analysis of fabH and pks18 
fabH has been previously listed as a non essential gene for M. tuberculosis growth in TraSH 
analysis of M. tuberculosis H37Rv (Sassetti et al. 2001; Sassetti et al. 2003), however there 
have been no successful reports of a fabH deletion mutant, and no functional redundancies 
have been identified. Also, FabH is indispensable in other Gram positive and Gram negative 
bacteria (Lai & Cronan 2003). These observations strongly suggest at possible essentiality of 
fabH. This led us to validate the essentiality of fabH in mycobacteria. Further, we probed 
redundancies in the β-keto acyl synthase function in case of non-essentiality of fabH. PKS18, 
a Type-III polyketide synthase was shown to share structural similarity with FabH and 
exhibit preference for short-chain fatty acids in a condensation reaction (Saxena et al. 2003). 
Interestingly, PKS18 shares only 27% identity with FabH.   
PKS18, a type-III polyketide synthase is evolutionarily related to plant chalcone 
synthases (CHS), with fusion active sites from CHS and mycobacterial β-ketoacyl synthases. 
Pks18 predicted to contain a classical thiolase fold (αβαβα), His-Cys-Asn catalytic triad, 
characteristic of β-ketoacyl synthases and CHS. CHS are typically involved in the synthesis 
of α-pyrones through decarboxylative condensation (Saxena et al. 2003). However, these 
metabolites have not been isolated in mycobacteria (Rukmini et al. 2004; Gokulan et al. 
2013). The structural similarity of the Pks18 to FabH and its preference for long chain CoA 
substrates encouraged us to probe its role as functional substitute for FabH. Additionally, 
functional redundancy in fabH was recently reported in Pseudomonas. An alternative β-
ketoacyl synthase encoded by PA3286, was shown to functionally substitute FabY 
(pseudomonas equivalent of FabH) (Yuan, et al. 2012a; Yuan, et al. 2012b). PA3286, shares 
low sequence identity with FabH (29%) and PKS18 (22%).      




2.3.2 Generation of null mutants and Southern blot analysis 
Specialised transduction, a highly efficient mycobacterial knockout method, was employed to 
generate null mutants in M. bovis BCG. The fabH gene was replaced with hyg and apramycin 
cassette separately. The genomic DNA from the hygromycin and apramycin resistance 
colonies was digested with KpnI and subjected to Southern blot analysis (Appendix 1) as 
described in Chapter 7. One confirmed knockout with a hyg cassette was labelled ∆fabH and 
one with an apramycin cassette was labelled ∆fabH_apra. Here, we report that fabH is not 
essential as suggested previously in the TraSH analysis by Sassetti et al. (2001). ∆fabH was 
used for all the lipid analysis.  
∆pks18 was a gift from Dr. A. Bhatt (University of Birmingham), where pks18 was 
replaced by a hygromycin cassette and was used for lipid characterisation. 
Multiple attempts to generate a double mutant ∆fabH::pks18 were unsuccessful. 
Further, attempts to generate a double mutant, in the presence of functional copy of one of the 
genes, are in progress. 
2.3.3 Lipid analysis 
To assess the effects of loss of fabH and pks18 function on the biosynthesis of mycolic acids, 
cultures of M. bovis BCG WT, ∆fabH and ∆pks18 strains were grown in 7H9 medium 
supplemented with 10% OADC and 0.05% Tween-80 and labelled with [
14
C] acetate. Apolar 
lipids were extracted and analysed by 2D-TLC using systems A-D, designed for the analysis 
of apolar lipids, and visualised by autoradiography (Dobson et al. 1985). 





Figure 2-2 2D TLC analysis of apolar lipids from M.bovis BCG WT, ∆fabH and ∆pks18 strains.(A) 
Direction 1- chloroform: Methanol (96:4 v/v); Direction 2- toluene: acetone (80:20 v/v); FA-fatty acid; MA-
mycolic acid. (B) Direction 1- Chloroform: methanol: water (100:14:0.8 v/v/v); Direction 2- chloroform: 
acetone: methanol: water (50:60:2.5:3 v/v/v/v); TMM-trehalose monomycolate; TDM-trehalose dimycolate; 
GMM-glucose monomycolate; DAT- diacyl trehalose. 
 
Figure 2-3TLC analysis of FAMEs & MAMEs extracted from M.bovis BCG WT, ∆fabH and ∆pks18 
strains, developed using petroleum ether: acetone (95:5 v/v) MAMEs- Mycolic acid methyl esters; FAMEs- 
Fatty acid methyl esters. 




System C (Figure 2-2, A) used for the analysis of free fatty acids and free mycolic 
acids, revealed biosynthesis of either is not affected in the ∆fabH and ∆pks18 knock out 
strains. System D (Figure 2-2, B), used for the analysis of trehalose bound mycolic acids 
namely trehalose monomycolates and trehalose dimycolates, revealed no significant 
difference between the WT and mutant strains. Further to probe any alteration in mycolic 
acid biosynthesis, cell wall bound mycolates were analysed. Cell wall bound mycolic acids 
were hydrolysed using TBAH and esterified to form mycolic acid methyl ester and analysed 
by TLC (Figure 2-3). The ∆fabH and the ∆pks18 knock out strains did not show any defect in 
mycolic acid biosynthesis. Thus, fabH is not essential for bridging FAS-I and FAS-II, which 
was previously thought to be an essential process, and fabH and pks18 may be functionally 
redundant. 
2.4 Discussion 
Mycolic acids are vital components of the mycobacterial cell wall and are critical for cell 
wall permeability and pathogenicity. The biosynthesis and transport of mycolic acids are of 
particular interest due to the enzymes involved in these process are essential for the survival 
of mycobacteria, and hence attractive anti-TB drug targets  (Brennan & Nikaido 1995; 
Steenken & Wolinsky 1952; Thomas et al. 1961; Protopopova et al. 2005). Mycolic acids are 
synthesised by the concerted effort of two FAS synthases. The short-chain (C20-26) CoA 
substrates are synthesised by FAS-I are channelled into FAS-II for reiterative steps of 
reductive decarboxylation. This is a critical step in the biosynthesis of mycolic acids as FAS-
II cannot initiate  denovo synthesis of mycolic acids (Bloch & Vance 1977; Mdluli et al. 
1998; Choi et al. 2000b; Laurent Kremer et al. 2002). FabH is a β-ketoacyl synthase that 
catalyses decarboxylative condensation of long-chain acyl CoA substrates with the acyl 
carrier protein AcpM, which is used as a starting substrate by FAS-II (Choi et al. 2000). 




FabH from M. tuberculosis is biochemically and biophysically well characterised. The crystal 
structure of mt.FabH has assisted development of several inhibitors targeting mycolic acid 
biosynthesis (Lv et al. 2009; Liu et al. 2012; Scarsdale et al. 2001).  
In spite of biochemical and structural insight into the mtFabH protein, the functional 
role of FabH is still not clear. Given that FAS-II cannot synthesise a fatty acyl chains de-novo 
and the essentiality of mycolates, mt.FabH or a similar protein should have a definite role in 
mycolate biosynthesis.  
TraSH analysis has listed mt.fabH as a non-essential for the growth of M. 
tuberculosis. However, TraSH predictions have exceptions, for example mmpL3 which was 
predicted as non-essential was later show to be essential (Sassetti et al. 2003; Varela et al. 
2012). Also, biochemical evidence suggests that the essential bridge reaction is catalysed by 
FabH. In the light of these observations, we sought to probe the essentiality of fabH. We 
employed specialised transduction method to generate a fabH null mutant in M. bovis BCG, 
showing fabH is non-essential for the survival of M. bovis BCG. Additionally, deletion of 
fabH, did not affect the biosynthesis of mycolic acids in a significant manner.  
This led us to hypothesise that there could be a functional substitute for FabH for the 
above stated reasons. Although, a sequence homology search did not yield any obvious hits, a 
structural homology search indicated that PKS18 as the best hit (Saxena et al. 2003). A β-
ketoacyl synthase (PA3286) that substitutes for FabY in Pseudomonas shared similar 
homology between FabH and PKS18, suggesting that PKS18 is the most likely replacement 
for FabH. Invitro substrate specificity experiments with purified PKS18 showed its 
preference for long-chain acyl CoA substrates over short-chain substrates. In vitro data is 
validated by preliminary structural data and modelling studies. Although, PKS18 is shown to 
produce fatty acid derived alkylpyrones in vitro, these metabolites have not yet been isolated 




in mycobacteria (Saxena et al. 2003; Gokulan et al. 2013; Rukmini et al. 2004). Further, 
mycobacterial PKS proteins are not implicated in the production of cyclic polyketide 
products unlike PKS proteins from other sources  (Austin & Noel 2003; Gokulan et al. 2013). 
Structural similarity of PKS18 with FabH, coupled with its substrate preference for long-
chain substrates (C16 -CoA), prompted us to probe its function in vivo. However, the pks18 
deletion mutant generated suggests that it is a non-essential gene and did not affect the 
biosynthesis of mycolic acids or other apolar lipids. We thus, sought to probe functional 
redundancy of FabH and PKS18. Our attempts to generate a double mutant of fabH and 
pks18 have not yet been successful. This suggests that, the function of one of the gene is 
essential for the survival of the mycobacteria. Work to confirm this by generation of a double 
mutant in the presence of a second copy of each gene is underway but could not be completed 












Structural and Biophysical characterisation of 














The key enzymes involved in the biosynthesis of mycolic acids were discussed in the 
previous chapter. This chapter particularly focuses on the transport of mycolic acids in 
mycobacteria. The current knowledge about mycolic acid biosynthesis and function stems 
from genetics, biochemical and structural studies of the enzymes involved in the mycolic acid 
biosynthesis (Vilchèze et al. 2000; Bhatt et al. 2005; Bhatt et al. 2007; Banerjee et al. 1998; 
Choi et al. 2000). While the biosynthesis of mycolic acids is thoroughly understood, the 
information about late stage processing and transport of mycolic acids is still rudimentary.  
An early insight into the transport of mycolic acids came from an identification of 
Myc-PL (6-O-mycolyl-β-D-mannopyranosyl-mono-phospho-heptoprenol), a polyprenol 
carrier-based intermediate accumulating in M. smegmatis (Besra et al. 1994). Following this, 
a hypothesis (Figure 3-1) was put forth by Takayama et al. (2005) who proposed that the 
nascent mycolic acid bound to the PPB domain (phosphopentotheine-binding; signature motif 
of acyl carrier proteins) of PKS13 is transferred onto polyprenol carrier by a yet unidentified 
mycolyltransferase (mycolyltransferase I). The mycolic acid is then transferred onto trehalose 
by a second mycolyltransferase (mycolyltransferase II), and subsequent dephosphorylation 
results in trehalose monomycolate (TMM), which is transported across the membrane by a 
transporter for cellwall mycolylation (Takayama et al. 2005).   
 





Figure 3-1 Schematic presentation of early hypothesis for transport of nascent mycolic acid for cell wall 
mycolylation. Nascent mycolic acid transferred from processing enzymes on to prenol carrier which is 
eventually transferred to trehalose to form TMM. TMM is then transferred across the membrane, where it acts 
as a substrate for mycolylation of cell wall AG. Man-p-heptaprenol- mannosylphosphorylheptaprenol; treh-
trehalose; AG-arabinogalactan; AG-M-arabinogalactan-mycolate; TMM-trehalose monomycolate and TDM- 
trehalose dimycolate. Mycolyl transferases and the phosphotase involved in the late processing of mycolic acid 
to convert them into TMM, are yet to be identified, and indicated in red. The transporter is now identified as 
MmpL3 and is indicated in green. Mycolyl transferases FbpA/B/C involved in the cell wall mycolylation and 
the synthesis of TDM, are indicated in blue. 
 
Advances in TB drug discovery have yielded several novel candidate drugs, that 
include the adamantyl ureas, THPP, SQ109 and BM212 (Protopopova et al. 2005; Deidda et 
al. 1998; J.R.Brown et al. 2011; Remuiñán et al. 2013). Target identification efforts by 
generating spontaneous durg-resistant mutants generated single nucleotide polymorphisms 
(SNP’s) in mmpL3. MmpL are a class of transporter proteins that are involved in the transport 
of complex lipid molecules in mycobacteria and related species. Biochemical characterisation 
of the resistant mutants showed accumulation of TMM inside the cell indicating that mmpL3 




is likely to encode a transporter protein responsible for mycolic acid transport (Tahlan et al. 
2012; Remuiñán et al. 2013; La Rosa et al. 2012; Grzegorzewicz et al. 2012). This evidence 
coupled with earlier reports on other MmpL proteins, which were shown to be involved in 
transport of various metabolites including complex lipid molecules, highlighted the 
possibility of its role in mycolic acid transport (Cole et al. 1998; Converse et al. 2003; Cox et 
al. 1999; Wells et al. 2013). Definitive genetic evidence to this hypothesis came when TMM 
accumulation was shown to occur following conditional depletion of MmpL3, in M. 
smegmatis mmpL3 conditional knock out strain (Varela et al. 2012). 
Although, several MmpL proteins have been implicated in the transport of lipid 
molecules, the underlying mechanism is still unclear. MmpL proteins belong to the RND 
(Resistance, Nodulation and Division) superfamily of proteins (Domenech et al. 2004). The 
RND superfamily is one of the five major families of bacterial efflux pumps. Although, RND 
proteins were initially identified and characterised from Gram negative bacteria, they are 
found in both Gram positive and Gram negative bacteria (Paulsen et al. 1996). The predicted 
topology of MmpL proteins suggests they share structural features of RND proteins and are 
characterised by the presence of twelve transmembrane (TM) helices with two non-TM 
domains. But unlike other RND proteins, such as AcrB, MexA, CusA and SecDF, MmpL 
proteins exhibit high substrate specificity (Converse et al. 2003; Cox et al. 1999; Sondén et 
al. 2005; Varela et al. 2012).  
RND protein mediated transport is shown to be driven by proton motive force (PMF) 
in other bacteria and the aminoacid residues involved have also been identified (Long et al. 
2010; Seeger et al. 2009; Sennhauser et al. 2009; Tsukazaki et al. 2013). Recent studies using 
a known PMF inhibitor carbonyl cyanide m-chlorophenyl hydrazone (CCCP) affected 




MmpL3 function, suggesting the possibility of PMF assisted transport by MmpL proteins 
(Yang et al. 2014).  
 
Figure 3-2 Schematic representation of mycolic acid processing highlighting the role of MmpL3 
 
While the above evidence draws similarity between other RND and MmpL proteins, 
RND proteins from other bacteria exhibit broad substrate specificity and the two non-TM 
domains have been shown to play a vital role in substrate recognition. The two non-TM 
domains occur between TM#1 and TM#2 and TM#7 and TM#8 in almost all the RND 
transporters. The non-TM domains from different RND transporters have been structurally 
and functionally characterised (Tsukazaki et al. 2013; Elkins & Nikaido 2002). Non-TM 
domains  were experimentally shown to contribute to substrate recognition and substrate 




binding in AcrB by loop replacement studies (Elkins & Nikaido 2002). Bacterial two hybrid 
system studies with MmpL7 cytoplasmic domains showed interaction with late biosynthetic 
enzymes involved in PDIM biosynthesis (Jain & Cox 2005). These reports implicate 
independent and diverse functional roles for non-TM domains.  
 Crystal structures of several RND transporters have been solved over the years and 
have led to a better understanding of a structure-function-relationship. These studies have 
also helped reveal important amino acid residues involved in both proton relay and substrate 
recognition and binding (Tsukazaki et al. 2013; Long et al. 2010; Yu et al. 2003; Seeger et 
al. 2009; Sennhauser et al. 2009). Most of our knowledge regarding the biochemical function 
and substrate specificity of MmpLs comes from genetic studies (Varela et al. 2012; Converse 
et al. 2003; Jain & Cox 2005; Sondén et al. 2005). No direct evidence of substrate binding or 
structural information has been reported. Structural and biophysical studies would help 
explain substrate specificity of the MmpLs and understand the mechanism of transport 
processess. Dependence of MmpLs on PMF for transport process still needs to be established 
and the amino acid residues involved are yet to be identified.  
 This chapter aims to answer some of these questions. Protein structure determination 
was one of the key aims of the project and for this; several constructs were designed using 
bioinformatics tools. Protein crystallography and cryo-electron microscopy was used to get 
structural insights of the protein. The different constructs generated were also used in 
stubstrate binding studies. Although, genetic studies have pointed that different MmpL 
protein specifically transport different substrates, the mechanism underlying substrate 
specificity is not yet known. In this project we used substrate analogues to evaluate substrate 
binding to MmpL3 protein and validated specificity of binding using specific inhibitors. 
Further, using gel permeation chromatography in combination with analytical 




ultracentrifugation, we attempted to evaluate the oligomeric status of the protein since other 
RND proteins have been shown to work as multimeric complexes. We also studied the 
mechanism underlying the transport mechanism through mutagenesis studies. Following 
section gives a detailed description of the selection of amino acid residues for mutagenesis 
and also other bioinformatics studies along with project pipeline. 
3.2 Project pipeline 
This section details the different phases of the project and describes the flow of the project. 
The initial phase of the project involved bioinformatics studies carried out in collaboration 
with Dr. Vassily Bavro (School of Bioscinces, University of Birmingham). Bioinformatics 
studies helped to establish a structural link between MmpL3 and other RND proteins. The 
available crystal structures of RND proteins were used to build MmpL3 model, which helped 
to design various constructs for biophysical and structural characterisation of MmpL3. The 
different constructs designed is schematically presented in Figure 3-3 (aminoacid sequences 
and molecular weight details in Appendix 4).  
 The different constructs designed include cytoplasmic domains (non-TM region 1- 
ML1, non-TM region 2- ML2) individually and the two cytoplasmic domains (ML) linked 
via artificial linker peptide mimicking the native spatial distance. The two cytoplasmic 
domains were linked using a linker peptide since there is no literature evidence available to 
show if these domains work individually or coherently. The rationale behind designing these 
constructs is that the cytoplasmic domains of other RND proteins and also other MmpL 
proteins have been shown to function independently. Further, the cytoplasmic domains across 
the RND family and MmpL proteins share similar structural features with a conserved folds. 
Additionally, working with large membrane protein such as MmpL3 could pose practical 




difficulties in expression and purification and hence, other possibilities using cytoplasmic 
domains were also explored. 
 RND proteins have been shown to utilise proton motive force to drive the transport 
and the amino acid residues involved in generating the proton motive studies have identified 
by mutational studies. By comparing MmpL3 model with available crystal structures of other 
RND proteins, amino acids that are likely to be responsible generating proton motive force 
were identified and mutational studies were planned to evaluate structure-function 
relationship.  
 While, early phases of the project focus on characterisation of cytoplasmic domains, 
efforts to optimise the expression and purification of full length protein was carried out 
simultaneously and was prioritised once the conditions were optimised. Thus the later stages 
of the project focus on characterisation of full length protein. Figure 3-4 outlines the flow of 
the project highlighting key points at different phases of the projects. 
 
Figure 3-3 Schematic representation of different constructs of MmpL3 used for structural and 
biophysical studies. A) Full length MmpL3 with its predicted topology, B) individual cytoplasmic domains and 
C) cytoplasmic domains linked using a peptide linker to mimick the native spatial distance. 





Figure 3-4 Flowchart of the project highlighting key points at different phases. 




3.3 Materials and Methods 
3.3.1 In silico analysis 
The gene sequence for mmpL3 was obtained from tuberculosis genome database 
(http://genolist.pasteur.fr/TubercuList/).The protein sequence alignments were done using 
blastp, two sequence alignments on (http://blast.ncbi.nlm.nih.gov/Blast). Structural homology 
studies were done by our collaborators Dr. Vassily Bavro. Topology prediction was done 
using TMpred (http://www.ch.embnet.org/software/TMPRED_form.html).   
3.3.2 Plasmids, strains and DNA manipulations 
Plasmids and bacterial strains used in this study are listed in Appendix 2. E. coli strains were 
routinely cultured in LB broth at 37°C unless mentioned otherwise. Antibiotics were added at 
following concentrations where required, ampicillin was routinely used at 100 µg/ml for E. 
coli strains and kanamycin was used at 50 µg/ml for E. coli strains unless mentioned 
otherwise. 
3.3.3 Generation of expression constructs 
The gene mmpL3 (Rv0206c) was amplified to obtain either full length, truncated or specific 
regions of the gene by PCR using M. tuberculosis H37Rv genomic DNA. The primers used 
for the amplification of the gene are listed in Appendix-3. PCR amplified products were 
purified using Qiagen gel extraction kit and digested using restriction enzymes. The digested 
PCR products were then ligated using the respective vectors also cut with same restriction 
enzymes. The ligation mix was transformed to E. coli Top10 cells as described in Chapter 7.  
The transformants were selected on antibiotic selection plates. The transformants were 
analysed for the presence of the gene of interest through restriction digestion analysis and 
confirmed through sequencing. 




To generate pET28b:ML (MmpL-Loops hereafter referred to as ML) construct, non-
TM region 1 (here after referred as ML1) and non-TM 2(here after referred to as ML2) were 
first identified using TMpred and amino acid boundaries of the region was confirmed through 
model predictions (done in collaboration with Dr. Vassily Bavro, School of Biosciences, 
University of Birmingham). The two regions were linked through flexible poly glycine-serine 
peptide linker amounting 10Å distance to mimic the native spatial distance. The fusion 
protein was then codon optimised for expression in E. coli. The gene was synthesised at 
Genscript.Inc and cloned into pET28b. 
pET41c_MmpL3-CB construct was generated  by adopting the codon alteration 
method where the  codon  at the 5’ end of the gene was altered for GC content to overcome 
possible secondary structure of the transcript that could hinder translation, a technique that 
has been successfully employed in mycobacteria (Usha et al. 2006). For this, the GC content 
in the forward primer (54mer) was optimised and full length mmpL3 is PCR amplified and 
cloned into pET41c. 
To generate pET28b: MmpL3 expression construct, mmpL3 gene was codon 
optimised for expression in E. coli and the gene was synthesised at Genscript.Inc and cloned 
into pET28b with c-terminal histidine affinity tag.  
3.3.4 Protein expression studies 
The expression constructs listed in Appendix 2 were introduced into an E. coli expression 
hosts BL21 (DE3), C41 (DE3), or Tuner cells by transformation. Recombinant strains were  
inoculated for overnight cultures (5 ml LB, 50 µg/ml kanamycin) which were fed into bulk 
medium (6 X 1L of LB, 50 µg/ml kanamycin) and grown under shaking at 37°C to A600~0.6, 
then induced with IPTG (1 mM) and incubated for further 3 hrs before harvesting the cells. 




For optimising the expression of full length MmpL3 protein, pET28b:MmpL3 was 
introduced into E. coli C41 (DE) or BL21 (DE3) cells by transformation. Recombinant 
strains were used to inoculate overnight cultures (5 ml LB, 50 µg/ml kanamycin). 25 ml LB 
containing 50 µg/ml kanamycin was aliquoted in 250 ml flasks were inoculated with 1% 
inoculums from overnight culture and incubated at different temperatures (37°C, 30°C and 
25°C) and grown under shaking to an OD600~ 0.5 then each set of cultures are induced with 
different concentrations of IPTG (10 µM, 20 µM, 50 µM, 100 µM, 250 µM and 1 mM). The 
growth was monitored over 20-36 hrs and cells were harvested at each time interval. The 
expression of the protein was monitored by Western blot.  
Western blot was performed routinely to monitor the expression levels of MmpL3 and 
purification. Anti-His IgG and anti-MBP IgG (mouse) were used as primary antibodies 
respectively against Histidine and Maltose binding protein fusion tags and anti-IgG (goat) 
coupled to alkaline phosphatase was used as secondary antibody. Nitro-blue tetrazolium and 
5-bromo-4-chloro-3’-Indolyphosphate (NBT/BCIP) was used for chromogenic visualisation.   
For overexpression of MmpL3 in M. smegmatis, pSD26: MmpL3 and pVV16: 
MmpL3 constructs were introduced by electroporation. The transformants were grown in 10 
ml TSB containing 100 µg/ml hygromycin or 25 µg/ml kanamycin at 37°C which were fed 
into bulk cultures (2 X 1L TSB, 100 µg/ml hygromycin or 25 µg/ml kanamycin) and grown 
at 37°C. The culture harbouring pSD26: MmpL3 was induced with 0.2% w/v acetamide and 
culture harbouring pVV16: MmpL3 expresses the protein constitutively. 




3.3.5 Protein purification 
3.3.5.1 Purification of non-TM regions of MmpL3 and non-TM fusion construct 
(ML1, ML2 and ML) 
Cells (10 g wet weight) were resuspended into 50 mM Tris.Cl (pH 8.0), 500 mM NaCl and10 
mM imidazole supplemented with 1 mM PMSF and Protease inhibitor cocktail (Roche) (1 
tablet/50 ml). Cells were subjected to probe sonication (MSE Soniprep 150, 12 micron 
amplitude, 20s ON, 30s OFF for 12 cycles on ice). The cell slurry was centrifuged at 27,000 
x g at 4°C for 40 min and the resulting clarified supernatant applied to a Ni
2+
NTA HiTrap 
column (GE healthcare, Amersham, UK) pre-equilibrated with 50 mM Tris.Cl (pH 8.0), 500 
mM NaCl and 10 mM imidazole supplemented with 1 mM PMSF. The column was eluted 
with 5 column volumes of equilibration buffer (5 ml) containing 10 mM, 20 mM, 40 mM, 60 
mM, 80 mM, 100 mM and 250 mM imidazole. The fractions were analysed by SDS-PAGE 
and fractions containing protein of interest were pooled and dialysed against 50 mM Tris.Cl 
(pH 8.0) and 150 mM NaCl and concentrated. The concentrated protein (1 mg/ml) is applied 
to Superdex-200 size exclusion column. The column was developed using Tris.Cl pH 8.0, 
150 mM NaCl. The fractions were collected and analysed by SDS-PAGE. The fractions 
containing protein of interest were pooled and concentrated. 
3.3.5.2 Purification of MmpL3 using SMALPs 
SMA is chemically styrene-co-maleic acid polymer that is amphipathic in nature that is used 
to extract membrane protein by encapsulating the membrane protein along with membrane 
lipid molecules. The principle and working of SMALP is schematically presented in 
Appendix 5. Cells (10 g wet weight) were resuspended into 50 mM Tris.Cl (pH8.0), 2mM 
EDTA, 5% glycerol supplemented with 1mM PMSF and protease inhibitor cocktail tablet. 
Cells were lysed by French press (10,000 psi 4 cycles). The cell slurry was centrifuged at 




10,000g at 4°C for 30 min and the resulting clarified supernatant containing the membrane 
fraction was processed further to purify the MmpL3 protein. The membrane fraction was 
separated by centrifuging at 100,000g at 4°C for 45 min. The membrane was homogenised 
into 50mM Tris.Cl pH 8.0, 500 mM NaCl, 10% NaCl supplemented with 1 mM PMSF and 
protease inhibitor cocktail tablet. The homogenised membrane was solubilised using styrene-
co-maleic acid polymers to generate SMALPs [poly (styrene-co-maleic acid) lipid particles]. 
For this 2.5% SMA polymer was added to homogenised membrane and incubated for 2 hrs at 
room temparature with gentle shaking. At the end of 2hrs the mix was centrifuged at 
100,000g for 45 min to remove insoluble debris. The supernatant was applied to a Ni
2+-
NTA 
HiTrap column (GE healthcare, Amersham, UK) pre-equilibrated with 50 mM Tris.Cl (pH 
8.0), 500 mM NaCl, 10% glycerol. The column was eluted with 5 column volumes of  
equilibration buffer (5 ml) containing 10 mM, 20 mM, 40 mM, 60 mM, 80 mM, 100 mM and 
250 mM imidazole. The fractions were analysed by SDS-PAGE and fractions containing 
protein of interest were pooled and dialysed against 50 mM Tris.Cl (pH 8.0) and 150 mM 
NaCl and concentrated. The concentrated protein (1 mg/ml) applied to a Superdex-200 size 
exclusion column. The column was eluted using Tris.Cl pH 8.0, 150 mM NaCl and the 
fractions were collected and analysed by SDS-PAGE. The fractions containing protein of 
interest were pooled and concentrated. 
3.3.6 Biophysical characterisation of proteins 
3.3.6.1 Analytical Ultra Centrifugation (AUC) 
AUC was performed to evaluate the oligomeric states of MmpL3. The experiment was 
performed at central facility using a Beckman Coulter XL ultracentrifuge. In a sedimentation 
velocity experiement sediment coefficients are calculated which depends directly on the mass 
of the particle. Briefly, the purified protein sample (0.8 mg/ml) was centrifuged at 40,000g at 




20°C using buffer as reference. The sedimentation was monitored by absorbance overnight 
and the data was analysed using Sedfit software.   
3.3.6.2 Circular Dichroism (CD) 
CD was performed using Jasco (J810) spectropolarimeter. To perform CD the protein was 
dialysed against 20 mM KH2PO4 buffer pH7.5, 100 mM NaCl and concentrated to 1 mg/ml. 
60 µl sample was taken in 0.1 mm cuvette, scanned between 280nm to 190nm and ellipticity 
was measured (in degrees). Ellipticity was plotted against wavelength to get a CD spectrum. 
3.3.6.3 Protein cross linking studies 
Protein cross linking studies were carried out using glutaraldehyde and EGS (ethylene glycol 
bis[succinimidylsuccinate]). The cross linking was done both in presence and absence of 
trehalose, trehalose monomycolate (C24) and trehalose monopalmitate. The protein (+/- 
substrate) is incubated with cross-linker and the reaction was stopped at different time 
intervels (0 to 30 min) using buffer containing amines at high pH (10µl of 1M Tris.Cl, pH 
8.0). The samples were warmed at 70°C for 2 min after adding SDS-loading dye and 
analysed on SDS-PAGE. 
3.3.7 Structural studies 
3.3.7.1 Protein crystallography 
Purified protein samples, MmpL3 non-TM region constructs and non-TM fusion protein, 
ML1, ML2 and ML proteins were concentrated to 10 mg/ml and 20 mg/ml using a centriprep 
centrifugal device at 4°C. Crystals were grown by hanging drop vapour diffusion method. 30 
µl reservoir solution was dispersed into wells and mixing 1 µl of protein with 1µl of reservoir 
solution in crystallisation wells and incubated at 18°C to facilitate crystal growth and 
monitored by observing the plate under microscope daily for a week. Different reservoirs 
were used to screen the condition for crystallisation and these include commercially available 




crystallisation screens namely, Structure Screen 1 & 2, Pact premier, JCSG, Midas, 
Morpheus, Hampton, Wizard 1 & 2 and Wizard 3 & 4. 
3.3.7.2 Protein structure studies using of Nuclear Magnetic Resonance (NMR) 
NMR was used to carry out initial studies on structural aspects of MmpL3 non-TM regions 
ML1 and ML2.  Respective constructs were transformed to E. coli C41 (DE3) cells and 
transformants were grown overnight in M9 minimal media containing 25 µg/ml kanamycin, 
which was fed into bulk cultures (2 x 1L M9 + 25 µg/ml kanamycin) and labelled with N
14
.  
Protein purification was done as described earlier. NMR experiment was done by our 
collaborator Dr. Mark Jeeves (School of Cancer Science, University of Birmingham).  
3.3.8 Ligand binding studies 
3.3.8.1 Intrensic Tryptophan Fluorescence (ITF) assay 
Intrensic tryptophan fluorescence (ITF) assay exploits the fluorescing property of tryptophan 
aminoacid which emits between 300 to 400 nm with a emission maxima at 335 nm, when 
excited at 285 nm. The emission was measured between 300 nm to 400 nm using Perkin-
Elmer Luminescence Spectrophotometer by exciting the sample at 285nm at 25°C.  Spectra 
were recorded for each addition of substrate (trehalose monopalmitate) aliquot (1 µl) added to 
500 µl of 6 µM non-TM fusion protein ML in 50mM Tris.Cl buffer pH 8.0, contanining 
150mM NaCl, until reaching the final concentration of 3 mM (15 additions) and on addition 
of known inhibitors of MmpL3 (adamantyl urea (J.R.Brown et al. 2011), BM212 (Deidda et 
al. 1998) and THPP (Remuiñán et al. 2013) compounds) for each aliquot (1 µl) added to 500 
ul of 1.5 µM MmpL3 (SMA-solubilised purified full length protein), until reaching the 
required final concentration. Data were collected using Hitachi FL Solutions 4.6 software and 
analysed in Prism 5 (Graphpad). 




3.3.8.2 TMP-BODIPY binding assay 
The substrate analogue trehalose mono palmitate tagged with fluorochrome BODIPY (boron-
dipyrromethene) was used as a substrate for binding studies.  The substrate analogue emits at 
515 nm when it is in hydrophobic environment or bound to protein on excitation at 485 nm. 
Binding of substrate analogue to ML, ML1 and ML2 was tested by recording spectra for each 
addition of substrate analogue (1 µl) to 500 µl of 6 µM protein in 50mM Tris.Cl buffer pH 
8.0, contanining 150mM NaCl, until reaching the final required concentration. Data were 
collected using Hitachi FL Solutions 4.6 software and analysed in Prism 5 (Graphpad). 
3.3.9 Site directed mutagenesis 
Site directed mutagenesis was performed using Q5 site directed mutagenesis kit and was 
done according to manufacturers recommendations. The primers were designed using 
NEBaseChanger
TM 
program (http://nebasechanger.neb.com/). Briefly, pMV261 
(apra):MmpL3 was amplified using primers carrying desired base change followed by 
removal of parental DNA from the mix using DpnI. The plasmid DNA carrying the mutation 
is transformed into E.coli NEB5-α strain. Plasmids isolated from transformants and 
sequenced to confirm the mutation. 
3.3.10 Fermentation 
pET28b:MmpL3 was introduced into E. coli BL21 (DE3) cells by transformation and 
transformants were inoculated (250 ml LB, 50 µg/ml kanamycin) prepare inoculum for 
initiating the fermentation. Fed batch fermentation was carried out in a Infors fermentor (3 L 
capacity) feeding inoculum into 2.5 L of LB supplemented with 1% glucose, 50 µg/ml 
kanamycin and 0.5 ml/L antifoam (25°C, 300rpm, pH 7.0). Protein expression was induced at 
A600~0.4 with IPTG and culture was fed with feeding medium (10X LB containing 500 




µg/ml kanamycin and 20% glucose, 10 ml/hr) for 20 hrs at the end of which the cells were 
harvested. 
3.4 Results 
3.4.1 MmpL3 bioinformatics studies 
The bioinformatics studies were carried out in collaboration with Dr. Vassily Bavro, School 
of Biosciences, University of Birmingham. Although, MmpL proteins have been catagorised 
into RND family of proteins, no comprehensive studies was carried out. Our colloborators, 
compared sequence of MmpL3 protein to other RND protein sequences from different 
organisms. The sequence comparision studies did not show significant similarity, however 
shared a structural similaty.  Our colloborators built a homology model by threading the 
aminoacid sequence through available crystal structures of other RND proteins, namely AcrB 
(1OY6.pdb) (Yu et al. 2003) from E. coli, MexB (2V50.pdb) (Sennhauser et al. 2009) from 
P. aeureginosa, and CusA (4DOP.pdb) (Su et al. 2012) from E. coli. Structural homology 
comparisions revealed few unexpected informations. While, as expected transmembrane 
regions aligned tightly, cytoplasmic domains exhibited variance in alignement, a detailed 
study, suggested a common fold shared among all the RND proteins (Figure 3-5). The 
variance in the cytoplasmic domains comes from insertions at different places in different 
protein and in some cases due to duplication of cytoplasmic domain as in AcrB. These 
Cytoplasmic domains have been shown to be involved in substrate recognition and substrate 
binding (Tsukazaki et al. 2013; Long et al. 2010; Yu et al. 2003; Seeger et al. 2009; 
Sennhauser et al. 2009). This prompted to us to evaluate the functional role of cytoplasmic 
domains in MmpL3 by constructing aforementioned cytoplasmic domain construct (detailed 
earlier in section 3.2).  





Figure 3-5 Schematic depiction of general topological structure of RND family of proteins and their non-
TM domains. (A) Topology of MmpL3 compared to other known RND transporter proteins shows a shared 
general architecture, (B) non-TM domain organisation in MmpL3, SecDF(with P4 domain), CusA (with L1-
extension) and AcrB (sub-domains 1 and 2 in each of the non-TM domains) proteins, (C) genreal fold of non-
TM domains showing mixed α-β arrangements and (D) variations in the general fold due to insertions in 
different RND transporter non-TM region-1 (L1) and non-TM region-2 (L2). ML1 and ML2 correspond to non-
TM region-1 and non-TM region-2 respectively. 




Structural predictions of MmpL3 supported earlier reports suggesting that MmpL3 
belongs to the RND family of proteins and  recently MmpL3 was shown to use proton motive 
force (PMF) as the energy source for its activity (Yang et al. 2014). Comparing the MmpL3 
structure prediction with available crystal structures of other RND transporters helped us to 
predict residues that are likely to be involved in generating a proton-motive force (Tsukazaki 
et al. 2013; Seeger et al. 2009). The amino acid residues that generate proton motive force 
resides on transmembrane helices TM#4 and TM#10 which aligns closely in 3-D space. The 
two negatively charged aspartate residues (D407, D408) on TM#4 facing a positively charged 
Lysine (K940) constitutes proton relay pump in AcrB. MmpL3 has a single aspartate residue 
(D251) on TM#4 in the same position however; do not possess a counter charged Lysine or 
arginine residue. However, it does possess two negatively charged glutamate residues (E262, 
E263), slightly lower on the TM#4 with a positively charged arginine (R653) on the TM#10, 
and is identical to one observed in SecDF proton pump (E351, E352 on TM#4 and R644 on 
TM#10). However SecDF also has another positively charged arginine (R671) on adjacent 
TM#11 which is not present in MmpL3. This prompted us to generate site directed mutants of 
these residues (I250T, Y252A, Y252D, D251A, E262A and R653A) to test whether these 
mutations affect proton relay and there by the transport of mycolic acids. 
 
Figure 3-6 Schematic representation of transmembrane regions involved in proton relay. Residues 
involved in proton relay are indicated; acidic residues indicated in red and positively charged amino acids in 
blue. Transmembrane helices are indicated above. 




3.4.2 Expression and purification of non-TM constructs 
Non-TM domains were expressed and purified individually for structural and biophysical 
studies. ML constructs (ML-CHIS and ML-NHIS) were expressed in E. coli C41 (DE3). Figure 
3-7 shows the expression of ML constructs (ML-CHIS and ML-NHIS). ML CHIS protein was 
purified using Immobilised Metal Affinity Chromatography (IMAC) and was further purified 
using ion exchange chromatography (Figure 3-8). The purified protein was used for further 
biophysical and structural studies. ML-NHIS protein was purified using affinity 
chromatography (Figure 3-9). Protein purified to homogeneity was used for structural studies. 
 
Figure 3-7 SDS-PAGE analysis of expression of ML. ML was expressed in E. coli C41 (DE3) cells and 
analysed by SDS-PAGE. Both NHIS and CHIS constructs expressed the protein significantly (indicated by 
arrows). 
 
Figure 3-8 SDS-PAGE analysis of purification of ML-CHIS using affinity and ion-exchange 
chromatography. ML was first purified using Ni
2+
-NTA column (A) and fractions containing pure protein (60 
mM-100 mM fractions) were concentrated and dialysed against buffer containing no salt. Dialysed protein was 
then purified using ion-exchange column developed using NaCl gradient (B), fractions containing pure protein 
(0 mM to 125mM fractions) were pooled, concentrated and used in downstream activities.  





Figure 3-9 SDS-PAGE analysis of expression of ML construct and purification of ML-NHIS protein using 
affinity chromatography. Fractions containing (40 mM to 150 mM fractions) pure protein were pooled, 
concentrated and dialysed. Purified protein was used for further structural studies. 
Non-TM domains ML1 and ML2 were also expressed in E. coli expression strain C41 
(DE3) as both NHIS and CHIS constructs. Both the constructs for ML1 expressed the protein 
significantly while only ML2-NHIS expressed protein significantly (Figure 3-10). ML1 and 
ML2proteins were purified using IMAC as described previously. Fractions containing protein 
of interest (Figure 3-11, Figure 3-12) were pooled, concentrated and dialysed for use in 
downstream biophysical and structural studies.   
 
Figure 3-10 SDS-PAGE analysis of expression of ML1 and ML2. ML1 and ML2 were expressed in E. coli 
C41 (DE3) cells and analysed by SDS-PAGE. Both NHIS and CHIS constructs for ML1 expressed significantly 
(indicated by arrows) while only NHISconstruct of ML2 expressed significantly (indicated by arrow). 





Figure 3-11 SDS-PAGE analysis of purification of MmpL3 non-TM domain ML1-NHIS and ML1-CHIS 
using affinity chromatography. ML1-NHIS was purified using Ni
2+
-NTA column (A) and fractions containing 
pure protein (60 mM-80 mM fractions) were concentrated and dialysed for downstream usage. ML1-CHIS was  
also purified using Ni
2+
-NTA column (B) and fractions containing pure protein (80 mM-100 mM fractions) 
were concentrated and dialysed for downstream usage. 
 
Figure 3-12 SDS-PAGE analysis of purification of MmpL3 non-TM domain ML2-NHIS using affinity 
chromatography. ML2-NHIS was purified using Ni
2+
-NTA column and fractions containing pure protein (100 
mM fraction) was concentrated and dialysed for downstream usage. 
 




3.4.3 Structural and biophysical characterisation of MmpL3 non-TM domains 
3.4.3.1 Size exclusion chromatography 
One of the key aims of the study was to decipher the oligomeric states of the protein. 
Towards this, size exclusion chromatography (SEC) was used to study oligomeric states of 
the ML-CHISprotein. The oligomeric state of the protein was predicted with the help of 
molecular weight standards corresponding to 30 kD and 60 kD (Appendix-3). The results 
(Figure 3-13) suggested that ML protein eluted as a single peak but over a range that 
corresponded to 30 kD and 60 kD, which means the protein could be a mix of monomer and a 
dimer but could not interpret confidently. 
 
Figure 3-13 Size exclusion chromatogram of ML-CHIS. ML chromatogram from size exclusion 
chromatography showing single peak corresponding to a mix of monomer and a dimer, analysis of protein by 
SDS-PAGE shown in the insert below. 
 
3.4.3.2 Protein cross linking studies 
Chemical cross linking of proteins in solution has been previously used to study the subunit 
stoichiometry of oligomeric proteins (Davies & Stark 1970). Oligomeric states of the protein 




could not be deciphered conclusively using SEC and thus decided to follow up with protein 
cross linking studies and analytical ultracentrifugation studies. Chemical cross-linking agents 
glutaraldehyde and EGS (Ethylene glycol bis[succinimidylsuccinate])were used to test the 
oligomeric states of ML-CHIS. The cross linking experiments with both glutaraldehyde 
(Figure 3-14, A) and EGS (Figure 3-14, B) suggested that a small fraction of the protein 
readily gets cross linked to form higher oligomers while a large fraction of the protein remain 
as monomers.  It was also observed that the cross linking slightly improves in the presence of 
its cognate substrate TMM and trehalose (Figure 3-14, C). However, since the bands of 
monomeric protein were not depleting either with increasing concentration of cross linker or 
with increasing incubation time, we could not clearly establish the oligomeric states of the 
protein.  
 
Figure 3-14 Chemical cross linking of ML to study oligomeric states of the protein. Protein crosslinking 
with glutaraldehyde revealed that higher oligomers were formed with increase in concentration of cross-linking 
agent (A) and results were reproducible with a different chemical cross linker (B). Further, extent of cross-
linking improved in the presence of its cognate substrate TMM and trehalose (C), suggesting that a small 
fraction of the protein readily gets oligomerised. Oligomers are indicated with arrows 1-monomer, 2-dimer and 
3- higher oligomers. 





To get conclusive data on oligomeric status of the protein, AUC was performed with ML, 
ML1, ML2 and a stoichiometric mix of ML1 and ML2. Analysis of the AUC data revealed 
that ML1 and ML2 exist as monomers and a stoichiometric mix of ML1 and ML2 does not 
oligomerise. ML gives significantly sediments as two distinct species corresponding to 30 kD 
and 61 kD, respectively, which represents monomeric and dimeric species of ML (Figure 
3-15). However, a large fraction of the protein behaves as monomer while only a small 
fraction forms dimer. This corroborates earlier observations made using protein cross-linking 
reagents. 
 
Figure 3-15 Analytical ultra centrifugation of MmpL3 non-TM domain constructs ML1, ML2 and ML. 
Analytical ultracentrifugation reveals that ML1, ML2 behaves as monomers (left) and ML, mainly exists as 
monomer but a small fraction behaves as dimer (right). 
 
Table 3-1 Analytical ultra centrifugation data 
  ML1 ML2 ML1+ML2 ML 
Frictional ratio 1.422982 1.493157 1.390529 1.95 
Rmsd 0.015109 0.025853 0.009866 0.0151 
Mr (kDa) (from 
analysis) 
  
21.7 16.66 26.7 30.6 
      61.2 
 




3.4.3.4 Protein crystallography 
MmpL3 non-TM domain constructs ML, ML1 and ML2 proteins were purified to 
homogeneity and were used to set up crystal trays (Hanging drop trays) using commercially 
available crystal screens. After screening several conditions for each protein only ML-CHIS 
produced crystals in 0.1 M Bis.Tris propane buffer pH 8.5, 0.2 M NaF and 20% w/v 
PEG3350.  The crystal however did not diffract and our attempts to reproduce crystallisation 
or to optimise conditions to grow fresh crystals were not successful. Repeated efforts to 
obtain ML1 and ML2 crystals were unsuccessful. Stoichiometric mixtures of ML1 and ML2 
were also used for protein crystallisation; however different stoichiometric mixtures did not 
produce any crystals.  
3.4.3.5 Protein-NMR to resolve the structure of ML1 and ML2 
Our collaborators Dr. Mark Jeeves (School of Cancer Sciences, University of Birmingham) 
did initial studies with [
15
N] labelled ML1 and ML2 using NMR. ML could not be used in 
this studies due to size limitation (>20kD). Initial studies revealed that the ML1 showed  
peaks corresponding to random coils and β sheets andML2 showed peaks corresponding  to β 
sheets with very little random coil. This bodes well with our predictions where ML1 at both 
insertion points shows large unstructured/randomly coiled structures but ML2 is more 
compact without such random coils. However this requires further NMR studies which could 
also help us solve the structures of ML1 and ML2.   
3.4.3.6 Ligand binding studies 
ITF exploits the spectral properties of aromatic amino acid residue tryptophan in proteins. 
Tryptophan emits with a emission maxima of 340nm when excited at 295nm. Ligand binding 
affects the fluorescence either by increasing or decreasing the intensity and/or causing shift in 
emission maxima. Our initial efforts to study substrate binding studies with trehalose, part of 




its cognate substrate TMM, gave very little evidence to show substrate binding. Change in 
fluorescence was equally affected in the presence and absence of the substrate. 
 
Figure 3-16 Ligand binding assay using ITF. Binding of trehalose to ML protein was evaluated by monitoring 
intrinsic tryptophan fluorescence. Increasing concentrations of trehalose did not affect the change in 
fluorescence significantly. 
To further evaluate substrate binding we have used fluorophore bound substrate 
analogue TMP-BODIPY (trehalose monopalmitate-boron dipyrromethane). TMP-BODIPY 
emits strongly at 515 nm when it is in hydrophobic environment or when bound to protein.  
Binding of TMP-BDIPY to ML was evaluated by monitoring fluorescence at 515 nm. 
Inhibitors previously shown to affect mycolic acid transport such as SQ109, BM212, 
adamantyl urea, Spiro (410A) and THPP (366A) were used to validate the assay and to 
evaluate the specificity of binding. Binding of TMP-BODIPY was inhibited by only selected 
compounds (410A and adamantyl urea) suggesting that binding of TMP-BODIPY is specific 
(Figure 3-16). 





Figure 3-17 Ligand binding evaluation using TMP-BODIPY fluorescence assay. Known inhibitors of 
mycolic acid transport were used to validate the specificity of the assay. Only adamantyl urea (C) and 410A (F) 
were shown to affect TMP-BODIPY binding to ML, however other inhibitors SQ109 (B), THPP-366A (D) and 
BM212 (E) did not affect the binding of TMP-BODIPY to ML. 
 
While characterising the non-TM regions of MmpL3, alternative attempts were made 
to optimise the expression of full length MmpL3. At this stage decision was made to pursue 
with the characterisation of full length protein which will be described in the following 
sections. 
 
3.4.4 Expression and purification of full length MmpL3 
For optimising the expression of full length MmpL3 protein, MmpL3 constructs (CHIS 
construct and NHIS construct) were expressed in E. coli expression strains C41 (DE3) and 




protein expression was induced with 1 mM IPTG. Western blot analysis revealed that 
MmpL3-CHIS construct expressed better than MmpL3-NHIS construct, however the level of 
expression was very low and equally distributed between soluble and insoluble fraction.  To 
optimise the expression levels, protein expression was induced at different temperatures 
(37°C, 25°C and 16°C) and best expression was seen at 37°C (Figure 3-18).  MmpL3-
CHISconstruct was used for further studies. 
 
Figure 3-18 Western blot analysis of expression of MmpL3 protein. MmpL3 protein expressed in E. coli 
strain C41 (DE3) at different temperatures 37°C, 25°C and 16°C. MmpL3-CHIS has expressed atlow quantities at 
37°C but expression was not detected at lower temperatures (A) but MmpL3-NHIS construct did not express 
protein at any temperatures tested. Analysed samples include whole cell lysate, pellet and supernatant (CL) from 
10,000 x g spin. Protein of interest indicated with an arrow. 
 
The presence of divalent cations in the growth media was shown to improve the 
soluble expression of proteins in E. coli (White S A. School of Biosciences, University of 
Birmingham, unpublished data). MgCl2 was used at a concentration of 2mM and 10mM as a 
supplement in the growth media to improve the solubility of protein. A parallel expression 




study was done in alternative growth media (Terrific broth) to test for improved protein 
expression. However, presence of MgCl2 did not have the desired results and MmpL3 
solubility was not improved (Figure 3-19). Use of Terrific broth as an alternative growth 
media did not improve the protein expression significantly either. 
 
Figure 3-19 Western blot analysis of MmpL3 expression in the presence of cations. MmpL3 protein 
expressed in E. coli strain C41 (DE3) in the presence of MgCl2 (lanes 1-6). MmpL3-CHIS expressed atlow 
quantities but protein was found in pellet fraction due to lack of soluble expression. Use of different media was 
not very helpful for soluble expression (lanes 7 to 9). 
 
A codon alteration strategy which optimises the GC content at the 5’ end of the gene 
which helps to ease the secondary structure formed in the transcript and thereby  facilitates 
better expression of the protein was adopted (Usha et al. 2006). For this, mmpL3 gene was 
PCR amplified using codon altered primers (Figure 3-20) and sub-cloned into pET41c. 
pET41c: MmpL3 (CB) was transformed into E. coli C41 (DE3) cells for expression studies. 
Protein expression experiment was done under the earlier described conditions. Western blot 











Figure 3-20 Codon alteration strategy used to optimise the expression of MmpL3. Codoon alteration 
strategy used to optimise GC content at the 5’ end of the gene.  Native sequence of the mmpL3 gene (A) and 
altered gene sequence (B) highlighting altered nucleotide residues in colour, used for priming PCR amplification 
of mmpL3 
 
Figure 3-21 Western blot analysis of MmpL3 expression from codon altered construct. MmpL3 protein 
expressed in E. coli strain C41 (DE3) using codon altered construct. Protein expression was not significant and 
expected band size is indicated with an arrow. 
 
One well known strategy to improve the expression of recombinant protein, is the use 
of alternate tags that may alter the solubility (Maina et al. 1988; Tropea et al. 2007; Smith & 
Johnson 1988).  We have used a maltose binding protein and glutathione S-transferase as 
fusion tags to improve protein expression and solubility. For this we cloned MmpL3 into 
pMALp2X and pGEX-4T-1 expression vectors for expression in E.coli C41 (DE3). Western 
blot analysis of expression revealed that fusion tag did not express the protein at detectable 
levels (Appendix-7). 




Mycobacterial chaperones Cpn60.1 and Cpn60.2 have previously been shown to 
improve solubility of proteins when co-expressed in E. coli(Henderson et al. 2010; Batt et al. 
2012). We have co-expressed MmpL3 with Cpn60.1 and Cpn60.2 in an effort to enhance 
solubility and improve protein yields. Co-expression with either Cpn60.1 or Cpn60.2 did not 
result in detectable level of expression of MmpL3.  
Codon optimisation has long been used to improve the expression of recombinant 
proteins in E. coli (Grosjean & Fiers 1982).  To investigate whether codon optimisation 
would improve the expression of MmpL3, the gene was codon optimised for expression in E. 
coli (synthesised from Genscript.Inc) and cloned into the pET28b expression vector with a C-
terminal His-tag. Expression studies were done as described earlier using E. coli C41 (DE3) 
strain. SDS-PAGE analysis followed by Western blot analysis using anti-His antibody 
showed improved expression of MmpL3 which allowed purification of MmpL3. 
Most methods of membrane protein purification involve the use of harsh conditions 
such as the use of detergents. We employed a SMA polymer previously described for the 
purification of membrane proteins from their native environment (Jamshad et al. 2011). The 
MmpL3 protein was purified using the SMA polymers that encapsulate the membrane protein 
along with the surrounding membrane. The MmpL3 was purified from solubilised membrane 
fraction (Section 3.3.5.2) using affinity chromatography. Purified fractions were analysed by 
SDS-PAGE and Western blot (Figure 3-22). Fractions containing MmpL3 were pooled, 
concentrated to 1 mg/ml and purified further using a size exclusion column (Figure 3-23). 
The purified protein was concentrated using Amicon centriprep (GE Amersham) and used for 
subsequent biophysical characterisation. 





Figure 3-22 Purification of SMA solubilised MmpL3 using affinity chromatography. Codon optimised 
MmpL3 was expressed in E. coli strain C41 (DE3) and purified using affinity chromatography, analysed by 
SDS-PAGE (A) and confirmed by Western blot analysis of the same showing purified MmpL3-CHIS (B). Protein 
of interest is shown with an arrow. 





Figure 3-23 Further purification of SMA solubilised MmpL3 using Size exclusion chromatography. 
MmpL3 partially purified using affinity chromatography was further purified using size exclusion 
chromatography. Purified fractions were analysed by SDS-PAGE (A) and confirmed by Western blot (B). 
Protein of interest is shown with an arrow. 
 
3.4.5 Biophysical characterisation of MmpL3 protein 
3.4.5.1 Size exclusion chromatography 
SMA solubilised MmpL3 purified to homogeneity, was evaluated using size exclusion 
chromatography, as an analytical tool to evaluate the oligomeric status of MmpL3.The 
protein distributes into two peaks across 20ml fractions when analysed usingWestern blot 
analysis (Figure 3-24). This suggests that MmpL3 exists in at least two oligomeric states. 
These fractions were subjected to AUC to ascertain their oligomeric status. 





Figure 3-24 Size exclusion chromatogram for MmpL3. MmpL3 chromatogram  reveals distribution of two 
peaks corresponding to different oligomeric states of the protein and Western blot analysis of fractions 
corresponding to peaks shown below in the insert. 
 
3.4.5.2 AUC 
One of the key aims of the study was to evaluate the oligomeric status of the MmpL3 which 
would help examine the similarities drawn with RND proteins. Other RND proteins exist in 
higher oligomeric states (Long et al. 2010; Murakami et al. 2002; Sennhauser et al. 2009).  
To determine the oligomeric status of the protein, purified MmpL3 fractions from size 
exclusion chromatography were subjected to AUC. Sedimentation velocity experiment data 
was analysed using SedFit software and revealed that MmpL3 distributes into two distinct 
species (Figure 3-25) that correspond to a dimer (221kDa) and the other corresponding to a 
tetramer (395kDa). This result corroborates the earlier results obtained with the MmpL3 non-
TM domain fusion protein (ML).    





Figure 3-25 Analytical ultra centrifugation of MmpL3. SMA solubilised MmpL3 was purified to 
homogeneity and subjected to analytical ultracentrifugation which revealed that MmpL3 exists in two distinct 
oligomeric states that corresponds to dimer (221 kD) and a small fraction exist as tetramer (395 kD). 
 
Table 3-2 Analysis of analytical ultra centrifugation data 
  MmpL3 (SMA solublised) 
Friction Ratio 1.50 
Rmsd 0.007567 
Mw 395 kDa 
Mw 221 kDa 
 
3.4.5.3 Circular Dichroism 
Heterologous and overexpression of proteins often leads to inappropriate folding of proteins, 
formation of inclusion bodies and protein aggregation (Baneyx & Mujacic 2004). Although, 
SMA encapsulates membrane proteins from its native environment, it does not give 
conclusive evidence concerning protein folding. Circular Dichroism (CD) has long been used 
to study secondary structural features of protein and to get insights into protein folding. UV-
CD (ultra violet circular dichroism) exploits the spectral properties of mainly peptide bonds 




at near UV regions to get insights into protein folding (Kelly et al. 2005).  Thus, CD was 
employed to study folding of SMA solubilised MmpL3.  CD spectra (Figure 3-26) revealed 
that that protein gave negative ellipticity at 222 nm and 208 nm and a positive ellipticity at 
193 nm, suggesting that MmpL3 mainly consists of α-helical structures, a characteristic 
feature of transmembrane proteins (MmpL3 has twelve transmembrane helices) and 
implicates that the secondary structure of the protein is intact. Signals that correspond to 
disordered protein (very low ellipticity at 210 nm and negative ellipticity at 193 nm) were not 
observed suggesting proper folding of the protein (Greenfield 2006).  
 
Figure 3-26 CD spectra of MmpL3. SMA solubilised MmpL3 folding was examined by using CD which 
revealed a negative ellipticity at 222 nm and 208 nm and a positive ellipticity at 193 nm typical of α-helical 






















3.4.5.4 Cryo electron microscopy (Cryo-EM) 
Another key aspect of this study was to obtain a crystal structure of the protein. However, 
MmpL3 could not be expressed in sufficient quantities to set up protein crystallisation trays. 
Thus, alternative tools to get this structural insight were sought. Cryo-EM was previously 
used to obtain low resolution structural data for proteins which are difficult to crystallise, 
such as the mycobacterial FAS-I complex (Boehringer et al. 2013). Cryo-EM also helps to 
validate model predictions and thus is a valuable tool for the study of protein structures.  
Cryo-EM studies were carried out in collaboration with Prof. Tim Dafforn, School of 
Biosciences, University of Birmingham. Data collection and analysis were performed by Dr. 
Sarah Lee, School of Biosciences, University of Birmingham and a MmpL3 model was built 
by Dr. Vassily Bavro and Dr. KlausFutterer , School of Biosciences, University of 
Birminghm. 
 Preliminary data analysis (Figure 3-27) indicates that the envelope could 
accommodate two molecules of predicted MmpL3 model, suggesting a dimeric status of the 
protein. This conclusively corroborates similar observations made with other experiments. A 
detailed analysis of the data will help us gain more structural information of the protein. 
 
 





Figure 3-27 The reconstituted particle of MmpL3 from cryo-electron microscopy.  MmpL3 model built on 
CusA template and fitted into the cryo-EM density. Lateral view of the fitted cryo-EM model shows 
arrangement of transmembrane regions and the two non-TM domain regions (ML1 and ML2) accommodated at 
the top (A) and view from top (on the left, B) and view from the bottom (on the right, B). Two molecules of 
MmpL3 are colour coded to highlight the dimeric state. 
 
3.4.5.5 Ligand binding studies 
ITFassay was employed to test ligand binding. The natural substrate of MmpL3, TMM and 
known inhibitors of MmpL3-adamantyl ureas, BM212, THPP, Spiro compounds were used 
as ligands. However, it was difficult to interpret the binding data since the protein 
encapsulated in SMALP contains hydrophobic membrane components which contributed to 
the change in fluorescence observed. Thus we could not conclusively differentiate between 
specific and non-specific binding.  




1-Anilinonaphthalene-8-Sulfonic acid (1,8 ANS) was used to design an alternative  
competition  binding assay. ANS is a amphiphilic dye that strongly fluoresces when exposure 
to water is lowered or in other words when in a hydrophobic environment. The assay was 
designed to monitor the decrease in fluorescence upon its displacement by ligands. However 
the hydrophobic environment contributed by membrane components resulted in no change in 
fluorescence even at high concentrations of ligand.  
3.4.6 Optimisation of fermentation conditions for increasing protein yield for 
structural studies 
To carry out structural studies using X-ray crystallography, we needed higher amounts of 
protein to set up crystal trays and to optimise conditions for crystal growth. We have initially 
tried to achieve this by bulk culturing (up to 12 L in shake flasks), however the protein 
induction across several flasks was not consistent along with batch to batch variation. Thus 
we sought to use fermentation for homogenous induction of protein in large volumes. To 
achieve this, we first optimised growth conditions in a shake flask experiments and later tried 
to extrapolate into fermentor system. Cell density, protein expression and plasmid retention 
were monitored through the optimisation process to estimate the protein yield. 
Earlier described conditions were used as a starting point for optimisation for 
fermentation. As it was previously described, protein expression in E. coli C41 (DE3) cells 
was better when induced with 1mM IPTG. However, plasmid retention was quite low at ~ 
15%. Thus even though cell density could reach as high at ~ 4.0 at OD600nm, protein yield 
was very low. Thus, to increase the plasmid retention a range of IPTG concentrations were 
tried. C41 (DE3) cells transformed with MmpL3-CHIS expressing plasmid were grown at 
37°C to an OD600 of 0.5 and induced with 10 µM, 50 µM, 250 µM and 1 mM IPTG. Cells 




were harvested at the end of 1 hr, 2 hrs, 4 hrs and overnight induction and analysed for 
protein expression (Figure 3-28).  
 
Figure 3-28 Western blot analysis of MmpL3-CHIS over-expression and growth kinetics of MmpL3-CHIS 
expressing cells.Western blot analysis of MmpL3 expression in E. coli C41 (DE3) cells monitored until 20 hrs 
after induction (A) Growth kinetics of MmpL3 expressing cells compared with WT C41 (DE3) cells (B). Best 
expression was observed after overnight induction however the plasmid retention was very low coupled with 
lower overall growth. Protein of interest is indicated with an arrow. 
These expression conditions were not optimal for higher protein yield due to very low 
plasmid retention and low expression levels. C41 (DE3) cells have very tight regulation of T7 
promoter which could explain low expression levels. Thus we used the BL21 (DE3) strain, 
where the T7 promoter is less tightly regulated, which allows better expression of protein. 
BL21 (DE3) cells transformed with MmpL3-CHIS expressing plasmid were grown at 25°C (to 
slow the growth and expression of protein) to an OD600 of 0.4 and induced with 50 µM, 100 
µM, 250 µM and 1 mM IPTG. Cells were harvested at the end of 10 hrs, 12 hrs, 14 hrs, 16 




hrs, 18 hrs and 20 hrs of induction and analysed for protein expression and grown kinetics 
(Figure 3-29). 
 
Figure 3-29 Western blot analysis of MmpL3-CHIS over-expression and growth kinetics of MmpL3-CHIS 
expressing cells. Western blot analysis of MmpL3 expression in E. coli BL21 (DE3) cells monitored until 20 
hrs after induction (A) Growth kinetics of MmpL3 expressing cells compared with WT BL21 (DE3) cells (B). 
Best expression was observed after 14-16 hrs induction however the plasmid retention was still low but the 
overall growth was similar to WT BL21 (DE3) cells. Protein of interest is indicated with an arrow. 
 
MmpL3 was expressed well at 250 µM and at 1 mM it was only marginally better. 
Cell density was optimum as well however plasmid retention was poor suggesting protein 
yield would be quite low. Thus we had to further optimise the conditions to improve protein 
yield (Figure 3-30).  We reduced the [IPTG] concentration for induction and started 
harvesting the cells 2 hrs after induction as opposed to 10hrs after induction.  The growth and 
induction temperatures were not changed. 





Figure 3-30 Western blot analysis of MmpL3-CHIS over-expression and growth kinetics of MmpL3-CHIS 
expressing cells. Western blot analysis of MmpL3 expression in E. coli BL21 (DE3) cells monitored until 20 
hrs after induction (A) Growth kinetics of MmpL3 expressing cells compared with WT BL21 (DE3) cells (B). 
Best expression was observed after 6 hrs of induction with 100 µM IPTG, also plasmid retention was high. 
Protein of interest is indicated with an arrow. 
 
Low [IPTG] concentrations improved plasmid retention drastically up to 85-90% and 
a moderate cell density of ~ 3.5 OD600 (cell mass ~ 0.75 dry weight/L) which resulted in 
better expression of protein. Since, these conditions resulted in optimum cell density, plasmid 
retention and protein expression, we have used these conditions for scaling up in a fermentor.  
Initial results from fermentation were encouraging in terms of protein expression. 
However, plasmid retention was very low (25%) even when induced with 25 µM [IPTG].  
Further optimisation for plasmid retention was required. We compromised on protein 
expression level and reduced the [IPTG] concentration to 8 µM, which resulted in better 
plasmid retention with a slight decrease in expression levels but compensated by better cell 
density. MmpL3 was purified (Figure 3-32) using SMA solubilisation method described 




earlier, from cells harvested from fermentation. Protein yield has increased 4 folds from 0.5 
mg/L to 2 mg/L. 
 
Figure 3-31 Growth kinetics of E. coli BL21(DE3) expressing MmpL3 in a fed batch fermentor. Time 
point 0 represents induction with 8 µM IPTG and red triangle indicating the initiation of feeding. 
 





Figure 3-32 SDS-PAGE analysis of purification of MmpL3-CHIS from fed-batch fermentation. MmpL3 
was solubilised using SMA and purified using first, affinity chromatography (A) and later using SEC (B). 
Protein of interest is indicated with an arrow. 
 
3.4.7 Site directed mutagenesis 
Our model predictions established the similarities between MmpL3 and other RND 
transporter proteins. Recent reports suggest that MmpL3, like other RND transporter proteins 
depend on proton motive force (Yang et al. 2014). Amino acid residues that participate in 
proton relay have been identified in other RND transporters AcrB and SecDF  (Tsukazaki et 
al. 2013; Seeger et al. 2009). MmpL3 model predictions have helped us identify amino acid 
residues that are likely to participate in a proton relay or affect proton relay (Figure 3-6).  
Aspartatic acid (D408) on TM4 facing lysine (K940) on TM10 forms a proton relay 
pump in AcrB and similarly aspartic acid (D340) on TM4 facing arginine (R671) on TM11 




forms a proton relay pump in SecDF (Thermus thermophilus). We have looked at similar 
regions on MmpL3 to find D-R or D-K pairs. We found D251 on TM4 but positively charged 
amino acid was not in close proximity to form a proton relay pump. Interestingly, further 
down in the same transmembrane helix (TM4) we found a glutamate (E262) residue facing an 
arginine (R653) from the neighbouring transmembrane helix (TM10). These residues were 
mutated to study structure function relationship. The mutations carried out involved I250T, 
D251A, Y252A, Y252D, E262A and R623A. 
To test the functionality, mmpL3 was cloned into the mycobacterial vector pMV261 
(apra) and mutations were carried out using Q5 site directed mutagenesis kit. The mutant 
constructs were introduced into aM. smegmatis conditional mutant ∆mmpL3 generated 
previously (Varela et al. 2012). The ability of the mutant constructs to complement MmpL3 
function in the absence of acetamide was monitored.  
We were successful in generating all six mutants (I250T, Y252A, Y252D, D251A, 
E262A and R653A), but could only test three mutants (I250T, Y252A and Y252D) in a 
survival experiment. I250T andY252A mutations did not significantly affect the function of 
MmpL3, but the Y252D mutation slightly affected the growth rate, although did not abolish 
the growth. The result suggests that the tested amino acid changes might not play a vital role 
in generating a proton motive force (Figure 3-33). 
 





Figure 3-33 Functionality analysis of MmpL3 site directed mutants. Functionality analysis of MmpL3 in 
∆mmpL3 strain through complementation studies using WT MmpL3 (A), MmpL3-I250A (B), MmpL3-Y252A 
(C) and MmpL3-Y252D (D). 
 
3.5 Discussion 
M. tuberculosis consists of family of proteins known as MmpLs that are involved in the 
transport of complex lipid molecules across the membrane (Varela et al. 2012; Reed et al. 
2004; Cole et al. 1998; Converse et al. 2003; Sondén et al. 2005). These MmpL proteins 
belong to the RND superfamily of proteins, characterised by twelve transmembrane helices 
and 2 non-transmembrane domains (Murakami et al. 2002; Tsukazaki et al. 2013). Twelve 
such MmpLs are found in M. tuberculosis of which only mmpL3is shown to be essential for 
viability (Domenech et al. 2005; Varela et al. 2012), thus is a target of several anti-TB drugs 
(Tahlan et al. 2012; La Rosa et al. 2012; Grzegorzewicz et al. 2012; Remuiñán et al. 2013). 
In recent years, MmpL3 has emerged as an important drug target for these reasons and 
structural studies would help advance MmpL3 as a drug target. No structural information 




isavailable for the MmpL family of proteins either from mycobacteria or from related species. 
In this chapter, some of the structural and mechanistic features have been revealed. 
 Recently, non-TM domains of these MmpL proteins have been shown to interact with 
late biosynthetic enzymes to form scaffolds assisting in transport of target lipid molecules 
suggesting their functional role (Jain & Cox 2005). Previously, non-TM regions from other 
RND proteins were shown to form independent, properly folded globular domains (Tsukazaki 
et al. 2013). Our model prediction studies revealed that these non-TM domains have a 
conserved motif across the superfamily, each domain consisting of four β-strands flanked by 
two α-helices (Figure 3-3 D). The two domains are homologous and come together to form a 
pseudo-symmetrical 8-stranded anti-parallel β-sheet structure (Tsukazaki et al. 2013). This 
lead us to design the ML constructs (fusion of two non-TM regions with an artificial linker 
peptide mimicking the native special arrangement) to study structural and biophysical 
properties. Although we could not obtain the crystal structure, the biophysical properties shed 
some light on its structural features. Protein cross-linking andAUC suggests a tendency to 
form dimers and higher oligomers. Initial NMR studies showed that the non-TM regions are 
mainly composed of β-strands supporting our model predictions. Limited ligand binding 
studies showed that ML could independently bind the TMM substrate analogue specifically 
and is displaced by known inhibitors of MmpL3, adding more confidence on specificity. 
However, more elaborative ligand binding studies could not be carried out since our focus 
was to solve the crystal structure of the full length protein. 
We have expressed MmpL3 in sufficient quantities and purified it to homogeneity. 
We have used a novel method that employs a SMA co-polymer to encapsulate the 
transmembrane protein in its native form (Jamshad et al. 2011). To our knowledge this is the 
first successful application of SMA solublisation process to purify a mycobacterial protein. 




Biophysical studies of MmpL3 revealed several key aspects of protein assembly in the 
membrane. CDstudies confirmed the proper folding of the protein inside the SMALP disc. 
CD studies also revealed that MmpL3 is mainly α-helical, characteristic of transmembrane 
proteins.  Learning about the oligomeric states is key to understand how MmpL3 functions. 
Previously other RND proteins namely AcrB, MexA, SecDF and CusA were shown to 
function as either dimer or trimers (Tsukazaki et al. 2013; Murakami et al. 2002; Long et al. 
2010; Sennhauser et al. 2009). Size exclusion chromatography  and AUC data has shed some 
light on oligomeric states of the MmpL3. Size exclusion chromatography data suggests that 
MmpL3 exists in more than one oligomeric state and AUC data has revealed that MmpL3 
mainly exist a dimer, with a small population of tetramer. We did not observe oligomeric 
mixtures, composed of at least two oligomeric states, of MmpL3 and one of the reasons could 
be that protein oligomers are encapsulated in the polymer and could not exist as mixtures. 
These results align well with the earlier results obtained with ML, which showed a tendency 
to form higher oligomers. 
Further, in collaborations with Prof. Tim Dafforn, SAXS and cryo-EM studies were 
carried out. Although, good quality data was obtained from SAXS, we were not able to 
process the data as the model building softwares could not account for the membrane 
components encapsulated within the SMALPS. Since, the SMA solublised protein 
purification process still in its infancy, software to process these data are not yet available and 
software development is in its final stages.  Our collaborators are processing the cryo-EM 
data and the early indications are that the results compare well with AUC data and suggest 
that MmpL3 exist as dimer.  
Ligand binding studies with full length MmpL3 did not yield much information on 
substrate specificity or binding affinity. This was due to difficulties in interpreting the 




binding data, as membrane components within SMALP encapsulation was interfering with 
ITF. Alternative assays were not very helpful either. Exploring binding assays with radio 
labelled ligand is a possibility. Another possibility is to use gel mobility shift assays. 
However, due to lack of time that could not be explored. Establishing these assays will have 
high impact as it can be used for in vitro screening of small molecule inhibitors against 
MmpL3.  
The protein yield of MmpL3 was successfully increased 4- fold (from 0.4 mg/L to 2.0 
mg/L) to using small scale fermentation. There is still scope to increase the cell density and 
there by protein yield. The initial results were promising and with further optimisation protein 
could be purified in sufficient quantity to set up protein crystallisation trays.   
In the future, resolving the MmpL3 structure will give insights into its function and 
also understand how other MmpLs work. Mycobacteria has 12 MmpLs involved in the 
transport of different class of lipids (Varela et al. 2012; Jain & Cox 2005; Reed et al. 2004; 
Sondén et al. 2005). Structural studies will shed light on the specificity of MmpL3 to a 
particular class of lipid and understanding of the mechanism of action will be made easier. 
Most of the RND transporters are driven by a proton motive force (Seeger et al. 2009; 
Tsukazaki et al. 2013) and in this chapter we have tried to test whether MmpL3, like its 
counterparts depend on a proton relay for its function. Recent studies with Corynebacterial 
CmpL3 using efflux pump inhibitors suggested this was the case, however important amino 
acid residues involved were not reported (Yang et al. 2014).  Our structural studies helped us 
predict which amino acids that could be involved in proton relay and were subsequently 
tested in a functional complementation assay. We could not make a definite conclusion 
because of two major hurdles. Firstly, complementation in mycobacterial strains was difficult 
as they could not tolerate a defect in mycolic acid transport, and secondly, all the planned 




mutations could not be finished due to time constrains. We have designed an alternative 
complementation assay system in the surrogate organism C. glutamicum and the validation of 
the assays is currently in process.   
Further, structural studies will open the door for structure based drug discovery. This 
is important as mmpL3 is an essential gene for mycobacterial survival and is a high value 
drug target. In this chapter, we have made significant steps towards achieving the goals.  We 
have optimised conditions for production of sufficient quantities of the protein and 
established its biophysical characteristics. Cryo-EM and SAXS experiments have been 
performed and these results are key to further establish our model which could serve as 


















Characterisation of function of genes 













The biophysical characterisation of the mycolic acid transporter protein MmpL3 was 
discussed in the previous chapter. This chapter describes work aimed at identifying missing 
links in the late processing of mycolic acids and proteins associated with MmpL3 that may 
facilitate mycolic acid transport. Towards this, the aim was to investigate the role of genes 
present in the extended mmpL3 cluster (Figure 4-1), which is conserved across the 
mycobacterial species, including M. leprae which has an ‘essential’ minimal genome. Of the 
eight genes in the cluster in M. tuberculosis, seven of them are conserved in M. leprae, and 
one of them (Rv0205) is annotated as a pseudogene. The function of two of the genes in the 
cluster, mmpL3 and mmpL11 are implicated with the transport of mycolic acids and related 
molecules (Varela et al. 2012; Pacheco et al. 2013). The function of other genes are however 
still unknown. 
 
Figure 4-1 Maps of the mmpL3-mmpL11 region in different mycobacteria. Comparison of the mmpL3 gene 
cluster shows mmpL3 in solid arrow, conserved genes in similar arrows. Pseudogene indicated with a hatched 
border arrow and genes exclusively found in M. smegmatis represented in dotted arrows. Genes of particular 
interest for this study arehomologues of Rv0201c (MSMEG0240c), Rv0204c (MSMEG0248c) and Rv0205 
(MSMEG0249). Although, Rv0205 lacks M. leprae orthologue, it is listed as essential gene in HIMAR-1 based 
Transposon mutagenesis studies (Sassetti et al. 2003). 
 




 Analysis of native molecular composition of protein complexes, in M. bovis BCG 
membrane fraction revealed that MmpL11, Rv0201c and Rv0204 (Rv homologues) forms 
protein complexes (Zheng et al. 2011). Previous studies with other MmpL proteins also 
suggest formation of a protein scaffold to achieve the transport of targeted substrates. Jain 
and Cox (2005) showed that MmpL7, involved in the transport of phthiocerol dimycocerosate 
(PDIM), interacts with PpsE, a late biosynthetic enzyme involved in the biosynthesis of 
phenolphthiocerol (Cox et al. 1999; Jain & Cox 2005). Also, MmpL8 responsible for the 
transport of sulfolipid has been shown to form a complex with Pks2, PapA1,FadD23 and a 
putative transposase (Rv3890c), suggesting possible formation of protein scaffold to achieve 
transport (Zheng et al. 2011; Bhatt et al. 2007). This suggests a common mechanism adopted 
for the transport of targeted molecules by MmpL proteins and we sought to investigate this 
possibility of other proteins encoded by the genes in the mmpL3 extended cluster 
participating in forming a protein complex to achieve the transport of mycolic acids and 
related products. 
 Additionally, MmpL3 and MmpL11belong to RND superfamily of proteins 
(Domenech et al. 2005). The RND proteins of other bacterial sources are invariably 
associated with periplasmic membrane fusion proteins (MFP), which interact cooperatively to 
enable the transport. In some cases this complex is shown to interact with a third family of 
channel forming proteins called outer membrane factor (OMF) family of proteins (Paulsen et 
al. 1996). Recently, periplasmic adaptor proteins, MmpS4 and MmpS5 have been identified 
in mycobacteria and structural studies revealed that MmpS4/S5 function as membrane 
adaptor proteins and facilitates MmpL4/L5 in the transport of siderophores (Wells et al. 
2013). The M. tuberculosis genome consists of five genes that encode MmpS proteins that 
co-localise with respective mmpL genes, with an exception to mmpL3. Additionally, outer 
membrane factor proteins have not yet been identified in mycobacateria which has led us to 




investigate whether the genes that co-localise mmpL3 and mmpL11 and annotated as 
hypothetical membrane proteins fulfil any of these roles.    
 
 
Figure 4-2 Schematic presentation of early hypothesis for transport of nascent mycolic acid for cell wall 
mycolylation. Nascent mycolic acid transferred from processing enzymes on to prenol carrier which is 
eventually transferred to trehalose to form TMM. TMM is then transferred across the membrane, where it acts 
as a substrate for mycolylation of cell wall AG. Man-p-heptaprenol- mannosylphosphorylheptaprenol; treh-
trehalose; AG-arabinogalactan; AG-M-arabinogalactan-mycolate; TMM-trehalose monomycolate and TDM- 
trehalose dimycolate. Mycolyl transferases and the phosphotase involved in the late processing of mycolic acid 
to convert them into TMM, are yet to be identified, and indicated in red. The transporter is now identified as 
MmpL3 and is indicated in green. Mycolyl transferases FbpA/B/C involved in the cell wall mycolylation and 
the synthesis of TDM, are indicated in blue. 
 
Another class of enzymes hypothesised to be involved in the processing of mycolic 
acids prior to its transport, are yet unidentified are the mycolyltransferases (Figure 4-2). The 
mycolyltransferases are characterised by a thioesterase activity that cleaves the thioester 




linkage between nascent mycolic acid and cystine residue on PKS13. Recently, Rv3802, 
encoding a thioesterase was identified from the mycolic acid biosynthetic cluster, which is 
conserved across the mycobacterial species including M. leprae, and was shown to be 
essential for mycobacterial growth and survival (Parker et al. 2009). Further, structural 
studies revealed a conserved α/β-hydrolase polypeptide fold and a catalytic triad formed by 
Serine-Glutamic acid-Histidine, that are characteristic of FbpA/B/C proteins, previously 
reported as mycolyltransferases (Meniche et al. 2009; Parker et al. 2009; Kremer et al. 2002; 
Ronning et al. 2000; Belisle et al. 1997). We thus tried to evaluate the involvement of 
Rv3802 in mycolic acid processing.  
 We employed genetic tools to characterise the function of the genes in the extended 
mmpL3 cluster using M. tuberculosis surrogate organism M. smegmatis. Further, we used 
protein-protein interaction studies to evaluate association of Rv0204, Rv0205 and Rv3802 
with MmpL3 and MmpL11 to assess if they play a role in facilitating the transport of mycolic 
acids or its related molecules.   
4.2 Materials and Methods 
4.2.1 In silico analysis 
Prediction of interacting partners of MmpL3 were determined by STRING, a database of 
predicted and actual protein-protein interaction networks for a set of over 1100 organisms 
(Franceschini et al. 2013). The selection criteria for testing possible interaction included co-
localisation with mmpL3 (Rv0201 (MSMEG_0240), Rv0204c (MSMEG_0248), Rv0205 
(MSMEG_0249)), literature (Rv0205, Rv3802), other proteins implicated with similar 
function (MmpL11). To test the possible interactions and to identify the role of individual 
genes, the study aims to generate null mutants of MSMEG_0240, MSMEG_0248 and 




MSMEG_0249 and also carry out protein-protein interaction studies using bacterial two 
hybrid interaction tools. The gene sequences for M. smegmatis genes MSMEG_0240, 
MSMEG_0248 and MSMEG_0249 were obtained from NCBI genome database 
(http://www.ncbi.nlm.nih.gov/genome). The gene sequences for M. tuberculosis genes 
mmpL3, mmpL11, Rv3802, Rv0204 and Rv0205 were obtained from the Tuberculist database 
(http://genolist.pasteur.fr/TubercuList/genome.cgi).  
4.2.2 Plasmids, DNA manipulations and bacterial growth conditions 
Table 4-1lists the plasmids, bacterial strains and recombinant mycobacteriophages used in 
this study. E. coli strains were routinely cultured in LB broth at 37°C. M. smegmatis strain 
mc2155 was cultured at 37°C in TSB supplemented with 0.05% Tween 80. The generation 
and propagation of mycobacteriophages was done on lawn of M. smegmatis at 30°C in 7H10 
basal plates overlaid with 7H9 soft agar as described in Chapter 7. High titres of 
mycobacteriophages were generated using protocols described in Chapter 7 (Larsen et al. 
2007). Antibiotics were added at required concentrations where required. Hygromycin was 
routinely used at 150 µg/ml for E. coli and at 100 µg/ml for M. smegmatis and kanamycin 
















Table 4-1 Plasmids and strains used in this study. 
Plasmids, phages and strains Description Reference 
Plasmids   
p0004S Cosmid vector containing Hyg-sacB cassette Larsen et al., 2007 
p∆MSMEG_0240 
Derivative of p0004s cosmid obtained by 




Derivative of p0004s cosmid obtained by 




Derivative of p0004s_Apramycin cosmid 
obtained by cloning upstream and 
downstream flanks of MSMEG_0249 
This work 
pTIC6a:MSMEG_0248 
Functional copy of MSMEG_0248 cloned 
into pTIC6a  under the regulation of 
inducible pTet promoter 
This work 
Phages   
phAE159 
Thermo sensitive, conditionally replicating 
shuttle phasmid derived fromlytic 
mycobactiophage TM4 
Larsen et al., 2007 
ph∆MSMEG_0240 
Derivative of phAE159 obtained by cloning 
p∆MSMEG_0240 into its PacI site 
This work 
ph∆MSMEG_0248 
Derivative of phAE159 obtained by cloning 
p∆MSMEG_0248 into its PacI site 
This work 
ph∆MSMEG_0249 
Derivative of phAE159 obtained by cloning 
p∆MSMEG_0249 into its PacI site 
This work 
Bacterial strains   
E. coli Top 10 
F– mcrA Δ(mrr-hsdRMS-mcrBC) 
Φ80lacZΔM15 ΔlacX74 recA1 araD139 
Δ(ara leu) 7697 galU galK rpsL 
(StrR) endA1 nupG 
InvitrogenTM 
E. coli HB101 
E. coli K-12 _F- mcrB mrr hsdS20(rB- mB-) 
recA13 leuB6 ara-14 proA2 lacY1 galK2 
xyl-5 mtl-1 rpsL20(SmR) glnV44 λ- 
InvitrogenTM 
M. smegmatis mc2155 
Wild type strain, Eptmutant of M. smegmatis 
strain mc26 
Snapper et al. 
1990 
∆MSMEG_0240 
M. smegmatis strain with MSMEG_0240 
replaced with Hyg-sacB cassette 
This work 
∆MSMEG_0249 
M. smegmatis strain with MSMEG_0249 
replaced with Hyg-sacB cassette 
This work 
4.2.3 Construction of knockout phages 
Approximately 1kb regions upstream and downstream of gene were PCR amplified using 
genomic DNA from M. smegmatis mc2155.  The PCR products were purified, digested with 
respective enzymes and cloned on either side of a hygromycin (hyg) cassette in the plasmid 
p0004S (Stover et al. 1991) to generate an allelic exchange substrate plasmids listed in Table 




4-1. The allelic exchange plasmids were sequenced to confirm the presence of upstream and 
downstream regions of the respective genes. The allelic exchange plasmids were then cloned 
into temperature sensitive phasmid phAE159 at a PacI site and packaged into empty λ-phage 
heads. The packaged phasmids were transduced into E. coli HB101cells and selected on 
hygromycin plates. Positive clones were identified by PacI digestion.  
One such positive phasmid for each gene was transformed by electroporation into M. 
smegmatis mc2155 and recovered at 30°C for 3-4 hrs in TSB supplemented with 0.05% 
Tween 80 (1 ml). The recovered cells were split into 200 µl and 800 µl and mixed with 100 
µl of log phase M. smegmatis and 5 ml of molten 7H9 soft agar. This mix was overlaid on 
7H10 basal plates and incubated at 30°C for 2-3 days for plaques to be formed. The plates 
were soaked in mycobacteriophage (MP) buffer for 4-6 hrs and syringe filtered and either 
used straight away or stored at 4°C. 
4.2.4 Generation of null mutants 
Specialised transduction of M. smegmatis mc2155 was performed as described before 
(Bardarov et al. 2002). M. smegmatis mc2155 cultures were grown in TSB supplemented with 
0.05% Tween 80 to an OD600nm of 0.8 and harvested. The cell pellet was washed twice with 
equal volume of MP buffer. Finally, the cells were suspended in small volume of MP buffer 
(2 ml). High titre (108-1010) phage lysate (1 ml) was mixed with 1 ml of cells for transduction 
and 1 ml of MP buffer mixed with 1 ml of cells for control reaction and were incubated at 
37°C for 3-4 hrs, harvested and recovered in TSB supplemented with 0.05% Tween 80 for   
at 37°C 4 hrs. The recovered cells were harvested and resuspended in 400-600 µl of TSB and 
plated on TSA containing 100 µg/ml hygromycin for selection. Hygromycin resistant 
colonies were inoculated into 10 ml of TSB supplemented with 0.05% Tween 80 and 100 




µg/ml of hygromycin for genomic DNA extraction and further Southern blot. Allelic 
exchange of each gene with hyg cassette in transductants was confirmed by Southern blot. 
4.2.5 Lipid analysis of M. smegmatis strains 
M. smegmatis mc2155, ∆MSMEG0240 and ∆MSMEG0249 strains were grown in TSB 
supplemented with 0.05% Tween to an OD of 0.8 and labelled with [14C] acetate (50 µCi/ml). 
The cells were harvested, washed and dried, and cell wall associated lipids were extracted 
using methods described by Dobson et al. (1985). Briefly, surface exposed, non-covalently 
bound lipids were first extracted using petroleum ether (60-80 bp). Cells were resuspended in 
2 ml of petroleum ether (60-80 bp) and mixed for 30 minutes. Upper layer containing lipids 
were removed into fresh tube and dried. This step was repeated twice for efficient extraction. 
Apolar and polar lipids were then extracted from the remaining cell pellet. Cell pellet was 
resuspended in methanolic saline (methanol: 0.3% NaCl, 10:1 v/v) and apolar lipids were 
extracted with 2 ml of petroleum ether (60-80b.p) twice, dried and re-constituted in 
chloroform: methanol (2:1). Polar lipids containing glycolipids were extracted first with 
chloroform: methanol: water (9:10:3) and twice with chloroform: methanol: water (5:10:4). 
The two extractions were pooled and mixed with 1.3 ml of chloroform and 1.3 ml of 0.3% 
NaCl, mixed and centrifuged. The lower organic layer containing polar lipids is collected, 
dried and re-constituted in chloroform: methanol (2:1). Apolar lipids were analysed by 2D 
TLC using SystemC and SystemD for altered mycolic acid biosynthesis/transport and 
visualised by autoradiographs (Dobson et al. 1985). 
4.2.6 Fatty acid methyl esters (FAMEs) and mycolic acid methyl esters 
(MAMEs) extraction from defatted cells and whole cells 
Alkaline hydrolysis was performed on de-fatted cells after the extraction of polar lipids as 
described in Chapter 7. Briefly, 2 ml of 5% aqueous tetrabutylammonium hydroxide (TBAH) 




was added to defatted cells and incubated at 100°C overnight. Base hydrolysed fatty acids 
and mycolic acids were extracted as methyl esters using 4 ml of dichloromethase (CH2Cl2), 
300 µl of methyl iodide (CH3I), and 2 ml of water with mixing for 30 min. The lower layer of 
organic phase containing FAMEs and MAMEs was removed and were washed three times 
with water and dried, and re-dissolved in diethyl ether. The organic layer was taken into 
separate tube and dried under air. The samples were dissolved in CH2Cl2 (200 µl), analysed 
by single dimension TLC using petroleum ether: acetone (95:5) and visualised by 
autoradiograph. 
4.2.7 Protein-protein interaction studies 
To identify proteins associated with MmpL3, the mycolic acid transporter Bacterial two 
hybrid system BACTH (Euromedex) (protocol detailed in Chapter 7) was employed 
(Karimova et al. 1998). Briefly, candidate genes were cloned into bait (pKT25) and prey 
(pUT18) vectors with complementary fragments (T25 and T18) of catalytic domain of 
adenylatecyclase as fusion tags. The interacting partners bring together the complementary 
fragments (T25 and T18) in physical proximity required to restore the activity of adenylate 
cyclase in cya- strain of E. coli, resulting in a cascade of reactions activating transcription of 
resident genes including lac and mal operons. MmpL3 and cytoplasmic domains Loop1 
(hereafter referred to ML1) and Loop2 (hereafter referred to as ML2) and MmpL11were 
cloned into pKT25 vector and genes for putative interaction partners Rv3802, Rv0204, 
Rv0205, were cloned into pUT18 vector. The pKT25 and pUT18 constructs were co-
transformed into E. coli cya- strain BTH101. The transformants were plated on MacConkey 
agar containing maltose for screening positive interactions. Maltose utilisation leads to 
lowering of pH turning the agar pink, and is considered positive for protein-protein 
interaction.  





4.3.1 In-silico analysis 
STRING, a database of predicted and actual protein-protein interaction networks for a set of 
over 1100 organisms, was used to analyse possible proteins interacting with MmpL3 
(Franceschini et al. 2013). STRING uses several criteria to predict/identify interacting 
partners which include neighbourhood, gene fusion, cooccurance, coexpression, experiments, 
database, textmining and homology and ranks the interacting proteins, generating a network 
of protein-protein interactions. To identify possible interactors of MmpL3, we used sa set of 
criteria using all of aforementioned filters, with a medium confidence (0.400) and generated 
network using top 10 ranked interactors which include only the direct intractor proteins. The 
possible interacting proteins of MmpL3 included other MmpL’s, probable conserved 
transmembrane proteins- MT0214 (Rv0204) and Rv0205, conserved hypothetical protein- 
MT0217 (Rv0207c) and a putative methyl transferase-TrmB (Figure 4-3). 
 
Figure 4-3 Predicted interacting partners of MmpL3 based on database mining by STRING. 
 




The genes Rv0205 and trmB are predicted to be essential (Sassetti et al. 2003) and 
disruption of Rv0204 was shown to affect virulence (Camacho et al. 1999). A detailed 
STRING analysis which also includes interacting proteins that are indirectly linked showed 
links between Rv0204 and MmpL11 (Appendix-5). This prediction was supported by blue 
native 2D SDS-PAGE analysis where MmpL11 was shown to form a complex with Rv0204 
and Rv0201(Zheng et al. 2011). Further, Varela et al.(2012) suggested that Rv0204 and 
Rv0205 could possibly play a role in mycolic acid transport. Thus, we attempted to probe 
into the functions of Rv0201c, Rv0204c and Rv0205 genes by generating knockouts of the 
homologues (MSMEG0240c, MSMEG0248c and MSMEG0249) in M. smegmatis. 
4.3.2 Generation of null mutants 
Specialised transduction, a highly efficient mycobacterial knock out method, was employed 
to generate null mutants in M. smegmatis. Null mutants MSMEG0240 and MSMEG0249 were 
successfully generated, indicating that they are non-essential for the survival of the organism, 
contradicting earlier reports, which suggested that homologue of MSMEG0249 was essential 
(Sassetti et al. 2003). However, repeated attempts to delete MSMEG_0248 were not 
successful. MSMEG0240 and MSMEG0249 knockouts confirmed by Southern blot 
(Appendix 10) were used for further characterisation.  
4.3.3 Analysis of total lipids from ∆MSMEG_0240 and ∆MSMEG_0249 
To assess the loss of MSMEG_0240 and MSMEG_0249 function on the cell wall lipids in 
general and mycolic acid transport in particular, WT and mutant strains were grown and 
lipids were labelled with [14C] acetate. Petroleum ether extracts containing surface exposed, 
non-covalently bound lipids and apolar lipids from WT and mutant strains were analysed by 
2D-TLC using the solvent systems described by Dobson et al. (1985). 2D TLC analysis of 
using System C (Figure 4-4, Figure 4-6) and System D (Figure 4-5, Figure 4-7) revealed no 




significant difference in mycolic acid and related lipids (TMM, TDM, GMM), indicating that 
MSMEG0249and MSMEG0240do not affect the biosynthesis and transport of mycolic acids.   
 
Figure 4-4 Lipid analysis of the ∆MSMEG0249 mutant.2D TLC analysis of [14C]-labelled lipids from the M. 
smegmatis WT and ∆MSMEG0249 mutant. Petroleum ether extracts (A) and intracellular apolar lipids (B) were 
separated using chloroform:Methanol (96:4 v/v) in Direction I and  toluene: acetone (80:20 v/v) in Direction II. 
Positions of mycolic acids (MA) and fatty acids (FA) are indicated with arrows. 





Figure 4-5 Lipid analysis of the ∆MSMEG0249 mutant. 2D TLC analysis of [14C]-labelled lipids from the M. 
smegmatis WT and ∆MSMEG0249 mutant. Petroleum ether extracts (A) and intracellular apolar lipids (B) were 
separated using Chloroform: methanol: water (100:14:0.8 v/v/v) in Direction I and chloroform: acetone: 
methanol: water (50:60:2.5:3 v/v/v/v) in Direction II. Positions of TMM, TDM and GMM indicated with 
arrows. 
 





Figure 4-6 Lipid analysis of the ∆MSMEG0240 mutant.2D TLC analysis of [14C]-labelled lipids from the M. 
smegmatis WT and ∆MSMEG0240 mutant. Petroleum ether extracts (A) and intracellular apolar lipids (B) were 
separated using chloroform:Methanol (96:4 v/v) in Direction I and  toluene: acetone (80:20 v/v) in Direction II. 
Positions of mycolic acids (MA) and fatty acids (FA) are indicated with arrows. 





Figure 4-7 Lipid analysis of the ∆MSMEG0240mutant.2D TLC analysis of [14C]-labelled lipids from the M. 
smegmatis WT and ∆MSMEG0240 mutant. Petroleum ether extracts (A) and intracellular apolar lipids (B) were 
separated using Chloroform: methanol: water (100:14:0.8 v/v/v) in Direction I and chloroform: acetone: 
methanol: water (50:60:2.5:3 v/v/v/v) in Direction II. Positions of TMM, TDM and GMM indicated with 
arrows. 
 
Further, cell wall bound mycolates were esterified as methyl esters and analysed using 
TLC (Figure 4-8), which revealed no significant difference in methyl esters of sub-classes of 
mycolic acids, suggesting that these genes may not contribute in either biosynthesis or to the 
transport of these lipids.  





Figure 4-8 TLC analysis of Mycolic acid methyl esters.[14C]- labelled, cell wall bound mycolic acids 
(MAMEs) from delipidated cells (A) and apolar lipids (B) were separated usingpetroleum ether: acetone (95:5 
v/v) as the solvent system. Methyl esters of the different sub-classes of mycolic acids are indicated with arrows. 
 
Figure 4-9 TLC analysis of Mycolic acid methyl esters.[14C]- labelled, cell wall bound mycolic acids 
(MAMEs) from delipidated cells (A) and apolar lipids (B) were separated usingpetroleum ether: acetone (95:5 
v/v) as the solvent system. Methyl esters of the different sub-classes of mycolic acids are indicated with arrows. 




4.3.4 Screening for protein-protein interactions using bacterial two hybrid 
system 
Parallel to the genetic approach, protein-protein interaction studies were carried out to 
identify the functions of Rv0204, Rv0205 and Rv3802 in the processing and transport of 
mycolic acids. MmpL3, ML1, ML2 and MmpL11 were used as ‘bait’ protein, to identify 
functional partners that facilitate the transport or bridge the biosynthesis and transport and to 
test whether this is a common model adopted by MmpL family of proteins (Zheng et al. 
2011; Jain & Cox 2005; Rao & Ranganathan 2004).  Table 4-2 lists the combinations of 
protein-protein interactions tested and summary of results.  
Table 4-2 Summary of bacterial two hybrid test from MacConkey agar screen 
 Rv3802 Rv0204 Rv0205 pUT-Zip 
MmpL3 - - - - 
ML1 - - - - 
ML2 - - - - 
MmpL11 - - - - 
pKT-Zip - - - + 
The positive interactions are indicated as (+) and negative interactions as (-) 
The candidate genes were cloned in-frame with adenylatecyclase T25 or T18 
fragments and expressed in E. coli cya- BTH101. The co-transformants containing two 
plasmids encoding putative interaction partners were plated onto selective MacConkey agar 
plates supplemented with 1% maltose, 0.5 mM IPTG and appropriate antibiotics. Interacting 
proteins bring T25 and T18 fragments in physical proximity restoring the catalytic activity 
and switches on the lac and maloperon, enabling the cya-strain BTH101 to use maltose as 
unique carbon source and consequent red colouration of the colony due to the acidification of 
the media. T25 and T18 fragments fused to leucine zipper protein was used as a Positive 
control and T25 and T25 Zip construct co-transformed with counter empty plasmid used as a 
negative control. Initial screening results from bacterial two hybrid test indicated that the 




candidate genes tested did not interact with any of the ‘bait’ proteins (Table 4-2, Figure 
4-10). Rv0204 interaction with MmpL3 was observed but was turned out to be a false 
positive, since the corresponding control with empty vector also gave positive interaction 
(Appendix 11). 
 
Figure 4-10 Bacterial two hybrid screening testing for interactions between ‘bait’ and ‘prey’ proteins on 
MacConkey agar plates. The candidate genes were cloned in-frame with adenylatecyclase T25 or T18 
fragments and expressed in E. coli cya- BTH101. The co-transformants containing two plasmids encoding 
putative interaction partners were plated onto selective MacConkey agar plates supplemented with 1% maltose, 
0.5 mM IPTG and appropriate antibiotics. The positive interaction is indicated by the red colouration of agar, on 
utilisation of maltose by reconstituted adenylatecyclase catalytic domain. T25 and T18 fragments fused to 
leucine zipper protein was used as a Positive control and T25 and T25 Zip construct co-transformed with 
counter empty plasmid used as a negative control. 





Mycolic acidsare a vital cell wall component essential for mycobacterial survival and 
pathogenicity (Takayama et al. 2005; Dubnau et al. 2000; Glickman et al. 2000). Mycolic 
acid biosynthesis has been thoroughly investigated however further studies are required to 
delineate the processing and transport of mycolic acids. Identification of the mycolic acid 
transporter MmpL3 was a major step forward in this regard (Varela et al. 2012).  However, 
enzymes catalysing the transfer of nascent mycolic acids to trehalose to generate TMM and 
its subsequent transfer to MmpL3 still need to be clarified.  
Jain and Cox (2005) have shown that non-TM domains of MmpL7 interact with 
polyketide synthase PpsE suggesting a link between biosynthesis and transport. Further, 
Zheng et al (2011) showed that these MmpLs form protein complexes with other proteins 
suggesting that the transport of different lipid molecules are brought about by protein 
scaffolds rather than single transporter. Previous studies have shown that mycolic acid 
biosynthesis is achieved through formation of large protein complexes that involve FabH, 
FAS-II components and PKS13 (Veyron-Churlet et al. 2004; Veyron-Churlet et al. 2005). 
However, beyond PKS13 step, its processing is not well studied. Transport of other complex 
lipid molecules viz. PDIM, sulfolipids, points at possible coupling of biosynthesis and 
transport (Domenech et al. 2004; Jain & Cox 2005).  
In this regard we have investigated the function of genes co-localised in themmpL3 
extended cluster and evaluated the possible formation of protein complexes to achieve 
transport. Towards this, we have generated null mutants of MSMEG_0240c and 
MSMEG_0249. Biochemical characterisation of these mutants revealed that these genes do 
not play a significant role in mycolic acid processing and transport. Although protein-protein 




interaction studies seem to support the biochemical data, lack of interaction observed could 
be due to several reasons, which will be discussed in the due course.   
Rv3802, a thioesterase with a conserved mycolyltransferase domain, is suggested to 
play a role in mycolic acid processing (Parker et al. 2009). The genetic locus of the gene also 
supports the hypothesis. The present hypothesis for the transfer of mycolic acids to its 
transporter suggest that the event is membrane associated and is likely to take place in the 
proximity of the transporter thus we have used MmpL3 as a bait protein in the bacterial two 
hybrid screens to identify possible proteins contributing to the process (Takayama et al. 2005; 
de Souza et al. 2008). Bacterial two hybrid screens did not help us to identify the links 
between these proteins. The lack of interaction between the combinations tested could be due 
to one of several reasons. There is a possibility that the interaction may require assistance of 
third protein or a recruiting factor which could not be accommodated in the bacterial two 
hybrid screens. Additionally, a lack of interaction could also be contributed by 
inappropriately expressed proteins or complete lack of either one or both the fusion proteins. 
Topological orientation of fusion proteins might also keep the complementary 
adenylatecyclase fragments apart, resulting in lack of interaction. This leaves a possibility 
that the hybrid proteins might still be interacting in-vivo but the interaction is not detectable. 
This limits us from completely ruling out the role of the tested proteins in facilitating mycolic 
acid transport. One possibility we have not tried in this chapter was to test whether any of 
these proteins interact with Pks13, the last known biosynthetic enzyme in the mycolic acid 
biosynthetic pathway. This could be important experiment since PKS13 was previously 
shown to form a complex with FAS-II enzymes (Veyron-Churlet et al. 2004; Veyron-Churlet 
et al. 2005) Interaction between Pks13 and MmpL3 could not be ruled out either since Pks13 
also contains a thioesterase activity required to transfer the mycolic acid to recipient and 
earlier studies with other MmpLs supports the hypothesis (Jain & Cox 2005). 




MmpL proteins belong to RND super family of proteins which are frequently found to 
be associated with a outer membrane protein and a membrane fusion protein (Paulsen et al. 
1996). Wells et al. (2013) showed that MmpS4/S5 are membrane associated proteins that 
facilitate the MmpL4/L5 in the transport of siderophores. This class of proteins may be 
involved in the transport of other lipid molecules in association with respective MmpL 
partners. Transposon insertion in mmpS3 gene resulted in slow growth pattern, however a 
detailed characterisation of the null mutant has not been carried out (Cole et al. 1998). The 
role of MmpS3 in mycolate transport and the link between MmpS3 and MmpL3 needs to be 
evaluated. Wells et al (2013) also showed that MmpS4 and MmpS5 are functionally 
redundant, which also opens up a possibility of other MmpS proteins associating with 
MmpL3 to facilitate mycolate transport. 
In summary, we show that MSMEG_0240c and MSMEG_0249 are non-essential for 
the growth and survival of mycobacteria, contradicting an earlier report that has listed 
MSMEG0249 homologue as essential. Biochemical characterisation of these mutants revealed 
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The complex mycobacterial cell wall contains several solvent extractable glycolipids, some 
of which occur in all strains eg. TDM, while some are found only in select species eg. 
sulfolipids, glycopeptidolipids, phenolic glycolipids and lipooligo-saccharides (LOSs) 
(Minnikin et al. 2002; Indrigo et al. 2003; Hunter et al. 1983; Ortalo-Magné et al. 1996). The 
LOSs are solvent extractable, highly polar sugar-containing lipids. LOS producers include the 
opportunistic pathogen M. kansasii, the fish pathogen M. marinum, and the M. tuberculosis 
complex strain M. canetti (Hunter et al. 1985; Minnikin et al. 1989; Daffe et al. 1991). An 
early understanding of LOS chemistry came from studies carried out in M. kansasii, where 
seven sub-classes of LOSs were identified and characterised (Hunter et al. 1983; Hunter et al. 
1984). The core consists of a polyacylated a trehalose which is further glycosylated. The 
variable sugars identified were xylose, 3-O-methyl-rhamnose, fucose and 4,6–dideoxy-2–O-
methyl-3-C-methyl-4-(2’-methoxy-propionamido)-α-L-mannohexo-pyranose (Hunter et al. 
1983; Hunter et al. 1985). 
However, most of the biosynthetic knowledge concerning LOS assembly comes from 
M. marinum (Burguière et al. 2005; Ren et al. 2007; Sarkar et al. 2011). The presence of 
LOSs in M. marinum was first shown by Minikkin et al. (1989), and subsequently 
characterised by Burguière et al. (2005). M. marinum produces 4 sub-classes of LOSs, each 
with an identical core consisting of a polyacylated tetra-glucose unit with a varying  
oligosaccharide (Minnikin et al. 1989; Burguière et al. 2005). The oligosaccharide was 
shown to contain 3-O-Me-rhamnose, xylose and unique sugar residues, caryophyllose (α-3,6 
dideoxy-4-C-(D-altro-1,3,4,5-tetrahydroxyhexyl)-D-xylo-hexopyranose) and an N-acyl 
amino sugar (N-acylated dideoxygalactose) (Burguière et al. 2005; Rombouts et al. 2009). 





Figure 5-1 Schematic presentation of LOS subclasses from M.kansasii. Glu: D-Gluco-pyranose; 3-O-Me-
Rha: 3-O- Methyl-α-L-Rhamno-pyranose; Xyl: β-D-Xylo-pyranose; Fuc: Fuco-pyranose; N-acyl-Kan: N-acetyl-
kansosamine. 
 




While M. kansasii has a similar cell wall lipid profile to that of M. tuberculosis, it has 
several antigenic glycolipids that are absent in M. tuberculosis. One class of such glycolipids 
are LOSs which renders the outer membrane of M. kansasii highly polar. The seven sub-
classes of LOSs are produced by M. kansasii have less complex structure than the four sub-
classes produced by M. marinum (Ortalo-Magné et al. 1996; Hunter et al. 1983; Hunter et al. 
1984; Hunter et al. 1985; Belisle & Brennan 1989). The LOSs of M. kansasii are similar to 
that of M. marinum and consists of 3-O-Me-rhamnose, xylose, fucose and a unique 
disaccharide, N-acyl-kansosamine. The first 3 sub-classes of LOSs have a 3-O-Me-rhamnose 
residue with increasing residues of xylose. The sub-classes IV-VII, which are more polar are 
characterised by the presence of a fucose residue and a novel species-specific N-acyl- 
kanosamine added to LOS-III, with increasing amounts of xylose residues between the fucose 
and 3-O-Me-rhamnose. Acylation occurs at 3, 4 and 6 position of the terminal glucose with 2, 
4-dimethyl tetradecanoic acid (Figure 5-1). M. canetti, a member of  the MTBC complex, 
produces only one LOS species, in which the trehalose residue was found to be methylated at 
position 6’ and is either 2,3,6- or 3,4,6- tri-O-acylated (Daffe et al. 1991). The 
oligosaccharide consists of glucose, 2-O-Me and 4-O-Me- rhamnose, 2-O-Me-fucose, N-acyl-
4-amino-4, 6-dideoxy-galactose.  
The presence of LOSs give the colonies of these strains a smooth texture and are 
closely linked to virulence. It has been shown that  rough variants of M. kansasii can establish 
chronic systemic infections in mice, whereas the smooth variants are quickly cleared from the 
organs of infected mice (Daffe et al. 1991; Collins & Cunningham 1981).  This early theory 
of clearance of smooth variants comes from the theory that the LOSs prevent the exposure of 
‘virulence factors’ thereby making the strains susceptible to host immune responses. This 
may explain why the rough variants of M. kansasii are successful at establishing an infection 
in mice (Daffe et al. 1991). Similarly, the LOS-producing MTBC strain M. canetti is an 




opportunistic human pathogen, unlike M. tuberculosis which is virulent in humans. These 
findings indicate that a loss of LOSs may be one, if not the only, defining factor in the 
increased virulence of M. tuberculosis in humans. Furthermore, the role of individual sub-
classes of LOSs in antigenicity and immunomodulation is poorly understood in the context of 
a correlation between LOS production and severity of disease. Recently, LOS-IV, but not the 
other LOS-subclasses from M. marinum were shown to inhibit TNF-α release in LPS-
activated macrophages (Rombouts et al. 2009).  Similarly, a LOS-IV-deficient mutantshowed 
increased virulence in infected Zebrafish embryos (van der Woude et al. 2012). Furthermore, 
Alibaud et al. (2014) observed that M. marinum strains deficient in LOS production were 
phagocytosed more efficiently than those accumulating only early LOS intermediates, while 
wildtype strains and only LOS-IV lacking mutants were least efficient. A fine dissection of 
the role of different LOS-subclasses and their correlation to the ability to cause disease in 
models, such as M. kansasii and M. canetti, can eventually help us better understand how M. 
tuberculosis, which has lost the ability to make LOS’s through reductive evolution (Ren et al. 
2007), became a more virulent human pathogen than other LOS producing members of the 
MTB complex, like M. canetti.  
To ascertain a definite role for LOSs, it is imperative to understand the biosynthesis of 
LOSs through genetic dissection of the biosynthetic pathway. A transposon mutant of 
MMAR2313 (losA) was identified to be defective in LOS biosynthesis, showing its role as a 
possible glycosyltransferase. The mutant was defective in producing LOS-IV, indicating that 
LosA inhibits  transfer of N-acylated-α-amino-4,6-dideoxy galactose to LOS-III (Burguière et 
al. 2005). Characterisation of M. marinum strain Mma7 supports this study. M. marinum 
strain Mma7 which carries a chromosomal deletion that extends from the 3’ end of losA to 
MMAR2318, accumulates LOS-III and cannot produce LOS-IV suggesting that the genes in 
this region may be involved in LOS-IV synthesis, supporting earlier studies (Rombouts et al. 




2009). There were three other genes that have been identified to have a biosynthetic role in 
LOSs biosynthesis. Transposon mutagenesis studies have shown that a UDP-glucose 
dehydrogenase (MMAR2309) and a carboxylase (MMAR2332) are essential for the 
biosynthesis of LOS, deletion of which led to the accumulation of intermediates of LOS-I and 
LOS-II. Further, deletion of MMAR2333, resulted in accumulation of LOS-II*, another LOS-
II intermediate (Ren et al. 2007; Sarkar et al. 2011). Interestingly, M. tuberculosis has also 
shown to possess a LOS biosynthetic gene cluster, however is missing a number of genes 
(Table 5-1) (Ren et al. 2007). The gene cluster responsible for LOSs biosynthesis has also 
been identified in M. kansasii. This led us to attempt to investigate the function of several 
glycosyltransferases, polyketide synthases and mycobacterial membrane protein large 
(MmpL) that are present in this gene cluster. Although, the genetic locus has not been 
identified and annotated for M. canetti, the recent publication of a whole genome sequence of 
M. canetti (Supply et al. 2013) has helped us to identify homologues regions for losA and 
mmpL12 and LOS biosynthetic cluster (Table 5-1). In this study we have attempted to 
generate LOS deficient null mutants in M. kansasii and M. canetti and characterise them in an 















Table 5-1 Comparative table of genes involved in LOS biosynthesis. LOS biosynthetic cluster from M. 
tuberculosis, M. kansasii and M. canetti was compared with genes involved in LOS biosynthesis in M. 
marinum. 









Methylmalonyl-CoA mutase small 




Methylmalonyl-CoA mutase large 
sub unit, MutB 
Rv1494 MCAN_15121 No homology No homology 
Hypothetical conserved 
protein/Antitoxin 






Arginine/ornithine transport system 
ATPase  
Rv1497 MCAN_15151 MKAN27360 MMAR_2305 LipL (esterase) 
Rv1498c MCAN_15161 No homology No homology Methyl transferase 
Rv1498a MCAN_15171 MKAN27365 MMAR_2306 Conserved hypothetical protein 
Rv1499 MCAN_15181 No homology No homology Conserved hypothetical protein 





 No homology No homology MKAN27375 MMAR_2308 Hypothetical membraneprotein 





 No homology MCAN_36461  MKAN27385 MMAR_2310 UDP-glucose 4- epimerase 
No homology No homology MKAN27390 MMAR_2311 Glycosyl transferase 
No homology No homology 
No homology 
MMAR_2312 
Nucleoside diphosphate sugar 
epimerase 
Rv1500 MCAN_15191 No homology MMAR_2313  Glycosyl transferase 
Rv1501 MCAN_15201 No homology MMAR_2314  Hypothetical conserved protein 
No homology No homology No homology MMAR_2315 Methyltransferase 
No homology No homology No homology MMAR_2316 Transcriptional regulator 
No homology No homology No homology MMAR_2317 O-methyltransferase 
Rv1502 MCAN_15211 No homology MMAR_2318  
Glycosyl hydrolase (GH 
superfamily) 
No homology No homology MKAN27395 MMAR_2802 Conserved membrane protein  





No homology No homology MKAN27405 No homology Hypthetical protein 
No homology No homology No homology MMAR_2333 Glycosyl transferase 









No homology No homology MKAN27415 MMAR_2924 Methyl transferase/SAM 
No homology No homology MKAN27420 No homology Hypothetical protein 
No homology No homology 
MKAN27425 
No homology 
Glycosyl transferase, GT-A type 
(DPM/DPG) 





 No homology  No homology MKAN27435 No homology Glycosyltransferase (GTA) 










 No homology  No homology MKAN27450 No homology Rhamnose epimerase 
 No homology  No homology MKAN27455 No homology Methyltransferase 
 No homology  No homology MKAN27460 No homology Perosamine synthase 
 No homology  No homology MKAN27465 No homology Carbomoyl phosphate synthase 
 No homology  No homology MKAN27470 No homology Hypothetical protein 
 No homology  No homology MKAN27475 No homology Methyltransferase 
 No homology  No homology MKAN27480 MMAR_2339 SAM methyltrasnferase 
Rv1527c MCAN_15481 MKAN27485 MMAR_2340  Polyketide synthase 
Rv1521 NC_019950 MKAN27490 MMAR_2341 Fatty acid co-A synthatase 
 No homology  No homology MKAN27495 No homology Hypothetical protein 
 No homology  No homology MKAN27500 MMAR_4618 Hypothetical conserved protein 
 No homology  No homology MKAN27515 No homology WhiB4 transcriptional regulator 
 No homology  No homology MKAN27525 No homology Hypthetical conserved protein 
Rv1522c   MCAN_15431 MKAN27530 MMAR_2342  MmpL family transport protein-12 
Rv1527c  MCAN_15481 MKAN27535 MMAR_2343 Hypthetical conserved protein 
 No homology  No homology MKAN27540 MMAR_2344 Polyketide synthase 
 No homology  No homology MKAN27545 No homology Hypothetical protein 
 No homology  No homology MKAN27550 MMAR_2345 Decarboxylase 
 No homology  No homology MKAN27555 No homology Thioesterase 
 No homology  No homology MKAN27560 MMAR_2346 Monooxygenase 
 No homology  No homology MKAN27565 No homology Transcriptional regulator 
 No homology  No homology MKAN27570 No homology Hypothetical protein 
 No homology  No homology MKAN27575 MMAR_2349 Rhamnosyl transferase 
 No homology  No homology MKAN27580 MMAR_2351 Glycosyl transferase 
 No homology  No homology MKAN27585 No homology Hypothetical protein 
 No homology  No homology MKAN27590 MMAR_2350 Mehtyl transferase 
 No homology  No homology MKAN27595 MMAR_2352 Hypthetical protein 
 No homology  No homology MKAN27600 MMAR_2353 Glycosyl transferase 




 No homology  No homology MKAN27605 MMAR_2354 Hypothetical protein 
 No homology  No homology MKAN27610 MMAR_2355 Acyl transferase 
 No homology  No homology MKAN27615 No homology Hypothetical protein 
 No homology  No homology MKAN27620 MMAR_2356 Isoleucyl t-RNA synthase 
 No homology  No homology MKAN27625 MMAR_1375 Aryl sulfatase 
 No homology  No homology MKAN27630 MMAR_2358 Methyl transferase type11 
 No homology  No homology MKAN27635 MMAR_2359 DNA polymerase IV 
 No homology  No homology MKAN27640 MMAR_2360 Asperginase 
 No homology  No homology MKAN27645 MMAR_2361 Lipoprotein peptidase 
 No homology  No homology MKAN27650 No homology RNA pseudo uridine synthase 
 No homology  No homology MKAN27655 No homology RNA polymerase 
 No homology  No homology MKAN27660 No homology RNA polymerase subunit sigma 70 
 No homology  No homology MKAN27665 No homology Hemin receptor 
 No homology  No homology MKAN27670 No homology Hypothetical protein 
 No homology  No homology MKAN27675 MMAR_2366 Oxido reductase 
 No homology  No homology MKAN27680 MMAR_2367 Keto acyl reductase 
 No homology No homology  MKAN27695 No homology Glycosyl transferase 
 
5.2 Materials and Methods 
5.2.1 In silico analysis 
The gene sequences for M. kansasii genes MKAN27435 (codes for a glycosyl transferase), 
MKAN27485 (codes for a polyketide synthase) and MKAN27530 (codes for mmpL12) were 
obtained from the M. kansasii database (http://www.ncbi.nlm.nih.gov/genome) and for M. 
canetti genes MCAN_15191 (losA) and MCAN_15431 (mmpL12) were obtained from M. 
canetti database (http://www.ncbi.nlm.nih.gov/genome). The protein sequence alignments 
were done using blastp, two sequence alignments on (http://blast.ncbi.nlm.nih.gov).  
5.2.2 Plasmids, DNA manipulations and bacterial growth conditions 
Table 5-2 lists the plasmids, bacterial strains and mycobacteriophages used in this study. E. 
coli strains were routinely cultured in LB broth at 37°C. M. smegmatis strain mc
2
155 was 
cultured at 37°C in TSB with 0.05% Tween 80. The generation and propagation of 




mycobacteriophages was done on a lawn of M. smegmatis at 30°C in 7H10 basal plates 
overlaid with 7H9 soft agar as described in Chapter 7. High titres of mycobacteriophages 
were generated using protocols described in Chaper 7 (Larsen et al. 2007). M. kansasii and 
M. canetti strains were grown in 7H9 broth supplemented with 10% OADC (oleic acid, 
albumin, dextrose and catalase) and 0.05% Tween 80, at 37°C. For growth on plate, 7H10 
media was supplemented with 10% OADC and incubated at 37°C. Antibiotics were added for 
selection where required. Hygromycin was used at 150 µg/ml and 100 µg/ml for E. coli and 
M. smegmatis respectively and at 50 µg/ml for M. kansasii and M. canetti. Kanamycin was 
used at 50 µg/ml for E. coli and at 25 µg/ml for M. smegmatis, M. kansasii and M. canetti.  
Table 5-2Plasmids, phages and Bacterial strains used in this study. 
Plasmids, phages and strains Description Reference 
Plasmids   
p0004S Cosmid vector containing Hyg-
sacB cassette 
Larsen et al., 2007 
p∆MKAN27435 Derivative of p0004s cosmid 
obtained by cloning upstream 
and downstream flanks of 
MKAN27435 
This work 
p∆MKAN27485 Derivative of p0004s cosmid 
obtained by cloning upstream 
and downstream flanks of 
MKAN27485 
This work 
p∆MKAN27530 Derivative of p0004s cosmid 
obtained by cloning upstream 
and downstream flanks of 
MKAN27530 
This work 
p∆MCAN_15191 Derivative of p0004s cosmid 
obtained by cloning upstream 
and downstream flanks of 
MCAN_15191 
This work 
p∆MCAN_15431 Derivative of p0004s cosmid 
obtained by cloning upstream 








, E. coli-mycobacterial 
shuttle vector (ColE1-MPhsp60) 
Stover et al., 1991 
pMV261- MKAN27435 Functional copy of MKAN27435 
cloned into pMV261 shuttle 
vector 
This work 
Phages   
phAE159 Thermo sensitive, conditionally 
replicating shuttle phasmid 
Larsen et al., 2007 






ph∆MKAN27435 Derivative of phAE159 obtained 
by cloning p∆MKAN27435 into 
its PacI site 
This work 
ph∆MKAN27485 Derivative of phAE159 obtained 
by cloning p∆MKAN27485 into 
its PacI site 
This work 
ph∆MKAN27530 Derivative of phAE159 obtained 
by cloning p∆MKAN27530 into 
its PacI site 
This work 
ph∆MCAN_15191 Derivative of phAE159 obtained 
by cloning p∆MCAN_15191 into 
its PacI site 
This work 
ph∆MCAN_15431 Derivative of phAE159 obtained 
by cloning p∆MCAN_15431 into 
its PacI site 
This work 
Bacterial strains   
E. coli Top 10 F– mcrA Δ(mrr-hsdRMS-
mcrBC) Φ80lacZΔM15 
ΔlacX74 recA1 araD139 Δ(ara 
leu) 7697 galU galK rpsL 
(StrR) endA1 nupG 
Invitrogen 
E. coli HB101 E. coli K-12 _F- mcrB mrr 
hsdS20(rB- mB-) recA13 leuB6 
ara-14 proA2 lacY1 galK2 xyl-5 




155 Wild type strain, Eptmutant of 
M. smegmatis strain mc
2
6 
Snapper et al. 1990 
M. kansasii ATCC12478 Wild type strain of M. kansasii Generous gift from 
DR. Ben Appelmelk, 
VUMC, Amsterdam 
M. canetti Wild type strain of M. canetti  
∆MKAN27435 M. kansasii strain with 
MKAN27435 replaced with hyg 
cassette 
This work 





5.2.3 Construction of knockout phages 
Approximately 1kb regions upstream and downstream of gene (s) identified in 5.2.1, were 
PCR amplified using genomic DNA from M. kansasii ATCC-12478 and M. canetti. The 
primer pairs are listed on Appendix-9. The PCR products were purified, digested with 
respective enzymes and cloned on either side of a hygromycin (hyg) cassette in the plasmid 
p0004S (Stover et al. 1991) to generate the allelic exchange substrate plasmid listed in Table 




5-2. The allelic exchange plasmids were sequenced to confirm the presence of upstream and 
downstream regions of the respective genes. The allelic exchange plasmids were then cloned 
into the temperature sensitive phasmid phAE159 at the PacI site and packaged into empty λ-
phage heads. The packaged phasmids were transduced into E. coli HB101cells.  
The positive phasmid for each gene was transformed by electroporation into M. 
smegmatis mc
2
155 and recovered at 30°C for 3 to 4 hrs in 1 ml of TSB containing 0.05% 
Tween 80. The recovered cells were split into 200 µl and 800 µl and mixed with 100 µl of 
log phase M. smegmatis and 5 ml of molten 7H9 soft agar. This mix was overlaid on 7H10 
basal plates and incubated at 30°C for 2 to 3 days for plaques to be formed. The plates were 
soaked in MP buffer for 4 to 6 hours and syringe filtered and either used straight away or 
stored at 4°C. 
5.2.4 Generation of null mutants 
Specialised transduction of M. kansasii ATCC-12478 and M. canetti were performed as 
described for other mycobacterial species (Bardarov et al. 2002). M. kansasii and M. canetti 
cultures were grown in 7H9 media containing 10% OADC and 0.05% Tween 80 to an 
OD600nm of 0.8 and harvested by centrifugation. The cell pellet was washed twice with an 
equal volume of MP buffer (composition in Chapter 7). Finally, the cells were suspended in 




) phage lysate (1ml) was mixed with 1 
ml of cells for transduction, and 1 ml of MP buffer mixed with 1 ml of cells for a control 
reaction and incubated at 37°C for 24 hrs, harvested and recovered on 7H9 media 
supplemented with 10% OADC and 0.05% Tween 80 for at 37°C. The recovered cells were 
harvested and resuspended 400-600 µl of 7H9 media and plated on 7H10 agar supplemented 
with 10% OADC and 50 µg/ml hygromycin for selection. After 3 to 4 weeks of incubation, 
hygromycin resistant colonies that appear on the plates were inoculated into 10 ml of 7H9 




media supplemented with 10% OADC, 0.05% Tween 80 and 50 µg/ml of hygromycin for 
genomic DNA extraction and further characterisation. Allelic exchange of each gene with 
hyg cassette in transductants was confirmed by Southern blot. 
 
5.2.5 Generation of complemented strains 
MKAN27435 was amplified from M. kansasii WT genomic DNA using the primer pair 
MKAN27435_F 5’ATGCGAATTCGTGGATTCGGTCAGCGTTG3’ and MKAN27435_R 
5’ATGCAAGCTTTCAGTCCGCCGGATTGTCGAAG3’. The PCR product was  digested 
with EcoRI and HindIII and cloned into mycobacterial replicative plasmid pMV261 (Stover 
et al. 1991). The cloned PCR product was verified by sequencing and subsequently 
electroporated into the ∆MKAN27435 strain. The transformants were selected on 7H10 plates 
containing 100 µg/ml hygromycin and 25 µg/ml kanamycin. One such transformant was 
called ∆MKAN27435-C and used for all subsequent characterisation. 
5.2.6 Analysis of cell wall lipids from M. kansasii strains 
M. kansasii WT, ∆MKAN27435 and ∆MKAN27435-C cultures were grown at 37°C, to mid-
log phase in 10 ml of 7H9 medium supplemented with 10% OADC and 0.05% Tween -80. 
[
14
C]-acetate, (50 µCi, 57 mCi/mmol, GE Healthcare, Amersham Biosciences) was added to 
a mid-log phase culture and grown for a further 24 hrs to label lipids. The labelled bacterial 
cultures were harvested and washed with PBS. The washed pellet was resuspended in 2 ml of 
methanolic saline (methanol: 0.3% NaCl, 10:1 v/v) and apolar lipids extracted using 2 ml of 
petroleum ether (60-80 bp). Polar lipids containing glycolipids were extracted first with 
chloroform: methanol: water (9:10:3) and twice with chloroform: methanol: water (5:110:4). 
The two extractions were pooled and mixed with 1.3 ml of chloroform and 1.3 ml of 0.3% 
NaCl, mixed and centrifuged. The lower organic layer containing polar lipids were collected, 
dried and re-constituted in chloroform: methanol (2:1). The polar lipids were analysed by 2D 




TLC visualised by autoradiography by exposing a Kodak MR film to the TLC plates 
overnight (Dobson et al. 1985). 
5.2.7 Purification of LOS’s from M. kansasii WT and Δ27435 mutant species 
180 mg of polar lipids extracted from 20 g of dried cells of M. kansasii WT and 
ΔMKAN27435 strains. DEAE-cellulose column was equilibrated with chloroform: methanol 
(2:1) before applying polar lipids. The column was eluted with first, 10 column volumes of 
chloroform: methanol (2:1) followed by 10 column volumes of 10 mM, 25 mM, 100 mM and 
500 mM ammonium acetate in chloroform: methanol (2:1). The fractions were collected and 
analysed using 2D TLC (Dobson et al. 1985) and visualised by spraying the TLC plates with 
α-naphthol/sulphuric acid.  
5.2.8 Mass spectroscopic analysis of LOS subclasses from M. kansasii WT 
and mutant 
The LOS subclasses from WT and mutant M. kansasii were permethylated using the sodium 
hydroxide procedure. For each sample, about 5 NaOH pellets were ground to fine powder in 
a dry mortar with a pestle. About 3 ml of anhydrous DMSO (for each sample) was added to 
form slurry. About 1 ml of the resulting slurry was added to the sample before 0.5 ml of 
methyl iodide was added. The reaction mixture was mixed on a vortex and then agitated on 
an automatic shaker for 30 minutes at room temperature. The reaction was quenched with 
water, while constantly shaking the tube. Permethylated samples were extracted with 1 ml of 
chloroform and washed several times with 3 ml of water. The chloroform was dried down 
under a gentle stream of nitrogen gas before sample purification using a Sep-Pak C18 
cartridge. The permethylated LOS were then dissolved in methanol before an aliquot was 
mixed at a 1:1 ratio (v/v) with 10 mg/ml 3, 4-diaminobenzophenone in 75% acetonitrile. The 
glycan-matrix mixture was spotted on a target plate and dried. MALDI-TOF MS data were 




obtained using a 4800 MALDI-TOF/TOF mass spectrometer (AB Sciex UK Limited) in the 
positive ion mode. The obtained MS data were viewed and processed using Data Explorer 4.9 
(AB Sciex UK Limited). 
5.2.9 Macrophage infection studies 
The ability of M. kansasii and ∆MKAN27435 strains to survive in macrophages was tested 
using J774 macrophage cell line. Briefly, J774 cells were grown in Dulbecco’s Modified 
Eagle’s Medium (DMEM) containing glutamine and 10% foetal bovine albumin, 100 µg/ml 
penicillin and 100 µg/ml streptomycin (complete DMEM). The J774 macrophage cells were 
enumerated on a haemocytometer and adjusted to 1 X 10
5
cells per ml and adhered to a 24 
well plate overnight at 37°C. M. kansasii WT, ∆MKAN27435 and ∆MKAN27435-C cultures 
were grown to late log phase and harvested. The harvested cultures were washed with PBS 
and resuspended in complete DMEM to give 1 X 10
6
 cells per ml. J774 macrophage cells 
were activated with 15 µg/ml PMA (phorbol 12-myristate 13-acetate) for 1 hour and infected 
with bacterial cultures resuspended in complete DMEM with a multiplicity of infection (moi) 
of 10 (i.e. 10 bacteria per macrophage cell) for 4 hrs. The infection was done in triplicates. 
The infection medium was removed at the end of 4 hrs, washed twice with PBS and once 
with complete DMEM containing 50 µg/ml gentamycin. Cells were incubated in 1 ml 
complete DMEM at 37°C. This post-infection media was collected after 24 hrs, 72 hrs and 
120 hrs for TNF-α analysis and intracellular bacterial survival is determined by lysing the 





on 7H10 plates supplemented with 10% OADC.  





5.3.1 In silico analysis 
We first compared the gene cluster from M. kansasii, M. canetti and M. tuberculosis with M. 
marinum to identify the LOS biosynthetic cluster (Table 5-1). MKAN27435 and 
MCAN_15191 were both annotated as putative glycosyltransferases (GTFs) in their 
respective genome databases. MKAN27485 was annotated as a polyketide synthase and 
MKAN27530 and MCAN_15431 were both annotated as MmpL that are involved in the 
transport of complex lipids in mycobacteria.  
BLASTP analysis using MKAN27435 revealed matches to LosA (MMAR2313) and 
WcaA (MMAR2333), but relatively low scores: 26% identity and 42% similarity with LosA 
and 23% identity and 43% similarity with WcaA. A preliminary amino acid sequence 
analysis of MKAN27435 revealed a domain characteristic of members of the GT-2 family of 
glycosyltransferases that are similar to eukaryotic dolichol phosphate mannose (DPM) 
synthases. These GTFs, that typically contain a GT-A fold, catalyse the transfer of sugarsto 
dolichol phosphate by using sugar nucleotide as substrates. Topology predictions also 
indicated the presence of two transmembrane helices, indicating a membrane-associated 
function. Additionally, the C-terminal region of MKAN27435 contains a domain similar to 
the solute binding domain of SLC5 proteins which are Na
+
/sugar co-transporters with affinity 
for D-galactose, D-glucose, and D-fucose. Given the presence of fucose in M. kansasii LOSs, 
it seemed likely that MKAN27435 played a direct or indirect role in the addition of a fucose 
residue during LOS biosynthesis in M. kansasii (Figure 5-2). 





Figure 5-2 Predicted topology of MKAN27435showing domain organisation (shown in colour) and 
transmembrane domains shown with bars along with spanning regions. 
 
BLASTP analysis of MCAN_15191 revealed homology to MMAR_2313 (Figure 5-3), 
annotated as losA, which is involved in the generation of a lipid bound N-acyl 4,6 
dideoxygalactose which is subsequently transferred by an extracellular glycosyltransferase to 
LOS-III to form LOS-IV (Burguière et al. 2005). Primary sequence analysis of MCAN_15191 
for a conserved domain also revealed the presence of a DPM-like domain. The genetic locus 
of MCAN_15191 near LOS biosynthesis genes and that it encodes for a putative GTF; is 
likely to be involved in LOS biosynthesis in M. canetti.   
MCAN_15191     1 MRLSIVTTMYMSEPYVLEFYRRARAAADKITPDVEIIFVDDGSPDAALQQAVSLLDSDPC 
MMAR_2313      1 MRLSIVTTLYMSEPYVLEFYRRVRAAADKITSDVEMIFVDDGSPDGSLDQAVSLLGKDPS 
                 ******** ************* ******** *** *********  * ******  **  
 
MCAN_15191    61 VRVIQLSRNFGHHKAMMTGLAHATGDLVFLIDSDLEEDPALLEPFYEKLISTGADVVFGC 
MMAR_2313     61 VRVIQLSRNFGHHKAMMTGLAHATGDLVFLIDSDLEEDPALLEQFYEKLIATDADVVFGC 
                 ******************************************* ****** * ******* 
 
MCAN_15191   121 HARRPGGWLRNFGPKIHYRASALLCDPPLHENTLTVRLMTADYVRSLVQHQERELSIAGL 
MMAR_2313    121 QAQRPGSWWKNFGPKMHYRASAMLCNPPLHENVLTVRLMRADYVRCLVQHQERELSIAGL 
                  * *** *  ***** ****** ** ****** ****** ***** ************** 
 
MCAN_15191   181 WQITGFYQVPMSVNKAWKGTTTYTFRRKVATLVDNVTSFSNKPLVFIFYLGAAIFIISSS 
MMAR_2313    181 WQITGFNQIPMSVHKASKGTTTYTFAHKVKALVDNVTSFSNKPLVFIFYLGAVIFMISSL 
                 ****** * **** ** ********  **  ********************* ** ***  
 
MCAN_15191   241 AAGYLIIDRIFFRALQAGWASVIVSIWMLGGVTIFCIGLVGIYVSKVFIETKQRPYTIIR 
MMAR_2313    241 AAGYLIIDRLFFRVLLGGWPSLIVSIWMLGGLTIFCLGLIGIYISKIFTETKQRPYTIIR 
                 ********* *** *  ** * ********* **** ** *** ** * *********** 
 
MCAN_15191   301 RIYGSDLTTREPSSLKTAFPAAHLSNGKRVTSEPEGLATGNR 
MMAR_2313    301 RIYGPNFTSQGPASLEAAFRAMPPASWERFGADPVRSPRGDR 
                 ****   *   * **  ** *       *    *     * * 
 
Figure 5-3 Alignment of the MCAN_15191with MMAR_2313, known glycosyl transferase. The conserved 
amino acids are marked by anasterisk (*) below the alignment. 




The gene MKAN27485 annotated as pks5, encodes for a putative polyketide synthase. 
MKAN27485 encodes a 2095 amino acid protein that shares 76% identities with 
MMAR_2340, which also encodes for pks5. Polyketide synthases are multi-domain enzymatic 
complexes and consist of an acyltransferase domain, Gro-ES like alcohol dehydrogenase 
domain, zinc-binding dehydrogenase domain, ketoreductase domain and a phosphpantheteine 
attachment site towards the C-terminus, that catalyse formation of polyketides by processive 
condensation reactions (Porter et al. 2013).   
MKAN27530 and MCAN_15431 are annotated as MmpL12 in M. kansasii and M. 
canettigenome databases, respectively. MmpL’s are transmembrane proteins with 12-13 
transmembrane helices and  are involved in the transport of complex lipid molecules across 
the membrane for cell wall assembly (Varela et al. 2012). Albeit, the role of MmpL’s in the 
transport of LOS are not well established. We wanted to test this hypothesis since these genes 
are located close to the LOS biosynthetic cluster. 
5.3.2 Generation of null mutants 
Specialised transduction, a highly efficient mycobacterial knock out method, was employed 
to generate null mutants in M. kansasii and M. canetti. This is the first report of the use of 
phages for delivering allelic exchange substrates for targeted gene knockouts in either 
species. We could only generate a null mutant of MKAN27435 out of three genes attempted 
and transductants were obtained for the two of the M. canetti genes. The gene deletion was 
confirmed by Southern blot (Appendix 12). The knock out strain was complemented by 
introducing a plasmid borne functional copy of MKAN27435 and henceforth will be refered 
to as ∆MKAN27435-C. 




5.3.3 Effect of deletion of MKAN27435 on colony morphology 
Colony morphology of mycobacteria is affected by changes in the composition of cell wall 
lipids (Chen et al. 2006; Alexander et al. 2004; Sarkar et al. 2011). Previously, a LOS 
deficient M. kansasii was shown produce rough colonies (Daffe et al. 1991).Thus, affecting 
LOS biosynthesis was expected to alter the colony morphology in the mutant strain. M. 
kansasii WT, mutant (∆MKAN27435) and complemented (∆MKAN27435-C) strains were 
grown 7H10 agar plates supplemented with 10% OADC. Surprisingly, the mutant strain 
∆MKAN27435 did not show any alterations in colony morphology (Figure 5-4).  
 
Figure 5-4 Colonies of M. kansasii WT, ∆MKAN27435 and ∆MKAN27435-C grown on 7H10 agar 
supplemented with 10% OADC, after incubation at 37°C for 10 days. 
 
5.3.4 Analysis of total lipids from the ∆MKAN27435 mutant 
To assess the effects of loss of ∆MKAN27435 function on cell wall lipid composition, 
cultures of M. kansasii WT, mutant (∆MKAN27435)and complemented (∆MKAN27435-C) 
strains were grown in 7H9 medium supplemented with 10% OADC and 0.05% Tween-80 
and labelled with [
14
C]-acetate. Polar lipids were extracted and analysed by 2D TLC using 
System E, designed to separate LOSs and phospholipids as described by Dobson et al. 
(1985). Autoradiographs of 2D TLCs, revealed an altered pattern of LOS species in the 
mutant strain; while the WT produced all the subclasses of LOS’s (LOS-I, LOS-II, LOS-III, 
LOS-IV, LOS-V, LOS-VI and LOS-VII)  the mutant produced LOS-I, LOS-II and LOS-III 
but LOS-IV, LOS-V, LOS-VI and LOS-VII were missing in the strain (Figure 5-5). 




Furthermore, a new set of less abundant polar lipid species were detected in the mutant strain 
(Figure 5-5). Synthesis of all LOS species was restored in the mutant strain on introduction of 
a plasmid-encoded copy of MKAN27435 (Figure 5-5), indicating that the observed alteration in 
LOS patterns in the mutant was solely due to the loss of MKAN27435 function. 
 
Figure 5-5 Autoradiograph of 2-D TLC analysis of polar lipids extracted from M. kansasii WT, 
∆MKAN27435, ∆MKAN27435-C strains. The different LOS species are indicated by arrows. I and II indicate 
system E dimension 1 and 2 respectively. Dimension I: Chloroform: methanol: water (60:30:6) and dimension 
II: Chloroform: acetic acid: methanol: water (40:25:3:6). 
 
Further, the polar lipids were analysed by 2D-TLC using system E and stained with 
phosphate stain. This was done to distinguish between phospholipids and LOSs.  
 
Figure 5-6:  2D-TLC analysis of polar lipids extracted from M. kansasii and ∆MKAN27435 strains and 
stained with phosphate stain to visualise phospholipids. I and II indicate system E dimension 1 and 2 
respectively. Dimension I: Chloroform: methanol: water (60:30:6) and dimension II: Chloroform: acetic acid: 
methanol: water (40:25:3:6). 




5.3.5 Purification of LOS sub-classes from M. kansasii WT and ∆MKAN27435 
Polar lipids extracted from M. kansasii WT and ∆MKAN27435 were separately applied to a 
DEAE-cellulose column and eluted with chloroform: methanol (2:1). All the subclasses of 
LOSs were expected not to bind to the column and come through in the flow through (FT), as 
LOSs are non-ionic polar lipids leaving behind charged phospholipids. The FT fraction was 
analysed by 2D-TLC using system E and visualised by α-naphthol/ sulphuric acid, which 
revealed, as expected all the LOS subclasses were present in the FT fraction (Figure 5-7). 
 
 
Figure 5-7: 2D-TLC analysis of purified LOSs from M. kansasii WT polar lipids. I and II indicate system E 
dimension 1 and 2 respectively. Dimension I: Chloroform: methanol: water (60:30:6) and dimension II: 
Chloroform: acetic acid: methanol: water (40:25:3:6). 
 
The LOS subclasses from ∆MKAN27435 polar lipids were eluted first with 
chloroform: methanol (2:1) followed by 10mM, 25mM and 100mM Ammonium acetate in 
chloroform: methanol (2:1). The fractions were analysed by 2D-TLC using system E and 
visualised by α-naphthol/ sulphuric acid. The 2D-TLC revealed that all the subclasses of LOS 
are produced by ∆MKAN27435 does not bind to the column and comes through in the FT 
fraction (Figure 5-8).  





Figure 5-8: 2D-TLC analysis of purified LOS fractions from ∆MKAN27435. (A) FT fraction containing all 
the subclasses of LOSs (B) 10 mM ammonium acetate fraction (C) 25 mM ammonium acetate fraction and (D) 
100mM ammonium acetate fraction 
  
5.3.6 Characterisation of LOSs 
Purified LOSs from M. kansasii WT and ∆MKAN27435 strains were subjected to mass 
spectroscopic analysis. For this, LOS’s were subjected to either per-O-methylation and then 
subjected to MALDI-TOF. All the subclasses of LOSs except LOS-VII were identified from 
M. kansasii WT purified LOSs while mutant showed the accumulation of LOS-P, precursor 
molecule for LOS biosynthesis and the presence of LOS-I, LOS-II and LOS-III (Figure 5-9). 
Higher subclasses of LOS’s namely LOS-IV, LOS-V, LOS-VI and LOS-VII were missing. 
Mass spectroscopic analysis of the LOSs from mutant ∆MKAN27435, also showed the 




presence of shunt product in relatively low abundance (Figure 5-9) (a detailed mass 
spectroscopic analysis provided in Appendix-13). The shunt products were characterised by 
incremental molecular weight corresponding to a pentose. The mass spectroscopic analysis is 
summarised in Table 5-4. 
 
Figure 5-9: Mass spectroscopic analysis of purified LOSs from WT and ∆MKAN27435 strains. LOS sub-
classes are indicated with corresponding m/z values. Species indicated with an asterisk (*) correspond to m/z 
values with an intact acyl group are indicated 
 
LOS-III is converted to LOS-IV by the addition of fucose through glycosidic linkage 
to xylose in the growing oligosaccharide chain. Further addition of N-acyl kansosamine to 
fucose yields LOS-IV. Similarly, LOS-V, LOS-VI and LOS-VII are formed by the addition 
of fucose and N-acyl kansosamine residues to LOS-III core with an additional xylose residue 
acting as precursor molecule.  Mass spectroscopic analysis reveals that the mutant strain is 
defective in adding fucose residue to the growing oligosaccharide chain thus accumulating 
shunt product lacking fucose and N-acyl kansosamine. Given the similarity of MKAN27435 
to DPM like glycosyl transferases, the findings suggest that MKAN27435 is involved in the 
transfer of nucleotide bound fucose residue to a polyprenol based lipid carrier. Polyprenol 
bound fucose could then be ‘flipped’ across the membrane and subsequently utilised as a 
substrate by an extracellular fucoosyl transferase to add the fucose to LOS-III.    




Table 5-3: MALDI-TOF mass spectroscopy analysis tabulated to list LOS species with corresponding m/z 
values in M. kansasii and ∆MKAN27435 strains. Asterisk (*) indicates species with an intact acyl group. 
Presence (+) or absence (-) of each species indicated for each species, m/z values correspond to [M+Na
+
]. 
m/z LOS sub-classes M.kansasii WT ∆MKAN27435 
1059.6 LOS-P + + 
1283.8 LOS-P* + + 
1219.7 LOS-I + + 
1443.91 LOS-I* + + 
1379.8 LOS-II + + 
1604 LOS-II* + + 
1539.9 LOS-III + + 
1764.1 LOS-III* + + 
2148.2 LOS-IV + - 
2372.4 LOS-IV* + - 
2308.3 LOS-V + - 
2532.5 LOS-V* + - 
2468.4 LOS-VI + - 
2692.6 LOS-VI* + - 
2628.5 LOS-VII - - 
2852.7 LOS-VII* - - 
 
 
Table 5-4 MALDI-TOF mass spectroscopic analysis tabulated to list shunt products and corresponding m/z 
values in ∆MKAN27435 strain; shunt products with an asterisk (*) correspond to m/z values with an intact acyl 
group. m/z values correspond to [M+Na
+
]. 
m/z Shunt product ∆MKAN27435 
1699.9 Shunt product-1 LOS-III +  pentose 
1860.1 Shunt product-2 LOS-III + 2 (pentose) 
2021.1 Shunt product-3 LOS-III + 3 (pentose) 
2181.2 Shunt product-4 LOS-III + 4 (pentose) 
2341.3 Shunt product-5 LOS-III + 5 (pentose) 
2501.6 Shunt product-6 LOS-III + 6 (pentose) 
1924.2 Shunt product-1* LOS-III + pentose 
2085.3 Shunt product-2* LOS-III + 2 (pentose) 
2245.3 Shunt product-3* LOS-III + 3 (pentose) 
2404.4 Shunt product-4* LOS-III + 4 (pentose) 









5.3.7 Intracellular survival of the MKAN27435 null mutant in macrophages 
Previous studies with LOS deficient strains of M. kansasii  has shown that they could persist 
longer in mice  (Collins & Cunningham 1981) and consistent with this observation, LOS 
deficient M. marinum strains were shown to be effectively phagocytosed (Alibaud et al. 
2014). But on the contrary, a M. marinum strain defective in LOS-IV production  was 
inefficient in entering murine macrophages (Burguière et al. 2005; Alibaud et al. 2014). 
However, both a LOS-IV deficient M. marinum mutant and LOS-II* accumulating M. 
marinum mutant had elicited increased levels of cytokine release (Burguière et al. 2005; 
Sarkar et al. 2011). The M. kansasii mutant strain ∆MKAN27435 was missing higher LOS 
species namely LOS-IV, LOS-V, LOS-VI and LOS-VII. In order to assess the role of 
MKAN27435 deficient strain in virulence, an intracellular survival assay was performed using 
the J774 macrophage cell line. Macrophages were infected with ∆MKAN27435 to determine 
the ability to survive in the macrophages and alter immune response. The number of 
intracellular bacteria (colony forming units) was enumerated by lysing the macrophages and 
plating the lysate dilutions on 7H10 agar plates. The infection experiments were done in 
triplicate. 
Disruption of MKAN27435 did not affect the ability of the mutant strain to survive 
with in J774 macrophage cell line (Figure 5-10). M. marinum strains with gene disruptions 
leading to defects in LOS biosynthesis had also showed similar results (Burguière et al. 2005; 
Sarkar et al. 2011), however it led to alteration in immune response. In order to assess this, 
TNF-α level in the cell culture supernatant was estimated. To detect the TNF-α levels ELISA 
was performed, which revealed that the mutant strain ∆MKAN27435 did not affect the TNF-α 
production significantly (Figure 5-11).  





Figure 5-10: Survival of M. kansasii strains in infected J774 macrophage cell line. Survival of the WT, 
mutant and complemented strains were measured by plotting CFU/ml on log scale as a function of time. CFU 
counting was done by lysing the infected macrophages and plating the dilutions of lysate on 7H10 plates. 
 
 
Figure 5-11: TNF-α production by J774 macrophages post infection with M. kansasii strains. Cytokine 
released in the spent media from the infected J774 cell line was measured using mouse TNF-α kit at different 
time points. 
 





M. kansasii causes chronic pulmonary disease in immune-compromised individuals and is the 
second most prevalent of non-tuberculosis mycobacterial (NTM) infection (Han et al. 2010; 
Anon 1997). M. kansasii is genetically close to M. tuberculosis and can be handled without 
BSL-3 facilities. These factors make M. kansasii an attractive model to study mycobacterial 
pathogenesis. 
Mycobacterial cell wall associated lipids play a vital role in virulence and antigenicity 
(Daffe & Draper 1998; Domenech et al. 2004). Lipooligosaccharides are one such antigenic 
surface glycolipid. Interestingly, the M. tuberculosis complex organism M. canetti is an 
opportunistic pathogen produces LOSs (Daffe et al. 1991), but the highly virulent M. 
tuberculosis does not produce LOSs. Recent studies have shown that approximately one third 
of the LOS gene cluster is present in M. tuberculosis (Ren et al. 2007). LOSs have been 
implicated to play a role in sliding motility, biofilm formation and eliciting an immune 
response (Ren et al. 2007; Burguière et al. 2005; Sarkar et al. 2011). The role of LOS’s in 
virulence has been shown in mice studies, wherein LOS deficient strains persisted longer in 
mice lungs as opposed to LOS producing strains (Belisle & Brennan 1989). While the 
structure of the LOS’s has been largely understood, there’s been little research on their 
biosynthesis (Minnikin et al. 1989; Picardeau et al. 1997). The role of individual LOS sub- 
classes in antigenicity and its immunomodulation can be made possible by generating 
deletion mutants that are defective in making particular LOS subspecies. 
 In this study, our aim was to dissect the biosynthesis of LOS’s by generating deletion 
mutants of genes involved in the LOS biosynthesis. In this regard, we have generated a 
deletion mutant of MKAN27435 that is defective in making four of the seven subclasses of 
LOS’s.  This study also demonstrates the utility of specialised transduction to generate null 




mutants of M. kansasii.  This is the first report of the use of phages for delivering the allelic 
exchange substrate for targeted gene knockouts in this species. Bioinformatics analysis of 
MKAN27435 revealed that it encodes a putative glycosyltransferase. A preliminary amino 
acid sequence analysis of MKAN27435 revealed a domain characteristic of members of the 
GT-2family of glycosyltransferases that are similar to eukaryotic dolichol phosphatemannose 
(DPM) synthases and a solute binding domain of SLC5 proteins which are Na
+
/sugar co-
transporters with affinity for D-galactose, D-glucose, and D-fucose. Given the presence of 
fucose in M. kansasii LOSs, it seemed likely that MKAN27435 plays a direct or indirect role 
in the addition of a fucose residue during LOS biosynthesis in M. kansasii. Consistent with 
the bioinformatics analysis, biochemical results implicated that MKAN27435 intercepts 
conversion of LOS-III to LOS-IV. Mass spectroscopic analysis and 2D TLC analysis 
revealed that mutant strain lacks the ability to produce higher LOS sub-classes viz. LOS-IV, 
LOS-V, LOS-VI and LOS-VII. Interestingly, LOS-VII was not identified in the mass 
spectroscopic analysis of purified LOSs from both M. kansasii WT and mutant strain. One 
possible explanation is that LOS profile is affected by growth phase and media conditions 
(Burguière et al. 2005).  
The resemblance of MKAN27435 to bacterial DPM-like synthases suggests that it is 
unlikely that the glycosyltransferase (GTF) is involved directly in the formation of LOS-IV 
or higher subclasses. It is very likely that it is involved in the generation of a sugar donor in 
the form of polyprenol phosphate or a similar lipid carrier. This carrier could then be flipped 
across the membrane by either the same protein or by yet unidentified ‘flippase’ where it is 
used as a substrate by an extracellular fucosyltransferase to add the fucose to LOS-III. In 
vitro confirmation of these activities could not be accomplished due to limitations such as, 
availability of substrates. This is the first insight into LOS biosynthesis in M. kansasii. The 
LOS biosynthetic gene cluster consists of few more DPM-like GTFs and further studies of 




these genes will confirm this hypothesis. That should also enable us to build a model for LOS 
biosynthesis and its subsequent transport across the cell membrane. In this study we had also 
attempted to generate a null mutant of MKAN27530 which encodes a transporter protein 
MmpL12, which could have shed light into the transport of LOSs.  
Alteration in the colony morphology was not observed on inactivation of 
MKAN27435. Disruption in the LOS biosynthesis was expected to lead to rough colony 
morphology, however the ∆MKAN27435 colony had a smooth/glassy appearance, which may 
be due to LOS-I, LOS-II and LOS-III still being formed in considerable amounts. 
Intervention of biosynthesis further upstream in the pathway may lead to abolition of 
complete biosynthesis and may lead to rough variant. Generating null mutants of other 
annotated glycosyltransferases identified in the gene cluster, such as MKAN27425 and 
MKAN27580 will add to our current understanding.  
Disruption of LOS biosynthesis by inactivating MKAN27435 in M. kansasii did not 
affect its ability to survive in macrophages. The three subclasses of LOSs are still made in 
considerable amounts in∆MKAN27435 and could explain unaltered pathogenicity. Abolishing 
LOS biosynthesis completely or further upstream of the pathway may be more useful in 
understanding the role of LOSs in virulence.  
Further, efforts to understand the role of LOS in mycobacterial virulence were 
attempted by generating null mutants in M. canetti. However, due to time constrains we could 


























Over the last seven decades or so our understanding of mycobacterial cell wall has made a lot 
of progress taking giant leaps in the last two decades. The complex nature of the cell wall has 
come under scrutiny and intense investigation by the international research community. 
Number of components that make up the complex cell wall has been shown to be 
indispensable for the survival of mycobacteria and the importance of mycolic acid for the 
integrity of the cell wall (Brennan 2003; Brennan & Nikaido 1995; Barry et al. 1998). 
Biosynthesis of mycolic acid is thoroughly studied and the enzymes involved are 
biochemically characterised (Bhatt et al. 2005; A. Bhatt, Molle, et al. 2007; Jackson et al. 
1999; Marrakchi et al. 2002; Quémard et al. 1995; Smith et al. 2003; Choi et al. 2000). Some 
of the key aspects of mycolic acids biosynthesis are however still remain as important 
research questions. One of the key steps in the mycolic acid biosynthesis is bridging FAS-I 
and FAS-II, which is believed to be carried out by a type-III β-ketoacyl ACP synthase, FabH. 
In-vitro enzyme assays and structural studies supported this belief, however in-vivo data is 
still elusive (Scarsdale et al. 2001; Choi et al. 2000). This criticality of this reaction stems 
from inability for de-novo synthesis of fatty acids by FAS-II and dependence on short chain 
acyl co-A (C20-26) substrates ligated to ACP for its initiation (Takayama et al. 2005; Choi et 
al. 2000a). Although, fabH is listed as non-essential (Sassetti et al. 2003), no reports of 
successful generation of fabH KO mutant points at possible essentiality. This led to 
biochemical and structural characterisation of the protein and pursuing it as an anti-tubercular 
drug target (Choi et al. 2000a; Scarsdale et al. 2001; Lv et al. 2009; Liu et al. 2012). The 
essentiality of both fabH and the reaction it catalyses was thus probed in this thesis.  
 The genetic studies was carried out in M. bovis, routinely used as a surrogate 
organism to study biochemical processes of M. tuberculosis; to generate deletion mutant of 
fabH. A successful generation of fabH deletion mutant indicated its non-essentiality. Further, 
deletion of fabH did not affect the biosynthesis of mycolic acids. These results provided 




direct evidence contradicting general belief and supporting TraSH data. A careful 
bioinformatics analysis and literature survey were carried out to identify redundant β-
ketoacyl synthases present in M. tuberculosis since previously functional redundancies have 
been reported both in mycobacteria and its surrogates (Puech et al. 2002; Brand et al. 2003; 
Sousa-D’Auria et al. 2003; Meniche et al. 2009). Also, recently functional redundancy was 
also reported for FabH function in pseudomonas (Yuan, Leeds, et al. 2012). Bio-informatics 
analysis and literature reports pointed at Pks18 as a potential substitute for FabH (Saxena et 
al. 2003). pks18, like fabH is also non-essential. Multiple attempts at generating fabH: pks18 
double KO was not successful indicating at requirement of at least one of the genes for its 
survival. We are now using a genetic tool termed CESTET, a tool designed to test the gene 
essentiality in mycoabacterial species, to generate the double KO (Bhatt et al. 2005). 
CESTET method involves generating a merodeploid by introducing a functional copy of the 
gene to be tested under the control of inducible promoter and then substituting the native 
copy of the gene with a selection marker. Generation of double KO will help us provide 
crucial evidence for functional redundancy in mycobacterial FabH function. 
Another important question we sought to answer in this study is to get insights into 
transport of mycolic acids. Although mycolic acid biosynthesis was studied for years, it’s 
processing and transport is still in its rudimentary stage. The initial suggestions on how 
mycolic acids processing and transport could occur was outlined by Takayama and later by 
de Souza (Takayama et al. 2005; de Souza et al. 2008). In the recent years several class of 
inhibitors that affect mycolic acid biosynthesis were shown to generate mutations in MmpL3, 
indicating its possible role in mycolic acids biosynthesis and transport (Tahlan et al. 2012; La 
Rosa et al. 2012). MmpL3 was later shown to play a central role in mycolate transport 
(Varela et al. 2012). However, the mechanism of transport and the proteins associated with 
MmpL3 still remain a research question. Since MmpL3 is a potential high value drug target, 




delineating its mechanism could help in accelerating the drug discovery apart from 
understanding the underlying biochemistry. 
Towards this, studies aimed to characterise MmpL3 using biophysical techniques and 
resolve its structure by combining molecular model predictions with low resolution structure 
determination using Cryo-EM. However, MmpL3 is a transmembrane protein with twelve 
transmembrane helices and heterologous expression of such huge protein itself is difficult 
that hinders downstream characterisation. Thus the issue was approached by first, trying to 
characterise soluble cytoplasmic domains (Loop1 (ML1) and Loop2 (ML2)) with parallel 
efforts to express full length protein in sufficient amounts for biophysical and structural 
studies. We were successful in expressing these domains in sufficient quantity and purifying 
them to homogeneity. We showed that these domains when fused with an artificial linker 
peptide, behaves as a dimer, albeit in a minor population. Attempts at crystallising these 
domains were futile. Initial studies using NMR spectroscopy suggested that these domains 
fold properly but requires detailed study for resolving the structure. We are currently 
establishing collaborations for detailed NMR studies. 
The conditions were optimised for the expression of sufficient amounts of full length 
protein and purified to homogeneity. A styrene based co-polymer was used to isolate 
membrane protein from its native environment to purify the protein (Jamshad et al. 2011). 
Purified protein was confirmed using western blot and mass spectrometric analysis of trypsin 
digested fragments. Circular Dichroism study indicated proper folding of protein and thus, 
was used for downstream biophysical studies. A large population of MmpL3 behaves as a 
dimer and this observation was consistent across different biophysical experiments carried 
out. Further this was supported by earlier observations made with cytoplasmic domains, 
which exhibited a tendency to form dimers.  




MmpL3 belong to a class of RND proteins with 12 transmembrane helices and two 
cytoplasmic domains. The general architecture of the protein is depicted in Chapter 3. The 
model was built (in collaboration with Dr. Vassily Bavro) using other RND proteins (AcrB, 
CusA and SecDF), crystal structures of which are available (Tsukazaki et al. 2013; Murakami 
et al. 2002; Long et al. 2010). Protein yield for MmpL3 was not sufficient to set up protein 
crystallisation. Previously, Cryo-EM was  reported to be useful in solving low resolution 
structure of large mycobacterial proteins or protein complexes that are difficult to crystallise 
and to validate the model prediction of the proteins (Boehringer et al. 2013). We used Cryo-
EM and SAXS to analyse the structure of MmpL3 and to validate our model predictions. 
Analysis of the SAXS data was made difficult due the presence of membrane components 
and the polymer used for purification. Our collaborators are optimising the model building 
tool to accommodate polymer which should allow us to get refined low resolution structure of 
MmpL3. Analysis of Preliminary Cryo-EM data (done by our collaborators Dr. Sarah Lee, 
University of Birmingham) revealed that MmpL3 is a dimer which is in line with our earlier 
observations and the predicted model fit in the electron density envelope generated by Cryo-
EM data analysis. More data is currently being collected to get a higher resolution images. 
Model predictions also suggested that the mycolate transport could be possibly driven by 
proton motive force (Seeger et al. 2009; Long et al. 2010; Tsukazaki et al. 2013). Results 
obtained so far could not conclusively prove this hypothesis and requires more experiments. 
The conditions are now optimised for the sufficient protein yield of MmpL3 using 
fermentation process. Fermentation has helped increase the yield nearly 4 fold from 0.5 mg/L 
to 2 mg/L, and bulk cultures should give enough protein to carry out protein crystallography. 
However, an alternative or a traditional purification steps needs to be optimised since no 
crystallisation success has been reported with use of SMA solubilised protein yet which could 
be due to presence of polymer that encapsulates individual protein molecule, which might 




interfere with crystallisation. The protein thus purified might also find its usefulness in ligand 
binding assays due to the inherent fluorescence of the polymer. Alternatively radiolabelled 
ligands could be used in place of fluorescent ligands to overcome the interference of polymer 
in the binding assays. With protein purified in sufficient quantity also allows us to develop 
functional assays which will be helpful in deciphering function of the protein and also 
mechanism of action. The functionality assay will also provide a platform to test site directed 
mutants generated in this study to understand the role of individual aminoacids in transport 
mechanism.  
Previous studies with other MmpL proteins show that these proteins are likely to 
function as protein scaffolds. This allows coupling of biosynthesis and transport of these 
complex lipid molecules. MmpS proteins association with some of the MmpLs have also 
been shown indicating that transport is facilitated by associated proteins (Jain & Cox 2005; 
Zheng et al. 2011; Wells et al. 2013). Studies of protein complexes in mycobacteria and the 
STRING database indicated that genes co-localised in mmpL3 cluster are the most likely to 
assist in mycolate transport (Zheng et al. 2011; Franceschini et al. 2013). Pacheco et al. 
provided evidence to support these prediction by showing MmpL11 role in transporting 
mycolate containing lipids (Pacheco et al. 2013). The function of MSMEG0240 (orthologues 
of Rv0201), MSMEG0248 (Rv0204) and MSMEG0249 (Rv0205) were probed and evaluated 
its association with MmpL3 using protein-protein interaction studies using comprehensive 
bacterial two hybrid screens. Multiple attempts to delete MSMEG0248 failed suggesting its 
possible essentiality.  
Bacterial two hybrid screens have proven helpful in deciphering protein interactions 
and understanding the networking in accomplishing biological processes in mycobacteria 
(Jankute et al. 2014). A comprehensive bacterial two hybrid screen was carried out using 




MmpL3 as a bait protein. However, the screen could not identify the interacting partner 
which could be due to one of the (a) the prey proteins tested did not interact with MmpL3 and 
are not associated with mycolate transport, (b) the prey proteins investigated are associated 
with mycolate transport however requires presence of third protein to interact with MmpL3 
or (c) either or both bait and prey proteins are not expressed/ folded properly to give positive 
interaction. Bacterial two hybrid system has its limitations in that it may not be best suited to 
express membrane proteins. The fact that we had difficulties in expressing MmpL3 in E. coli 
suggests (c) would be the likely scenario. Using yeast two hybrid system in the place of 
bacterial two hybrid system may help to overcome these difficulties and yield conclusive 
results. Biophysical techniques such as AUC, size exclusion chromatography and protein 
cross linking studies have proven useful in studying protein-protein interactions require large 
amounts of purified protein (Roy et al. 2013; Tang & Bruce 2009). Availability purified 
MmpL3 in sufficient quantity will now help explore these avenues. Further, purified protein 
may also help generating protein specific antibodies that could be used in co-
immunoprecipitation experiments.    
This study has also attempted to understand the biosynthesis and transport of other 
important components of mycobacterial cell wall, lipooligosaccharides (LOSs). Interestingly 
virulent strains of mycobacteria viz. M. tuberculosis has selectively lost the ability to produce 
LOSs (Ren et al. 2007; Burguière et al. 2005) and also LOS deficient strains of opportunistic 
pathogen M. kansasii are more virulent (Collins & Cunningham 1981). These data indicates 
that LOSs behaves as surface antigens and plays a role in immunomodulation. Dissecting 
biosynthesis of LOSs through defined null mutants have proved useful in understanding 
specific role of LOSs in general (Ren et al. 2007; Rombouts et al. 2009; Rombouts et al. 
2010  Sarkar et al. 2011; Alibaud et al. 2014). Most of our current biosynthetic knowledge 
stems from genetic studies carried out in M. marinum. In this study we have attempted to 




study biosynthesis and transport of LOSs from two other mycobacterial strains that are 
evolutionary closely related to M. tuberculosis; M. kansasii and M. canetti (Veyrier et al. 
2009; Veyrier et al. 2011). LOS biosynthetic gene clusters were identified in M. kansasii and 
M. canetti by comparing it with M. marinum and representative genes from three classes of 
enzymes involved in LOS biosynthesis and transport were chosen for study. The three classes 
included glycosyltransferases, polyketide synthases and transporter proteins (MmpLs). Using 
a Specialised transduction, a null mutant of MKAN27435, a glycosyltransferase involved in 
LOS biosynthesis in M. kansasii, was generated (Bardarov et al. 1997). This is first report of 
targeted gene knock out using Specialised transduction in M. kansasii. Characterisation of the 
mutant revealed that the gene is involved in the conversion of LOS-III to LOS-IV and 
intercepts before the addition of fucose moiety. Deletion of MKAN27435 resulted in loss of 
higher subspecies of LOSs and accumulation of shunt products in low abundance. Loss of 
LOS subspecies did not affect TNF-α release from activated human macrophages nor 
survival.  
To date there is no clear idea about the location of the different stages of biosynthesis 
of LOSs. Sarkar et al. (2011) have suggested that early stages of biosynthesis occur in 
cytoplasm and the later stages are carried out by extra-cytoplsmic glycosyltransferases. Like 
in M. marinum, DPM like glycosyltransferases also found present in M. kansasii which are 
involved in generating polyprenol bound sugar substrates which are ultimately utilised by 
extracytoplasmic glycosyltransferases to generate higher subspecies of LOSs. In M. marinum 
the xylose is predicted to be added from a polyprenol donor by extracytoplasmic 
glycosyltransferase with polyprenol bound sugar substrate generated by a DPM like glycosyl 
transferase. Thus, one could suggest, in M. kansasii, LOS-I precursor synthesised in the 
cytoplasm is flipped across the membrane by a transporter protein (MmpL12) encoded by 
MKAN27530. M. kansasii LOS biosynthetic cluster consists of three DPM like 




glycosyltransferases encoded by MKAN27390, MKAN27425 and MKAN27695 and a DPM 
like active site containing glycosyltransferase encoded by MKAN27435, which are likely be 
involved in polyprenol bound sugar donors and a separate set of glycosyltransferases encoded 
by MKAN57580 and MKAN57600 which might be involved in elongation of oligosaccharide 
chain of LOSs to generate different subspecies of LOSs. However, generating null mutants of 
individual genes might shed more light into the biosynthesis of LOSs and the null mutant of 
MmpL12 would not only show its role in transport but also would help in understanding the 
location of different stages of LOS biosynthesis. 
Deletion of MKAN27435 did not affect the ability of the mutant to survive in activated 
macrophages nor did it induce or suppress the release of TNF-α. Earlier studies with purified 
LOS-IV showed suppression of TNF-α release from LPS activated macrophages (Rombouts 
et al. 2009). In a recent study an inverse relationship was established between phagocytosis 
and the LOS production in M. marinum (Alibaud et al. 2014). It would be interesting to test 
phagocytosis of the mutant generated in this study. Also intercepting LOS production at 
earlier stages would be interesting in terms of understanding its role in antigenicity, since 
more drastic changes might needed to see these effects.  
In conclusion, the study establishes the non-essentiality of fabH and suggests possible 
functional substitute in the form of pks18. Biophysical characterisation of MmpL3 revealed 
its oligomeric status and preliminary Cryo-EM data validates model predictions. The 
conditions for production of sufficient quantities of protein are now optimised, which was a 
bottleneck in the structural studies. The study also shows a clear role for MKAN27435, a 
























7.1 Media preparations 
7.1.1 Luria-Bertani (LB) broth 
LB broth was routinely prepared by dissolving 25 g of LB (Tryptone-Yeast extract-NaCl 
2:1:2 w/w/w) (Sigma-Aldrich) in 1 litre of distilled water and sterilised by autoclaving. 
7.1.2 LB agar 
LB agar was routinely prepared by dissolving 37 g of LB agar mix (Tryptone-Yeast extract-
NaCl-Agar 2:1:2:3 w/w/w/w) (Sigma-Aldrich) was dissolved in 1 L of distilled water and 
autoclaved. Alternatively, 15 g of bacto agar (BD) was added to 1 L LB broth and 
autoclaved. Antibiotics were added where required, to molten agar after cooling it down to 
approximately 55°C, mixed thoroughly before pouring into petri dishes (25 ml) aseptically. 
7.1.3 Tryptic Soy Broth (TSB) 
Tryptic soy broth was prepared by dissolving 30 g of TSB mix (Pancreatic casein digest- 
Papaic soybean digest-dextrose-NaCl-K2HPO4 34:6:5:10:5 w/w/w/w/w) (Sigma Aldrich) in 1 
L of distilled water and sterilised by autoclaving. 
7.1.4 Tryptic Soy Agar (TSA) 
TSA was prepared by adding 15 g of agar in 1 L of TSB and sterilised by autoclaving. 
Antibiotics were added where required, to molten agar after cooling it down to approximately 
55°C, mixed thoroughly before pouring into petri dishes (25 ml) aseptically. 
7.1.5 Middlebrooks 7H9 broth 
7H9 broth was prepared by dissolving 4.7 g of the Middlebrook 7H9 media (BD) in 900 ml 
of distilled water. 2 ml of glycerol was added to this and was sterilised by either filter 
sterilisation or autoclaving. 7H9 broth was supplemented with 10% ADC or OADC (BD) as 
required. 




7.1.6 Middlebrooks 7H10 agar 
7H10 agar was prepared by dissolving 19 g of the 7H10 Middlebrook media (BD) in 900 ml 
distilled water containing 5 ml glycerol and was sterilised by autoclaving. 100 ml of OADC 
(BD) and antibiotics were added to molten agar after cooling it down to approximately 55°C, 
mixed thoroughly before pouring into petri dishes (25 ml) aseptically. 
7.1.7 Middlebrooks 7H11 agar 
7H11 agar was prepared by dissolving 4.7 g of 7H11 Middlebrook media (BD) in 900 ml 
distilled water containing 5 ml glycerol and was sterilised by autoclaving. 100 ml of OADC 
(BD) and antibiotics were added to molten agar after cooling it down to approximately 55°C, 
mixed thoroughly before pouring into petri dishes (25 ml) aseptically. 
7.1.8 7H9 soft agar 
7H9 soft agar or top agar was prepared by dissolving 4.7 g of 7H9 Middlebrook media in 1 L 
of distilled water containing 2 ml glycerol. Bacto agar (BD) was added to a final 
concentration of 0.75% (7.5 g/L) and wassterilised by autoclaving.  
7.1.9 MacConkey agar 
MacConkey agar was prepared by dissolving 40 g of MacConkey agar base media (Difco) in 
1 L distilled water and autoclaved. Glucose free Maltose (10%) was filter sterilised and added 









7.1.10 Antibiotics and supplements 
Table 7-1: List of antibiotics and supplements 
Additives Stock concentration Storage 
Hygromycin B 50 mg/ml 4°C, protected from light 
Kanamycin 50 mg/ml -20°C, filter sterilised 
Ampicillin 100 mg/ml -20°C, filter sterilised 







Tween80 10% Room temperature, protect from light 
IPTG 1M -20°C, filter sterilised 
X-gal 40mg/ml -20°C, filter sterilised 
Maltose 20% Room temperature 
Acetamide 20% Room temperature 
 
7.2 Molecular biology techniques 
7.2.1 DNA electrophoresis 
Agarose gel electrophoresis was routinely used for analysis of PCR products, restriction 
digestion of plasmid constructs and genomic DNA. Different percentage of agarose gels 
(0.7% to 1.0%) were prepared by dissolving/melting molecular biology grade agarose 
(Bioline) in 1X-Tris acetate EDTA (TAE) buffer. DNA samples were separated under a 
horizontal electric field (100-140 V, 400mA). DNA was visualised by staining the gel with 
ethidium bromide and viewing under UV light (Bio-Rad Gel Doc systems). 
7.2.2 Polymerase chain Reaction (PCR) 
Table 7-2: PCR mix using Phusion polymerase 
Component Volume (µl) Stock concentration Final concentration 
Forward Primer 1 10 µM 0.5 µM 
Reverse Primer 1 10 µM 0.5 µM 
Template DNA 1 10 ng/µl 10 ng 
dNTP 0.8 2 mM 200 µM 
Polymerase 1 100Units 1 Unit 
GC buffer 20 5X 1X 
DMSO 5 100% 5% 
MgCl2 2 50 mM 1 mM 
Milli Q water  Made up to total of 100 µl   




7.2.3 Restriction digestion of DNA 
20 µl restriction digestion reactions were set up for either single (using one restriction 
enzyme) or double (using more than one restriction enzyme, usually two) digestion. 5 µl (~ 1 
µg) of purified DNA (plasmid DNA/genomic DNA/PCR product) was mixed with 2 µl of 
10X digest buffer, 1 µl (~5-10 units) of restriction enzyme and made up to 20 µl with 
nuclease free water. Reaction mix was supplemented with 2 µl of 10X BSA (Bovine Serum 
Albumin) wherever required. Reaction mix was incubated at 37°C (or as required for specific 
enzymes) for 30-60 min. Digested DNA was purified using Qiagen PCR purification kit and 
used for ligation.  
7.2.4 Ligation 
Digested DNA fragments with compatible ends were ligated using T4 DNA ligase (NEB). 10 
µl reaction mix containing vector and insert fragments at required concentration, 1 µl (5-10 
units) of T4 DNA ligase enzyme, 2 µl of 10X T4 DNA ligase reaction buffer and nuclease 
free water to make up the volume, were incubated at room temparature for 30 min or 4°C 
overnight.  
7.2.5 Preparation of chemically competent E. coli cells 
Required strain of E. coli was streaked onto LB agar to get isolated colonies. 5 ml of LB 
media was inoculated with a single colony of E. coli to prepare overnight cultures. The 
overnight culture was then used to inoculate 100 ml LB medium containing 20 mM MgSO4. 
Cells were grown to an O.D600nm of 0.4-0.6. The cells are then harvested by centrifugation at 
4500xg for 10 min at 4°C. Cell pellets were gently washed with 25 ml ice cold TFB1. The 
resuspended cells were incubated for 15 min on ice and centrifuged at 4500xg for 10min at 
4°C. The cells were then resuspended in 8 ml ice cold TFB2. Cells were incubated on ice 15-
60 min and then aliquoted and flash frozen. The aliquots are stored at -70°C for further use. 






30 mM Potassium acetate 
10 mM CaCl2 
50 mMMnCl2 
100 mM RbCl2 
15% glycerol 
Filter sterilised and stored at 4°C 
 TFB2 
10 mM MOPS or PIPES pH 6.5 
75 mM CaCl2 
10 mM RbCl2 
15% glycerol 
Filter sterilised and stored at 4°C 
Table 7-3: Strains of E. coli used for different purpose 
Strain Purpose 
Top10 Cloning 
C41(DE3) Protein expression 
BL21(DE3) Protein expression 
BL26 (DE3) (Tuner) Protein expression 
 
  
7.2.6 Transformation of E. coli competent cells 
Competent cells of E. coli strain to be transformed were thawed on ice. The ligation mix (5 
µl) or plasmid (100 ng) was added to the cells, gently mixed and incubated on ice for 30 min 
and transformed by heat shock at 42°C for 45 seconds. Transformed cells are cooled on ice 
before adding 1 ml of LB broth for recovery. Transformation mix was incubated at 37°C for 




about 45 min with shaking/ standing. At the end of 45 min recovery period cells were plated 
onto LB agar plates containing appropriate selection markers. 
7.2.7 Plasmid extraction 
Plasmid constructs were routinely extracted using Qiagen plasmid purification kits according 
to manufacturer’s recommendation.  
7.3 Generation of knock out phage for null mutant creation using 
Specialised Transduction 
Primers were designed to amplify approximately 1kb sequences of the upstream and 
downstream of the target gene (geneX). Using this set of primers, the upstream and 
downstream regions of the gene was amplified from M. smegmatis, M. kansasii, M. canetti or 
M. bovis BCG. The PCR products were purified using Quiagen pcr clean up kit and the 
primer incorporated Van91I/DraIII/BstAPI/AlwNI sites were digested with right choice of 
enzyme. Digested PCR fragments were cloned into Van91I-digested (all enzymes are 
mutually compatible for ligation) p0004s (or p0004S-Apra version) to generate allelic 
exchange plasmid p∆geneX. The allelic exchange plasmid p∆geneX was sequenced to 
confirm the presence of right DNA fragments. 
p∆geneX and phAE159 DNA were digested with the PacI and ligated. Ligation mix 
was then packaged into empty λ-phage heads and transduced into E. coli HB101 competent 
cells. Cells containing phasmid DNA were selected for on LB agar containing hygromycin or 
apramycin at 37°C. Presence of allelic exchange plasmid on phage DNA was confirmed by 
PacI digestion. The positive phasmids were electroporated into M. smegmatis mc
2
155 
electro-competent cells at 1800V and recovered at 30°C for ~ 4 hrs in TSB. The recovered 
cells were then harvested by centrifuging at 10000xg for 10 min and resuspended in 200 ml 
of MP buffer. This was mixed with 200 µl of freshly growing M. smegmatis mc
2
155 cells and 




5 ml molten 7H9 soft agar (50°C) and overlaid onto 7H10 agar plates. The plates were 
incubated at 30°C for 2-3 days to allow formation of plaques. The plates were soaked in 
minimum amount (2.5 ml to 3 ml) of MP buffer for 5-6 hrs to extract phages into solution 
and the solution containing phages was filtered and stored at 4°C.  
Specialised transduction of M. kansasii, M. canetti, M. smegmatis and M. bovis BCG 
was performed as described previously (Bardarov et al. 2002). The cultures were grown in 50 
ml of 7H9 + 10% OADC (or TSB for M. smegmatis) with 0.05% Tween 80 to an OD600 of 
~0.8 and harvested by centrifugation at 4500g for 10 min. The cell pellet was washed twice 
with 50 ml of MP buffer and resuspended in 2 ml of MP buffer and high titre (10
10 
pfu/ml) 
phage lysate (2 ml) was mixed with the cells. A control was set up where 0.5 ml of 
resuspended cells was mixed with 0.5 ml of MP buffer. The mix was incubated overnight at 
37°C followed by harvesting and recovered with 10 ml of 7H9 + 10% OADC with Tween-50 
at 37°C overnight (4-5 hrs for M. smegmatis).  This was plated onto 7H10 + 10% OADC- 
agar plates with hygromycin (or apramycin as required) and plates were incubated at 37°C 
for 1-4 weeks depending on the strain of mycobacteria. Hygromycin resistant colonies 
obtained after transduction were inoculated in 10 ml 7H9 + 10% OADC- Tween 80 with 
hygromycin for genomic DNA extraction and further characterisation. Allelic exchange of 
geneX with a hygromycin resistance cassette in hygromycin resistant transductants was 
confirmed by Southern blot. One such transductant was chosen for subsequent experiments. 
7.3.1 Genomic DNA extraction 
The cells were grown by inoculating a single colony in 10 ml of appropriate broth and 
growing them to an OD600nm of ~ 1.0. The cells were harvested by centrifugation at 4500g for 
10 min at room temperature. The cells are resuspended in 500 µl GTE buffer containing 10 
mg/ml lysozyme and incubated at 37°C overnight for complete lysis of the cells. 100 µl of 




10% SDS and 50 µl of 10 mg/ml Proteinase K is added to the mix and incubated at 55°C for 
3-4 hrs. While SDS aids in efficient lysis of cells, Proteinase K, a broad spectrum serine 
protease digests the proteins. To this mix, 200 µl of 5 M NaCl is added. The protein and cell 
debris is then removed by using Chloroform and Chloroform: Isoamyl alcohol (24:1) mix. 
The DNA is precipitated using Isopropyl alcohol and washed with 70% ethanol. DNA is air 
dried to get rid of organic solvents and dissolved in distilled water. 
7.3.2 Southern blot 
The genomic DNA is digested with appropriate restriction enzyme such that wild type and 
the mutant would give different restriction patterns. The digested DNA was run on 0.7% 
agarose gel. The gel was then depurinated using 0.25 M HCl. The depurinated gel is then 
treated with alkali solution (1.5 M NaCl, 0.5 M NaOH) for denaturation. The alkali is then 
neutralised with 0.5 M Tris-HCl pH 7.2 buffer containing 1 M NaCl. The DNA is then 
transferred onto a nylon membrane (Nylon membrane, positively charged, No. 11209299001, 
Roche) by capillary transfer using high salt solution (20X SSC, 3 M NaCl, 0.3 M Sodium 
citrate, pH 7.0), overnight. The transferred DNA was then cross linked to membrane under 
UV light. The cross linked membrane was further used for hybridisation, labeling and 
detection which was performed as described in DIG High Prime Labeling and Detection 
Starter Kit II (cat. No.11555614910, Roche). The kit uses digoxigenin, a steroid to label 
DNA probes by random priming. The hybridised probes are then immunodetected using an 
antibody against digoxigenin which is tagged with Alkaline phosphatase that aids in 
visualisation by chemiluminiscence. 
7.3.3 Preparation of mycobacterial electrocompetent cells 
Mycobacterial strain was grown to an OD600 of 0.6 and harvested by centrifugation at 4500g 
for 20 min.  The cells were washed twice with sterile 10% ice cold glycerol by centrifugation 




at 4500g for 20 min. Washed cells were resuspended in 1/10
th
 volume of sterile 10% ice cold 
glycerol and aliquoted. The Aliquots were frozen at -70°C. 
7.3.4 Electroporation of mycobacteria 
Electro-competent cells were thawed on ice and ~1 µg (max. 10 µl) of plasmid was added. 
The mix was placed into a 1mm electroporation cuvette and incubated on ice for further 15 
min. Electroporation was done using Eppendorf Electroporator (model No. 2510) at 1800V. 
The electroporated cells were recovered in 1 ml 7H9 (TSB for M. smegmatis) containing 
0.05% Tween 80 at 37°C for one generation time (4 hrs for M. smegmatis, 24 hrs for M. 
kansasii, M. canetti and M.bovis BCG). At the end of the recovery period, cells were 
harvested and resuspended in 200 µl of recovery media and plated on to TSA (M. smegmatis) 
or 7H10 or 7H11 (for M. kansasii, M. canetti and M. bovis BCG) with appropriate selection 
marker. 
7.3.5 Radioactive labelling of lipids 
10 ml of mycobacterial culture was grown to mid log phase and was then labelled with 50 
µCi/ml of [
14
C]-acetate (50 mCi/ml, Amersham Pharmacia Biotech). The labelled culture was 
incubated for 12 hrs (M. smegmatis) or 24 hrs (M. kansasii, M. canettiand M. bovis BCG). 
The labelled cells were harvested by centrifugation at 4500g for 10 -20 min at RT and 
washed with PBS before freeze drying. 
7.4 Lipid extraction 
Polar and apolar lipids were extracted from harvested cells (cold lipids) or cells labelled with 
[
14
C]-acetate, using methods described by Dobson et al., (1985). Cells/ labelled cells were 
resuspended in 2 ml of CH3OH/0.3% NaCl (100:10, v/v). Apolar lipids were extracted twice 
with 2 ml of petroleum ether (b.p. 60-80
0
C). 2 ml of petroleum ether was added the cells 
resuspended in mathanolic saline and mixed on a rotator for 30 min. The mixture was 




centrifuged at 4000g for 5 min to for two layers. The upper layer was removed and stored in a 
separate tube labelled apolar lipid.  2 ml of petroleum ether was added to lower fraction for 
complete extraction of apolar lipids. The mixture was allowed to mix on a rotator for 30 min 
before it was centrifuged again to collect the non polar lipids from upper layer. The combined 
upper layers’ containing apolar lipids was dried under liquid nitrogen and was used for 
analysis (Besra 1998). 
Polar lipids were extracted from the lower fraction by adding 2.3 ml of 
CHCl3/CH3OH/0.3% NaCl (90:100:30, v/v/v). The mixture was mixed on a rotator for 1 hr 
and centrifuged at 4000g for 5 min. The supernatant was removed and stored in a fresh tube. 
The remaining pellet was extracted twice with 0.75 ml of CHCl3/CH3OH/0.3% NaCl 
(50:100:40, v/v/v) and mixing for 30 min each time before centrifugation and removal of 
supernatant. 1.3 ml of CHCl3 and 1.3 ml of 0.3% NaCl was added to the pooled fraction and 
mixed for 10 min, centrifuged and the lower layer recovered and dried under Nitrogen for 
polar lipids. The dried apolar and polar lipids were dissolved in 200 µl of CHCl3/CH3OH 
(2:1, v/v); and 5 µl dried in a scintillation vial and then mixed with 5 ml scintillation fluid and 
radioactivity incorporated was measured in terms of counts per minutes. The defatted cells 
were used for further analysis (Besra 1998). 
7.4.1 Fatty acid methyl esters (FAMEs) and Mycolic acid methyl esters 
(MAMEs) extraction from defatted cells and whole cells 
Alkaline hydrolysis was performed on de-fatted cells using 2 ml of 5% aqueous 
tetrabutylammonium hydroxide at 100°C overnight. CH2Cl2 (4ml), CH3I (300 µl) and water 
(2 ml) was added to the reaction mixture and was mixed on a rotator for 30 min. The mixture 
was then centrifuged at 4000g for 5 min and the upper aqueous layer was discarded. The 
lower organic layer was washed 3 times with water and evaporated to dryness. MAMEs were 




re-dissolved in diethyl ether, sonicated and vortexed and centrifuged. The organic layer was 
taken into separate tube and dried under air. The samples were dissolved in either, CH3Cl: 
CH3OH, 2:1 v/v or CH2Cl2 (200 µl) and 5 µl was used for counting of labelled samples. 
7.4.2 Thin layer Chromatography (TLC) analysis of lipids 
Equivalent amounts of cold or labelled lipids (10 µg or 25,000 to 50,000 cpm) of each sample 
were spotted on TLC plates (5554 silica gel 60F524; Merck). TLC plates were developed 
using one of the following Systems mentioned below. Cold lipids were visualised by spraying 
MPA spray, α-naphthol spray or phosphate stain. [14C]- labelled lipids were revealed by 24-
72 hrs exposure to Kodak X-Omat AR film. 
7.4.2.1 Solvent systems for 2D TLC analysis 
Apolar lipids were separated by system A, B, C and D. Polar lipids were separated using 
systems D and E as described by Dobson et al. (1985). TLC plates should be air dried well 
before each solvent run and after spotting the samples. 
 System A 
Direction 1 
Thrice with petroleum ether (b.p.60-80
0
C)/ethyl acetate - 95:2 (v/v) 
Direction 2 
Once with petroleum ether (b.p.60-80
0
C)/acetone - 92:8 (v/v) 
 System B 
Direction 1 
Thrice with petroleum ether (b.p.60-80
0
C)/ acetone – 92:8 (v/v) 
Direction 2 
Once with toluene/acetone – 95:5 (v/v) 
 





 System C 
Direction 1 
Once with Chloroform/methanol –96:4 (v/v) 
Direction 2 
Once with toluene/acetone – 80:20 (v/v) 
 System D 
Direction 1 
Once with Chloroform/methanol/water – 100:14:0.8 (v/v/v) 
Direction 2 
Once with Chloroform/acetone/ethanol/water – 50:60:2.5:3 (v/v/v/v) 
 System E 
Direction 1 
Once with Chloroform/methanol/water – 60:30:6 (v/v/v) 
Direction 2 
Once with chloroform/acetic acid/methanol/water – 40:25:3:6 (v/v/v/v) 
 
Note: TLC plates were activated by baking at 100°C for 1 hr before application of samples 
for running in system E. One hour drying between the runs is also required for system E. 
 
7.4.2.2 TLC analysis for Fatty Acid Methyl Esters (FAMEs) and Mycolic Acid 
Methyl Esters (MAMEs) 
The FAMEs/MAMEs mixture (~ 25,000 cpm) were analysed by developing the TLC using 
petroleum ether (b.p.60-80°C): acetone – 95:5 (v/v). [14C]-labelled FAMEs/ MAMEs were 
revealed by overnight exposure to Kodak X-Omat AR film. 




7.5 Techniques in protein chemistry 
7.5.1 Checking the expression of protein expressed in E. coli 
Cells of E. coli expression strain were transformed with plasmid harbouring gene of interest. 
Overnight cultures of transformants were prepared by inoculating into 5 ml LB broth 
containing appropriate selection marker with transformants. Overnight cultures were used to 
inoculate  10 ml of LB broth containing appropriate selection marker and incubated at 37°C 
(or 30°C or 25°C or 16°C where required) with shaking. The cultures were induced for 
protein expression with IPTG (at required concentration) at OD600 ~0.5 and continued to 
incubated for required time (3hrs to O/N as required). Cells were harvested at the end of 
induction period by centrifugation at 4500g for 10-20 min. The cells were washed with an 
equal volume of PBS. The cells were then resuspended in 300-400 µl of ice cold protein 
extraction buffer (50 mM Tris-HCl, pH 7.5, 5 mM EDTA, 0.6% SDS, 10 mM Sodium 
phosphate, protease inhibitor cocktail tablet 1 in 50 ml) and mixed with equal volume of 2X 
SDS gel loading dye. The mix was boiled for 10 min to break open the cells and release the 
proteins and spun at high speed on a microfuge to pellet down the cell debris. The samples 
are loaded on to SDS-PAGE gel to visualise the bands.  
7.5.2 Scaling up protein expression 
Overnight cultures of required strain harbouring expression construct was used to inoculate 
up to 12 L of LB broth to an initial OD600 of 0.1 and incubated at 37°C (or as required for the 
experiment) with vigorous shaking till OD600 reached 0.5. Protein expression was induced 
using 1 mM [IPTG] (or as required by the experiment) and further incubated for another 3 hrs 
(or O/N at lower temperatures). Cells were harvested at the end of induction period and 
washed with PBS. Cell pellet was either used immediately or frozen at -70°C for later use.  




7.5.3 SDS PAGE 
Precast protein gels (any Kda, Biorad) or 8-12% SDS-PAGE gels were used for the analysis 
of proteins. SDS-gel sample buffer was added to samples and boiled for 10 min. The samples 
were then spun for 5 min at maximum speed in a microfuge and loaded on to gel.  The gel is 
run using Tris-glycine-SDS buffer with a current of 35- 45 mA and potential difference 
200V. The gel is stained using either instant blue or coomassie brilliant blue stain. 
7.5.4 Affinity chromatography 
His trap HP column (Amersham Biosciences) was used for the purification of His-tagged 
proteins. The column has highly cross linked agarose beads on which a chelating group is 
immobilised. The Ni
2+
 is coupled to the chelating matrix. The column is washed with 5-10 
column volume of distilled water and equilibrated with 5 column volumes of 50 mM 
Potassium Phosphate buffer pH 7.9, containing 500 mM NaCl. The cells are lysed using a 
sonicator (30s on/30s off, 10 cycles). The sonicated lysate is then spun at 15,000g for 45 min. 
The supernatant is loaded on to the column. The column is washed with different 
concentration of imidazole (10 mM to 1 M) to wash the contaminant proteins and elute the 
protein of interest. The fractions are collected and analysed on SDS-PAGE gel.   
7.5.5 Ion exchange chromatography 
QHP ion exchange column (Amersham biosciences) was used for purification of proteins. 
The column is washed with 5-10 column volume of distilled water. The column is then 
equilibrated with 20 mM Tris-HCl, pH 8.0. Cell lysate or partially purified protein from 
affinity chromatography is then loaded on to the column. The column is washed with 
increasing concentration of NaCl (20 mM to 1 M) to wash contaminant proteins and elute the 
protein of interest. The fractions are collected and analysed on SDS-PAGE gel. 




7.5.6 Gel filtration chromatography 
Gel filtration chromatography was used as a preparative tool to further purify proteins and 
analytical tool to get insight into oligomeric status of the protein. Partially purified protein 
from earlier purification methods was concentrated to ~ 1 mg/ml and loaded to Superdex-200 
10/300GL (GE healthcare) column equilibrated with 50 mM Tris.Cl, 150 mM NaCl. Protein 
was eluted by washing the column with elution buffer (50 mM Tris.Cl, 150 mM NaCl). 0.5 
ml (or 2 ml) fractions were collected and analysed by SDS-PAGE analysis. 
7.5.7 Purification of membrane protein using SMALP 
Cells expressing membrane protein was harvested and washed with PBS and resuspended in 
Buffer-1. Cell lysis was done using French press (10,000psi 4 cycles). Cell debris was 
removed by centrifugation at 10,000g for 30min. The membrane fraction was then separated 
from cell lysate by centrifugation at 100,000g for 45min. Membrane thus separated was 
weighed and resuspended in Buffer-2 to a final concentration of 40 mg/ml and homogenised. 
The homogenised membrane was then solubilised using SMA [poly (styrene-co- maleic 
acid)] (SMA2000-P). The mix was incubated at room temparature for two hours on a rocker 
to facilitate solubilisation and to generate SMA-solubilised protein (SMA-lipid particle 
encapsulating protein). SMA-solubilised membrane fraction was centrifuged at 100,000g for 
45 min to remove insoluble membrane particles. The supernatant consisting of SMA-
solubilised protein was then incubated with affinity matrix (Ni
2+
-NTA) at 4°C for O/N to 









Composition of buffers: 
 Buffer 1: 
50 mM Tris.Cl pH 8.0 
2 mM EDTA 
5% Glycerol 
1 mM PMSF 
Protease inhibitor cocktail 1 tablet/50 ml 
 
 Buffer 2  
50 mM Tris.Cl pH8.0 
500 mM NaCl 
10% Glycerol 
1 mM PMSF 
Protease inhibitor cocktail 1 tablet/50 ml 
7.5.8 Western blot analysis 
Protein samples run on SDS-PAGE were transferred onto PVDF membrane (Pierce, Thermo 
scientific) using transfer buffer (25 mM Tris, 190 mM Glycine and 20% methanol) (30V and 
300 mA, 3 hrs) at cold. Membrane was incubated in blocking solution (1% BSA or 3% Milk 
powder) to prevent non-specific binding of antibodies to the membrane, for 1 hr at RT or O/N 
at 4°C. The membrane was thoroughly washed with TBS containing 0.1% Tween 20 three 
times and incubated with required dilution of primary antibody (anti-His or anti-MBP). After 
one hour of incubation, membrane was again washed with TBS containing Tween 20. 




Membrane blot was later incubated with alkaline phosphatase coupled secondary antibody for 
one hour. Membrane blot was washed before developing signal to visualise the proteins using 
chromogenic substrate BCIP/NBT (Sigma Aldrich) solution.          
7.5.9 Analytical ultracentrifugation 
Analytical ultracentrifugation was routinely used to evaluate the oligomeric status of the 
protein. Protein samples were prepared by adjusting the concentration of the purified protein 
to ~ 0.5 to 1.0 mg/ml (either by concentrating or diluting). Ultracentrifugation was performed 
using sedimentation velocity protocol at 20000g (or 30000g where required) for 16 hrs at 
20°C in a Beckman Coulter XL ultracentrifuge. Absorbance data collected was analysed 
using Sedfit program. Parameters required for data analysis was deduced from protein 
sequence and buffer composition using Sednterp program. 
7.5.10 Protein-protein interaction studies 
Genes of interest were cloned into pKT25 (T25 fusion tag) or pUT18 (T18 fusion tag) using 
standard DNA manipulation protocols (Karimova et al. 1998). Two plasmids, expressing bait 
and prey proteins as fusion tags of T25 fragment and T18 fragment respectively were co-
transformed into E. coli cya
-
 strain BTH101. Cells were spread on LB plates containing 
streptomycin (100 µg/ml), ampicillin (100 µg/ml) and kanamycin (50 µg/ml) and incubated 
at 30°C for 48 hrs. Overnight cultures were prepared by inoculating several colonies into 5 
ml LB broth containing above mentioned antibiotics and 0.5 mM IPTG to induce protein 
expression and incubated at 30°C with shaking. The cultures were then washed three times in 
minimal M63 media and either spotted or spread on MacConkey agar plates supplemented 
with above mentioned antibiotics and nutrients.  





Figure 7-1 Schematic presentation of flow chart of steps involved in protein-protein interaction studies. 
Domain organisation of Bordetella pertusis adenylate cyclase showing T25 fragment (in blue) and T18 fragment 
(in orange). (A) Expression of chimeric adenylate cyclase alone in E. coli cya
-
 strain BTH101 leads to residual 
cAMP synthesis (B) when the individual fragments are physically separated its activity is lost leading to 
cessation  of cAMP synthesis (C)  Individual fragments brought in physical proximity by interacting protein 
restores cAMP synthesis. Bait and prey proteins are cloned with T25 and T18 fragments of adenylate cyclase 
domain of Bordetella pertusis adenylate cyclase. Plasmids harbouring genes for expression of bait and prey 
proteins were co-transformed into E. coli cya
-
 strain BTH101. Screening for interactions was done by plating the 
co-transformants on McConkey agar containing kanamycin and Ampicillin. Further, quantitative β-
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Southern blot analysis of fabH mutant.  (A) Map of fabH region in the parental M. bovis 
BCG and its corresponding region in the ΔfabH mutant. res, γδ resolvase site; hyg, 
hygromycin resistance gene from Streptomycin hygroscopicus; sacB, sucrose counter 
selectable gene from Bacillus subtilis. Digoxigenin-labeled probes were derived from ∼1 kb 
upstream and downstream flanking sequences that were used to construct the knockout 
plasmid. DraIII-digested bands expected in a Southern blot are indicated in roman numerals 
with sizes.  (B) The gel below shows the Southern blot of DraIII-digested genomic DNA 






Plasmids Description Reference 
pET28a E. coli expression vector with  histidine 
affinity tag 
Novagen 
pET28b E. coli expression vector with  histidine 
affinity tag 
Novagen 
pET41c E. coli expression vector with  histidine 
affinity tag 
Novagen 
pGEX-4T-1 E. coli expression vector with 
glutathion affinity tag 
GE Lifesciences 
pMAL-p2X E. coli expression vector with maltose 
binding protein affinity tag 
New England Biolabs 
pSD26 Mycobacterial expression vector with 
histidine affinity tag 
Daugelat et al., 2003 
pVV16 Mycobacterial expression vector with 
histidine affinity tag 
BEI resources, NIAID, 
NIH 
pET28a:ML1 MmpL3 non-transmembrane region 1 
cloned into pET28a vector in frame 
with N-term His tag 
This work 
pET28a:ML2 MmpL3 non-transmembrane region 2 
cloned into pET28a vector in frame 
with N-term His tag 
This work 
pET28b:ML1 MmpL3 non-transmembrane region 1 
cloned into pET28a vector in frame 
with C-term His tag 
This work 
pET28b:ML2 MmpL3 non-transmembrane region 2 
cloned into pET28a vector in frame 
with C-term His tag 
This work 
pSD26:ML1 MmpL3 non-transmembrane region 1 
cloned into mycobacterial expression 
vector pSD26 vector in frame with C-
term His tag 
This work 
pSD26:ML2 MmpL3 non-transmembrane region 2 
cloned into mycobacterial expression 
vector pSD26 vector in frame with C-
term His tag 
This work 
pET28b:ML Non-transmembrane region 1 and  2 
fused with artificial linker peptide 
(ML) cloned into pET28b expression 
vector in frame with C-term His tag 
This work 
pET41c:MmpL3 MmpL3 cloned into  expression vector 
pET41c in frame with C-term His tag 
This work 
pET28a:MmpL3 MmpL3 cloned into  expression vector 
pET28a in frame with N-term His tag 
This work 
pGEX:MmpL3 MmpL3 cloned into  expression vector 
pGEX-4T-1 vectorin frame with N-




pMAL:MmpL3 MmpL3 cloned into  expression vector 
pMALp2X in frame with N-term MBP 
tag 
This work 
pSD26:MmpL3 MmpL3 cloned into mycobacterial 
expression vector pSD26 vector in 
frame with C-term His tag 
This work 
pVV16:MmpL3 MmpL3 cloned into mycobacterial 
expression vector pVV16 vector in 
frame with C-term His tag 
This work 
pET41C:MmpL3-CB MmpL3 cloned into  expression vector 
pET41c in frame with C-term His tag 
This work 
pET28b:MmpL3 MmpL3 gene codon optimised for 
expression in E. coli cloned into  
expression vector pET28bin frame with 
C-term His tag 
This work 
pMV261(apra): MmpL3 pMV261 vector with Apramycin 
selection marker harboring full length 
mmpL3 gene for constitutive 
expression in M. smegmatis 
This work 
Bacterial strains   
E. coli BL21 (DE3) F
–










E. coli C41 (DE3) F
–







E. coli Tuner F
−




−) λ(DE3 [lacI 






















Primer name Primer Sequence 
MmpL3_CB_41c F C GTA CAT ATG GTG TTT GCA TGG TGG GGT CGT ACT GTA TAT CGA TAC CGG TTC 
ATC GTA ATC 
MmpL3_41c_F C GTA CAT ATG GTG TTC GCC TGG TGG GGT C 
MmpL3_41c_R C GTA AAG CTT AAG GCG TCC TTC GCG GC 
MmpL3_pGEX_F C GTA AGA TCT GTG TTC GCC TGG TGG GGT C 
MmpL3_pGEX_R C GTA GAA TTC TTA AAG GCG TCC TTC GCG GC 
MmpL3_pSd26_F GTC AGA TCT ATG GTG TTC GCC TGG TGG GGT C 
MmpL3_pSd_R C GTA AAG CTT CTA GTG GTGGTGGTGGTGGTGGTGGTG AAG GCG TCC TTC GCG GC 
MmpL3_CB_28a F 
C GTA GAA TTC GTG TTT GCA TGG TGG GGT CGT ACT GTA TAT CGA TAC CGG TTC 
ATC GTA ATC 
MmpL3_28a_F C GTA GAA TTC GTG TTC GCC TGG TGG GGT C 
MmpL3_28a_R C GTA AAG CTT TTA AAG GCG TCC TTC GCG GC 
MmpL3_pVV16_R C GTA AAG CTTC AAG GCG TCC TTC GCG GC 
ML1 41cF ATC CAT ATG CTG AGC CTC GGC AAG CAC 
ML1 41cR ATC AAG CTTCAC CGC CAC CAA CGG CAG 
ML2 41cF ATC CAT ATG AAGCTGTCATTGGGCGGG 
ML2 41cR ATC AAG CTT CAC CAT CAG CGG CAT C 
mmpL3_pMV261F GT CAA GCT TGGGTG TTC GCC TGG TGG GGT C 
mmpL3_pMV261R C GTA ATC GAT CTA AAG GCG TCC TTC GCG GC 
ML-NHIS-F CAC GAA TTC CTG TCT CTG GGC AAA CAC 
ML-NHIS-R ATC CTC GAG TCA TTC CAG TGC CGG CGT GCC 
ML1-NHIS-R AGT CTC GAG TCA TTC CAT GCG ACG CTG ATC 
ML1-CHIS-F AGT ACC ATG GGC CTG TCT CTG GGC AAA CAC 
ML1-CHIS-R GTA CTC GAG TTC CAT GCG ACG CTG ATC 
ML2-NHIS-F CAC GAA TTC GGT ATC TCT GAA AAA TAT CTG 
ML2-CHIS-F AGT ACC ATG GGC GGT ATC TCT GAA AAA TAT CTG 
ML2-CHIS-R GTA CTC GAG TTC CAG TGC CGG CGT GCC 
 
SDM primers for Q5 SDM kit: 
I250T (72C) ATC-ACC  
I250T F: GGGGATCGCCaccGACTACGGGT 
I250T R: AGACCGATCAGCGACACCACG 
Y252A (65C) TAC-GCC 
Y252A F: CGCCATCGACgccGGGTTGTTCATC 
Y252A R: ATCCCCAGACCGATCAGC 
Y252D (67C) TAC-GAC 
Y252D F: CGCCATCGACgacGGGTTGTTCA 
Y252D R: ATCCCCAGACCGATCAGC 
214 
 
W731G (71C)  
W731G F: CGATGACTGCgggTGGGCACCGC 
W731G R: CCGAGCAGCTTCATCACCGATG 
E262A (71C) GAA-GCA 
E262A F: CCGGTTCCGCgcaGAGATCGCCG 
E262A R: CTCACGATGAACAACCCGTAGTCG 
R653A (65C) CGA-GCA 
R653A F: GGTCGAGGCGgcaGAGCGCGGCA 
R653A R: ATCCGGGACACCAAGAAC 
D251A (69C) GAC-GCC 
D251A F: GATCGCCATCgccTACGGGTTGT 

























































































Clone Primer set Enzym
es 
Vector 
MmpL3-CHis Genscript construct NcoI/X
hoI 
pET28b 
ML-CHis Genscript construct NcoI/X
hoI 
pET28b 


























Schematic presentation of extraction of membrane protein using SMA. SMA polymer 
which is amphipathic in nature,  encapsulates membrane protein above pH 6.5 and 













Size exclusion chromatogram of Gel filtration Standards. Peak 1 corresponds to Carbonic 








Western blot analysis of MmpL3-MBP fusion protein expression 
 
 






























MCAN_15191_LR TTTTTTTTCCATTTCTTGG TGCGTACATAGTCGGCTGTC 
MCAN_15191_RL TTTTTTTTCCATAGATTGG GCCCATGTCCGTAAACAAG 














1 Appendix 10 
 
Southern blot analysis of MSMEG0249 mutant.  (A) Map of MSMEG0249 region in the 
parental M. smegmatis mc
2
155 and its corresponding region in the 
ΔMSMEG0249 mutant. res, γδ resolvase site; hyg, hygromycin resistance gene 
from Streptomycin hygroscopicus; sacB, sucrose counter selectable gene from Bacillus 
subtilis. Digoxigenin-labeled probes were derived from ∼1 kb upstream and downstream 
flanking sequences that were used to construct the knockout plasmid. (B) The gel below 
shows the Southern blot of KpnI-digested genomic DNA from the two strains with expected 





2 Appendix 11 
 
Bacterial two hybrid screening testing for interactions between ‘bait’ and ‘prey’ 
proteins on MacConkey agar plates. The positive interaction observed with both Rv0204 





3 Appendix 12 
 
Southern blot analysis of Mkan27435 mutant.  (A) Map of MKAN27435 region in the M. 
kansasii WT and its corresponding region in the mutant; hyg, hygromycin resistance gene 
from Streptomyces hygroscopicus, SacB, sucrose counter selectable gene from Bacillus 
subtilis. (B) Lanes represents KpnI digested genomic DNA from M. kansasii WT strain and 
mutant. Expected restriction digestion pattern: WT- bands corresponding to 2.6 kb and 1.3 kb 
and ∆MKAN27435- bands correspond to 4.1 kb and 3.0 kb; positive control- two bands 






















 Mass spec analysis of Per-O-methylated LOSs from WT and mutant strains 
MALDI-TOF analysis of per-O- methylated LOSs from WT (top panel) and mutant (lower 
panel). Fig. A-D per-O-methylated LOSs without acyl and Fig. G per-O-methylated LOSs 
with acyl intact, m/z (mol.wt +Na
+
) corresponding to each LOSs products indicated above the 
peak 
 
